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Abstract 
Dengue viruses (DENV) are mosquito-borne flaviviruses that cause a severe 
febrile illness, and sometimes a potentially lethal syndrome called dengue 
haemorrhagic fever (DHF). Despite decades of effort, the global resurgence of 
dengue is testament to the inadequacy of current control measures. Dengue has 
become an immense international public health concern: WHO estimates that 
there are 50-100 million dengue infections and 500,000 cases of DHF hospitalised 
each year. Thus dengue has a major economic impact in the developing world 
through loss of healthy life and utilisation of constrained health resources. 
 
Global dengue control is likely to require a combined approach based on the 
development of successful strategies for immunization and antiviral drugs, as well 
as vector control. Better understanding of DENV pathogenesis presents new 
opportunities for design of rationally attenuated vaccine candidates and antiviral 
therapies. This thesis focuses on understanding a critical step in DENV 
pathogenesis: evasion of human innate immune responses mediated by interferon. 
A lentiviral vector system was developed to express dengue non-structural (NS) 
proteins in human cells, and we used this to show that expression of dengue NS5 
alone inhibited IFN-α, but not IFN-γ, signalling. The IFN-α signalling cascade is 
blocked downstream of Tyk2 phosphorylation: NS5 binds to the transcription 
factor STAT2 and inhibits its phosphorylation. The polymerase domain of NS5 is 
sufficient to block IFN-α induced signal transduction, and inhibition does not 
require NS5 nuclear translocation. We finally tested several hypotheses to explain 
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why STAT2 degradation occurs in both DENV-infected and replicon-containing 
cells, but not when NS5 is expressed alone. 
 
The most important conclusion from this work is that DENV NS5 is a potent 
and specific type I IFN antagonist. The results of this study are an important step 
in defining the molecular pathogenesis of dengue, and provide clues to potential 
new approaches to combat this disease. 
 5 
 
Acknowledgements 
I would like to thank my supervisor Dr Michael Jacobs for his help and 
guidance throughout this project, for his trust and support, and for his enthusiasm, 
attention and rigorousness at any stage of this work. 
Thanks to Mel and Angela for the warm welcome in the group, and for teaching 
me all I needed to know about the lab and about the country... Special thanks to 
Mel for the invaluable technical help and for her preliminary work on STAT2 and 
NS4B.  
I owe special thanks to my second supervisor Professor Benny Chain, who 
allowed me to join his group and access the facilities in his lab, and who offered 
me his helpful advice and support in any circumstance. Special thanks also to all 
the people in his group and on the fourth floor of the Windeyer for their help, their 
friendship and for all the funny moments that we had together. 
I would like to thank all the students who worked in our lab, in particular Luis 
Ureña, who undertook his Master Degree thesis in our lab under my supervision 
and carried out some steps of the cloning described in chapter 6.  
Thanks to Dr Andrew Davidson for providing us with constructs and antibodies, 
and for all helpful conversations and inspiring brainstorming about DENV and 
science. 
Special thanks to Stan Wickremasinghe for sharing with me his great expertise 
in immunoblotting and proteomic techniques, and for all our interesting 
conversations about science, music and life. 
 6 
 
. 
Thanks to all the people at the Royal Free, students, supervisors and staff, for 
making the U3 a friendly and pleasant place to work. 
Finally I would like to thank my parents and all the people who have walked 
next to me in these three challenging and beautiful years. 
 7 
 
Table of contents 
ABSTRACT 3 
ACKNOWLEDGEMENTS 5 
TABLE OF CONTENTS 7 
LIST OF FIGURES 14 
LIST OF TABLES 16 
ABBREVIATIONS 17 
CHAPTER 1. INTRODUCTION 24 
1.1 EVOLUTION AND SOCIAL IMPACT OF DENGUE VIRUS 25 
1.1.1 Epidemiology of dengue 25 
1.1.2 Phylogeny of DENV 27 
1.2 STRUCTURE AND REPLICATION OF DENGUE VIRUS 29 
1.2.1 Transmission cycle 29 
1.2.2 Target cells of DENV infection in human 30 
1.2.3 DENV life cycle 32 
1.2.3.1 Fusion and entry 32 
1.2.3.2 Genome organisation 37 
1.2.3.3 Genome translation 39 
1.2.3.4 Genome replication 39 
1.2.3.5 Virion assembly and release 41 
1.2.4 DENV non-structural proteins 42 
1.2.4.1 NS1/NS2A 43 
1.2.4.2 NS2B/NS3 44 
1.2.4.3 NS4A 46 
1.2.4.4 NS4B 46 
1.2.4.5 NS5 47 
 8 
 
1.3 DENGUE AND DHF: CLINICAL MANIFESTATIONS AND RISK 
FACTORS 50 
1.3.1 Dengue clinical manifestations 50 
1.3.2 Risk factors for DHF 51 
1.3.2.1 Viral factors 51 
1.3.2.2 Human factors 52 
1.3.2.3 Pre-existing immunity and ADE 53 
1.3.3 Pathogenesis of DHF 54 
1.4 PROGRESS AND SETBACKS OF VACCINE AND ANTIVIRAL 
DRUG DEVELOPMENT 57 
1.4.1 Live vaccines 58 
1.4.1.1 Live-attenuated vaccines 58 
1.4.1.2 Chimaeric vaccines 59 
1.4.2 Inactivated vaccines 60 
1.4.3 Recombinant subunit vaccines 60 
1.4.4 Antiviral treatments 61 
1.5 DENV INHIBITION OF INNATE IMMUNITY 62 
1.5.1 DENV and NK cells 62 
1.5.2 DENV and type I IFN 64 
1.5.2.1 The type I IFN system 65 
1.5.2.1.1 Viral induction of type I IFN 65 
1.5.2.1.2 Type I IFN signalling 66 
1.5.2.1.3 Viral evasion of type I IFN 70 
1.5.2.1.4 Flavivirus inhibition of type I IFN 71 
1.5.2.2 DENV inhibition of type I IFN 72 
CHAPTER 2. MATERIALS AND METHODS 77 
2.1 MOLECULAR CLONING 78 
2.1.1 High-Fidelity Polymerase Chain Reaction (PCR) 78 
2.1.1.1 Primer design 78 
2.1.1.2 High-Fidelity PCR 79 
2.1.2 Agarose gel 81 
 9 
 
2.1.3 Subcloning in pGEM®-T Easy Vector System 81 
2.1.3.1 A-tailing 83 
2.1.3.2 PCR purification 83 
2.1.3.3 Ligation in pGEM®-T Easy Vector 84 
2.1.3.4 Transformation 84 
2.1.4 DNA preparation 85 
2.1.4.1 Mini-DNA preparations (minipreps) 85 
2.1.4.2 Midi-DNA preparation (midipreps) 86 
2.1.5 Enzymatic Digestions 86 
2.1.6 Ethanol precipitation of DNA 87 
2.1.7 Insert preparation 88 
2.1.8 Backbone preparation 88 
2.1.8.1 Dephosphorylation of linearised DNA fragments 88 
2.1.9 Isolation of DNA from agarose gel 89 
2.1.10 Cloning in lentiviral vector 89 
2.1.10.1 Ligation 89 
2.1.10.2 Transformation 90 
2.1.11 DNA sequencing 90 
2.2 PRODUCTION OF LENTIVIRAL VECTORS 90 
2.2.1 Virus production 90 
2.2.1.1 Cell plating 91 
2.2.1.2 Transfection 91 
2.2.1.3 Supernatant collection 92 
2.2.1.4 Virus concentration 92 
2.2.2 Virus titration 93 
2.2.3 Transduction 94 
2.3 REVERSE TRANSCRIPTION AND REAL TIME PCR 94 
2.3.1 RNA extraction 94 
2.3.2 DNAse treatment 95 
2.3.3 cDNA reverse transcription 95 
 10 
 
2.3.4 Taq Polymerase Chain Reaction 96 
2.3.5 Real time PCR 97 
2.4 IMMUNOCHEMISTRY TECHNIQUES 100 
2.4.1 SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) 100 
2.4.1.1 Sample preparation 100 
2.4.1.2 Electrophoresis 100 
2.4.2 Western blotting 101 
2.4.2.1 Protein transfer 101 
2.4.2.2 Blocking 101 
2.4.2.3 Blotting 101 
2.4.2.4 Development 102 
2.4.3 NS5-FLAG Immunoprecipitation 103 
2.4.4 NS1 ELISA 104 
2.4.5 Surface Staining and Flow Cytometry 105 
2.5 TRANS-RESCUE ASSAY 107 
2.6 CELL MAINTENANCE 108 
CHAPTER 3. DEVELOPMENT OF K562 CELL LINES 
EXPRESSING INDIVIDUAL DENV NON-STRUCTURAL 
PROTEINS 109 
3.1 INTRODUCTION 110 
3.2 OBJECTIVES 113 
3.3 RESULTS 113 
3.3.1 Generation of lentiviruses encoding individual DENV NS proteins 113 
3.3.1.1 Design of DENV NS cassettes 113 
3.3.1.2 Cloning of DENV NS protein cassettes into the lentiviral vector pHRSIN 
CSGWdINotI_pUb_Em 114 
3.3.1.3 Virus preparation 117 
3.3.2 Development of K562 cell lines expressing individual DENV NS proteins
 117 
 11 
 
3.3.2.1 Transduction of K562 117 
3.3.2.2 Protein expression 118 
3.3.2.3 Transgene expression is diminished over the time 119 
3.3.3 Enhancement of protein expression over the time: cloning of the MESV 
leader sequence into lentiviral constructs 120 
3.3.3.1 Cloning of the “leader sequence” into the lentiviral vectors encoding 
DENV NS protein cassettes 125 
3.3.3.2 Transduction of K562 125 
3.3.3.3 DENV NS message and protein expression 126 
3.4 DISCUSSION 132 
3.5 CONCLUSIONS 135 
CHAPTER 4. IDENTIFICATION OF NS5 AS A POTENT IFN- 
ANTAGONIST 136 
4.1 INTRODUCTION 137 
4.2 OBJECTIVES 138 
4.3 RESULTS 138 
4.3.1 DENV NS proteins expressed separately do not induce STAT2 
degradation 138 
4.3.2 NS5 inhibits the type I IFN response 140 
4.3.2.1 NS5 inhibits the dose-dependent induction of ISGs. 140 
4.3.2.2 The antiviral effect of IFN- is suppressed in NS5 expressing cells 141 
4.3.3 NS5 does not inhibit cellular responses to IFN- 147 
4.3.4 DENV-2 TSV01 NS5 also inhibits type I IFN response 149 
4.4 DISCUSSION 152 
4.5 CONCLUSIONS 157 
CHAPTER 5. NS5 BINDS STAT2 AND PREVENTS ITS 
PHOSPHORYLATION 158 
5.1 INTRODUCTION 159 
 12 
 
5.2 OBJECTIVES 162 
5.3 RESULTS 163 
5.3.1 NS5 inhibits type I IFN signalling downstream of STAT2 
phosphorylation 163 
5.3.1.1 NS5 inhibits STAT2 phosphorylation in response to IFN- 163 
5.3.1.2 NS5 does not inhibit the IFN- signalling cascade upstream of STAT2 
phosphorylation 164 
5.3.2 NS5 binds STAT2 167 
5.3.2.1 Expression of NS5-FLAG 167 
5.3.2.2 NS5 specifically binds STAT2, but not STAT1 or Tyk2 168 
5.3.3 Co-transduction of NS5 and other NS proteins is not sufficient to induce 
STAT2 degradation 171 
5.3.3.1 DENV NS4B contains a BC-box consensus sequence 171 
5.3.3.2 Co-expression of NS5 and NS4B does not reduce cellular levels of STAT2
 172 
5.3.3.3 Combination of NS5 with other DENV NS proteins is not sufficient to 
induce STAT2 degradation 176 
5.4 DISCUSSION 177 
5.5 CONCLUSIONS 179 
CHAPTER 6. IDENTIFICATION OF THE REGION WITHIN NS5 
REQUIRED FOR TYPE I IFN ANTAGONISM 181 
6.1 INTRODUCTION 182 
6.2 OBJECTIVES 183 
6.3 RESULTS 186 
6.3.1 Expression of the DENV NS5 RdRp domain alone is sufficient to inhibit 
the type I IFN response 186 
6.3.1.1 Cloning strategy 186 
6.3.1.2 Development of K562 cell lines expressing the MTase1-260 domain and the 
RdRP223-900 domain 186 
6.3.1.3 The RdRp223-900 is sufficient to inhibit cellular response to IFN- 187 
6.3.2 Deletion of the region containing the NLS abolishes the IFN antagonism
 13 
 
 190 
6.3.2.1 Cloning strategy and development of K562 cell lines expressing the 
RdRp405-900 domain 190 
6.3.2.2 The region 223-404 is critical to type I IFN inhibition 190 
6.3.3 IFN inhibition occurs only when the “inter-domain” 223-404 is expressed 
in the context of the RdRp 191 
6.3.3.1 Cloning strategy and development of K562 cell lines expressing the “inter-
domain” 223-404 alone or at the C-terminal of the MTase domain 191 
6.3.3.2 The “inter-domain” 223-404 alone or at the C-terminal of the MTase does 
not inhibit IFN- response 192 
6.3.4 Nuclear translocation of NS5 is not required for the inhibition of type I 
IFN signalling 195 
6.3.4.1 Development of a K562 cell line expressing a mutant of NS5 that does not 
translocate into the nucleus 195 
6.3.4.2 NS5 inhibition of cellular response to IFN- is preserved in the absence of 
nuclear translocation 196 
6.4 DISCUSSION 198 
6.5 CONCLUSIONS 203 
CHAPTER 7. FINAL DISCUSSION 204 
REFERENCE LIST                                                                                                  209 
 
 14 
 
List of figures 
Chapter 1 
Figure 1.1| Schematic diagram of DENV replication cycle ......................................... 33 
Figure 1.2| Organisation, membrane fusion and maturation of DENV E protein ........ 36 
Figure 1.3| Schematic representation of DENV genome and predicted membrane 
topology of DENV polyprotein ............................................................... 38 
Figure 1.4| Type I and type II IFN signalling cascade ................................................. 67 
Chapter 2 
Figure 2.1| Map of the pGEM®-T Easy Vector and sequence reference points .......... 82 
Chapter 3 
Figure 3.1| Schematic representation of the lentiviral vector pHRSIN-
CSGWdINotI_pUb_Em .................................................................... 112 
Figure 3.2| A. Gel elecrophoresis of PCR products amplified from the DNA replicon 
CprMEPAC2A. B. Gel electrophoresis of lentiviral vectors containing 
individual DENV NS protein cassettes, before and after double digestion 
BamHI-NotI ............................................................................................. 116 
Figure 3.3| Transduction efficiency of the lentivirus NS1/NS2A at MOI 1, 4, and 7.
 ................................................................................................................. 121 
Figure 3.4| Transduction efficiency of K562 cells transduced by different lentiviral 
vectors ...................................................................................................... 122 
Figure 3.5| NS1 expression in K562 cells transduced at different MOI with the 
lentivirus NS1/NS2A ............................................................................... 123 
Figure 3.6| Expression of GFP and NS1 in K562_NS1/NS2A over the time ............ 124 
Figure 3.7| Insertion of the MESV leader sequence into the lentivector pHRSIN-
CSGWdINotI_pUb_Em ........................................................................ 125 
Figure 3.8| Transduction efficency of the lentivirus NS1/NS2A conatining the leader 
sequence at different MOI ....................................................................... 128 
Figure 3.9| Transduction efficiency of K562 cells transduced by different lentiviral 
vectors containing the MESV leader sequence ........................................ 129 
Figure 3.10| Presence of the NS gene transcripts in K562 cells transduced with the 
lentiviral vector NS1/NS2A, NS3B/NS3, NS4A, NS4B and NS5 ....... 130 
 
 15 
 
Figure 3.11| Comparison of NS1 and NS5 protein levels in DENV replicon containing 
cells and in K562 transduced with the corresponding lentiviral vectors
 ............................................................................................................... 131 
Chapter 4 
Figure 4.1| STAT2 is degraded in the presence of DENV NS proteins expressed 
together but not separately ..................................................................... 139 
Figure 4.2| NS5 inhibits the induction of the IFN stimulated gene MX1 .................. 143 
Figure 4.3| NS5 inhibits the dose-dependent induction of ISGs ................................ 144 
Figure 4.4| NS5 inhibits cellular response to IFN- .................................................. 144 
Figure 4.5| The antiviral effect of IFN- is suppressed in NS5 expressing cells ...... 145 
Figure 4.6| NS5 inhibits STAT1 phosphorylation ..................................................... 146 
Figure 4.7| NS5 does not inhibit cellular response to IFN- ...................................... 148 
Figure 4.8| TSV01_NS5 inhibits cellular response to IFN-..................................... 151 
Chapter 5 
Figure 5.1| Schematic representation of the ubiquitination complex ......................... 161 
Figure 5.2| NS5 blocks STAT2 phosphorylation ....................................................... 165 
Figure 5.3| NS5 does not alter IFN- receptor levels on the cell surface .................. 166 
Figure 5.4| NS5 specifically binds the transcription factor STAT2 ........................... 170 
Figure 5.5| NS4B “BC-box” motif is conserved between the four serotypes of DENV
 ............................................................................................................... 174 
Figure 5.6| STAT2 is not degraded in cells transduced with DENV NS5+NS4B ..... 175 
Chapter 6 
Figure 6.1| Ribbon representation of DENV-2 NS5 MTase domain ......................... 184 
Figure 6.2| Ribbon representation of DENV-3 NS5 RdRp domain (amino acids 273-
900) ......................................................................................................... 185 
Figure 6.3| Schematic representation of DENV NS5 sequence and of the truncated 
versions generated in this study ............................................................. 188 
Figure 6.4| IFN- antagonism is mediated by the polymerase domain of NS5 ......... 189 
Figure 6.5| Deletion of the region 223-404 of NS5 RdRp restores cellular response to 
IFN- ....................................................................................................... 193 
Figure 6.6| Transduction of K562 cells with the region 223-404 alone or in association 
with NS5 MTase domain does not inhibit IFN- response ..................... 194 
Figure 6.7| IFN- antagonism does not require NS5 nuclear translocation ............... 197 
 16 
 
      List of Tables 
Chapter 1 
Table 1.1| Mechanism of inhibition of type I IFN signalling by different viruses....... 71 
Chapter 2 
Table 2.1| Primers employed for PCR amplification of DENV NS cassettes and for 
DNA sequencing ........................................................................................ 79 
Table 2.2| Reagent mix for High-Fidelity Phusion PCR .............................................. 80 
Table 2.3| Cycling conditions for High Fidelity Phusion PCR .................................... 80 
Table 2.4| Reagent mix for A-tailing reaction .............................................................. 83 
Table 2.5| Reagent mix for subcloning into pGEM®-T Easy vector ........................... 84 
Table 2.6| DNA mix for triple transfection of 293T cells ............................................ 92 
Table 2.7| Primers for amplification from cDNA of NS2B/NS3 and NS5 .................. 96 
Table 2.8| Reagent mix for PCR from cDNA .............................................................. 97 
Table 2.9| Cycling conditions for PCR from cDNA .................................................... 97 
Table 2.10| Primers employed for real time PCR ........................................................ 98 
Table 2.11| Cycling conditions for real time PCR ....................................................... 99 
Chapter 5 
Table 5.1| Combinations of NS proteins tested in order to study STAT2 degradation
 ................................................................................................................. 176 
 
 17 
 
Abbreviations 
ADE: Antibody Dependent Enhancement 
APC: Allophycocyanin 
APS: Ammonium Persulfate 
ATP: Adenosin Triphosphate 
bp: base pair 
BHK: Baby Hamster Kidney  
BSA: Bovine Serum Albumin 
C/EBP: CCAAT Enhancer Binding protein 
CBP: CREB Binding Protein 
CIP: Calf Intestine Phosphatase 
CK2: Casein Kinase 2 
CRD: Carbohydrate Recognition Domain 
CREB: cAMP Response Element Binding 
CRM: Chromosome Region Maintenance 
CT: Threshold cycle 
Da: Dalton 
DC: Dendritic Cell 
DC-SIGN: Dendritic Cell-Specific Intercellular Adhesion Molecule-3-Grabbing Non-
Integrin 
 18 
 
DDBP: Damage-specific DNA Binding Protein 
ddH2O: double distilled water 
DENV: Dengue Virus 
DF: Dengue Fever 
DHF: Dengue Haemorrhagic Fever 
DMEM: Dulbecco`s Modified Eagle Medium 
DMSO: Dimethyl sulfoxide 
dsRNA: double strand RNA 
DSS: Dengue Shock Syndrome 
DTT: Dithiothreitol 
ECL: Enhanced Chemiluminescence 
EDTA: ethylenediaminetetraacetic acid 
EGTA: Ethylene Glycol Tetra acetic Acid 
eIF2Eukaryotic translation initiation factor 2A 
ELISA Enzyme-Linked Immunoadsorbent Assay 
Em: Emerald 
EMCV: Encephalomyocarditis Virus 
ER: Endoplasmic Reticulum 
FACS: Fluorescence Activated Cell Sorting 
FcR: Fc Receptor 
FCS: Fetal Calf Serum 
 19 
 
GAPDH: Glyceraldehyde 3-Phosphate Dehydrogenase 
GFP: Green Fluorescent Protein 
GMP: guanosine monophosphate 
GPI: Glycosylphosphatidylinositol 
GRP: Glucose Regulated Protein 
HBSS: Hank's Buffered Salt Solution 
HBV: Hepatitis B Virus 
HCMV: Human Cytomagalovirus 
HEPES: 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HIV: Human Immunodeficiency Virus 
HLA: Human Leukocyte Antigen 
hnRNP: Heterogeneous nuclear ribonucleoprotein 
HRP: Horseradish Peroxidase 
HSP: Heat Shock Protein 
HSV: Herpes Simplex Virus 
IFN: Interferon 
IL: Interleukin 
IFNAR: IFN- Receptor 
IP: Immunoprecipitation 
IRF: Interferon Regulatory Factor 
ISG: Interferon Sensitive Genes 
 20 
 
ISGF: Interferon Stimulated Gene Factor 
ISRE: Interferon Stimulated Response Element 
IB: Inhibitor of NFB 
JAK: Janus Kinase 
JEV: Japanese Encephalitis Virus 
kb: kilobase 
KO: Knock Out 
LB: Luria Broth 
LGTV: Langat Virus 
LPS: Lipopolysaccharide 
LTR: Long Terminal Repeat 
MESV: Murine Embrionic Stem Cell Virus 
min: minute 
MLV: Murine Leukemia Virus 
MN: Mannose 
MOI: Multiplicity of Infection 
MTase: Methyltransferase 
MX: Mixovirus resistence gene 
NDV: Newcastle Disease Virus 
NES: Nuclear Export Signal 
NFB: Nuclear FactorB 
 21 
 
NGC: New Guinea C 
NK: Natural Killer 
NLS: Nuclear Localisation Signal 
NS: Non-Structural 
OAS: 2'-5'-oligoadenylate synthetase 
OD: Optical Density 
ORF: Open Reading Frame 
PAGE: Poly Acrylammide Gel Elecrophoresis 
PAMP: Pathogen-Associated Molecular Pattern 
PBS: Phosphate Buffered Saline 
PCR: Polymerase Chain Reaction 
PE: Phycoerythrin 
pfu: plaque forming unit 
PKR: Protein Kinase R 
PMSF: Phenylmethanesulfonylfluoride 
PPT: Poly Purine Tract 
PRR: Pattern Recognition Receptor 
PVDF: Polyvinylidine Fluoride  
PVP: Polyvinylpyrrolidone 
Rbx: Ring finger protein 
RdRp: RNA dependent RNA polymerase 
 22 
 
RER: Rough Endoplasmic Reticulum 
rpm: rotations per minute 
RPMI: Roswell Park Memorial Institute 
RRE: Rev Responsive Elements 
RSV: Respiratory Syncytial Virus 
RT: Reverse Transcription; Real Time 
RTPase: RNA Triphosphatase 
SDS: Sodium Dodecyl Sulfate 
SFFV: Spleen Focus-Forming Virus 
SH2: Src Homology 
SOCS: Suppressor Of Cytokine Signalling 
TAE: Tris Acetate EDTA 
TBEV: Tick Borne Encephalitis Virus 
TBS: Tris Buffered Saline 
TEMED: Tetramethylethylenediamine 
Tm: Melting temperature 
TMB: Tetramethylbenzidine 
TNF: Tumor Necrosis Factor 
Tyk: Tyrosin Kinase 
Ubi: Ubiquitin 
UTR: Untranslated Region 
 23 
 
UV: Ultraviolet 
VSV: Vesicular Stomatitis Virus 
WHO: World Health Organization 
WNV: West Nile Virus 
WPRE: Woodchuck hepatitis virus Post-transcriptional Regulatory Element 
YFV: Yellow Fever Virus 
 24 
 
 
 
 
 
 
 
 
 
Chapter 1.  
                INTRODUCTION 
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1.1 EVOLUTION AND SOCIAL IMPACT OF 
DENGUE VIRUS 
The dengue viruses (DENVs) constitute a group of mosquito-borne flaviviruses, 
characterised by a positive single-strand RNA genome surrounded by 
nucleocapsid and lipid envelope. DENVs are one of the main causes of arboviral 
diseases in tropical and subtropical countries, and 3.5 billion people worldwide 
are currently at risk for DENV infection (Kyle and Harris 2008). WHO currently 
estimates that there may be 50 million DENV infections worldwide each year, 
with 500,000 people hospitalised for dengue haemorrhagic fever (DHF), the most 
severe form of dengue disease (WHO 2009). Dengue and dengue haemorrhagic 
fever, fact sheet N˚117, March 2009). DENV is responsible for more than 24,000 
deaths per year, mainly amongst children under 15 years old (Gibbons and 
Vaughn 2002), and since the 1950s, the incidence of DHF has increased over 500-
fold (Kyle and Harris 2008). The increasing incidence and severity of dengue 
episodes go along with failure of mosquito containing measures and with the 
unavailability of vaccines and antiviral therapies. After more than 50 years of 
research, dengue remains an alarming public health problem, with high economic 
and social impact, weighing heavily on the financial and human resources of 
developing countries. 
1.1.1 Epidemiology of dengue  
There is no consensus about when dengue first appeared in the human 
population. Descriptions of an illness clinically compatible with dengue fever 
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(DF) can be found in a Chinese Medical Encyclopaedia dating back to 992 A.D 
(Gubler 1998). Late in the XVIII century, a disease strongly resembling dengue 
was causing intermittent epidemics in Asia and America, but it was only during 
the XIX and XX centuries that the disease widely spread in tropical and 
subtropical regions (Hayes and Gubler 1992; Monath 1994). After the Second 
World War, a new dengue-associated disease, DHF, was reported in endemically 
infected areas in Southeast Asia (HAMMON et al. 1960). The first well 
documented outbreak of DHF occurred in Manila in 1953-1954 (HAMMON et al. 
1960), followed by a larger outbreak in Bangkok in 1958 (Halstead 1980b); since 
then, DHF has become endemic in all countries in Southeast Asia (Holmes and 
Twiddy 2003). Despite intensive mosquito control measures, DHF now represents 
a significant health problem in the Americas (Guzman et al. 1984a; Guzman et al. 
1984b). Although major epidemics are less commonly reported in Africa, due to 
the extremely poor surveillance the presence of dengue in this continent is not 
clear (Holmes and Twiddy 2003). 
 
Dengue epidemics are strongly correlated with demographic and societal changes. 
In the last 60 years the population in the tropics has grown rapidly, leading to 
uncontrolled urbanisation. In most large cities, inadequate management of water 
and waste has provided additional breeding sides for the mosquito vectors, 
promoting co-circulation of multiple virus strains (Gubler 1998; Gibbons and 
Vaughn 2002). In 2004, Cummings and colleagues provided evidence that urban 
environments promote the generation of new epidemic strains, demonstrating the 
existence of epidemic waves of dengue that originate in Bangkok and spread 
throughout Thailand every three years (Cummings et al. 2004). Further, while in 
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the past sporadic introductions of new strains were brought only by sea travel, air 
travel now enables infected people to act as proper human vectors, importing 
viruses into non-endemic areas (Rosen 1977; Gubler 1998; Gibbons and Vaughn 
2002).  
In the future, global warming is expected to shift the spectrum of many infectious 
diseases, especially those transmitted by insects. Even though there is no 
consensus about the impact of global warming on dengue diffusion, the 
distribution of the Aedes mosquito, the main vector of DENV, is strictly regulated 
by climate: should the planet become warmer, DENV is likely to spread beyond 
the current subtropical areas. A 2˚C increase in temperature would also lengthen 
the mosquito lifespan, resulting in more infected vectors for a longer period of 
time (Kyle and Harris 2008).  
1.1.2 Phylogeny of DENV  
Amongst the mosquito-borne flaviviruses, DENV falls into a distinct serogroup 
that is phylogenetically related to the Japanese encephalitis serogroup and yellow 
fever virus (YFV) (Kuno et al. 1998).  
The most recent common ancestor of DENV serogroup is estimated to have 
originated about 1000 years ago (Twiddy et al. 2003). Today there are four 
distinct serotypes of DENV: DENV-1, DENV-2, DENV-3 and DENV-4. Within 
each serotype, a group of DENVs “having no more than 6% sequence divergence 
over a chosen interval” is defined as a genotype (Rico-Hesse 1990). Based on 
sequences of the envelope (E) gene or of the E-NS1 boundary, DENV-1 is further 
divided into four to five genotypes, DENV-2 into six, DENV-3 into four, and 
DENV-4 into two (reviewed in Kyle and Harris 2008).  
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DENV was originally a sylvatic pathogen mainly infecting non-human primates 
(Wang et al. 2000). When the human population was sufficiently large to sustain 
viral transmission, sporadic outbreaks in humans could occur following 
encroachments into the forest habitat. The first strains able to infect humans 
probably became extinct once the supply of susceptible hosts was exhausted, and 
this has probably been the case for most virus strains causing dengue outbreaks 
before urbanisation (Wolfe et al. 2001; Twiddy et al. 2003).  
Some hypotheses suggest that the four serotypes evolved within a single 
population due to natural selection: according to these theories, distinct serotypes 
would constitute an evolutionary advantage because of the antibody-dependent 
enhancement phenomenon (ADE, see section 1.3.2.3), which actively promotes 
secondary infection by different serotypes. However, if genetic diversity were 
mainly dependent on ADE, than the virus would be expected to be subject to 
continual immune selection pressure: studies on natural selection in DENV show 
that this is not the case and it is now believed that the four serotypes have evolved 
independently, and that ADE is more likely to be a consequence rather than the 
cause of their existence (Holmes and Twiddy 2003). Over the past 200 years, 
genetic diversity within each serotype has risen dramatically, and understanding 
the rate at which such diversity is changing and whether specific determinants 
exert selection pressure on DENV evolution could be critical to predict changes of 
virulence and to design more efficient control strategies.
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1.2 STRUCTURE AND REPLICATION OF DENGUE 
VIRUS 
1.2.1 Transmission cycle 
DENV replication and spread is perpetuated by a circular transmission cycle 
involving humans and Aedes species mosquitoes (Aedes aegypti, Aedes 
albopictus, Aedes polynesiensis) (Smith 1956). The mosquito remains infected for 
life, but the virus is only known to cause illness in humans (Gibbons and Vaughn 
2002). Aedes mosquitoes are dispersed worldwide between latitudes 35ºN and 
35ºS. They live in close proximity to humans, and feed preferentially on human 
blood. Differently from Anopheles mosquitoes -the malaria vector-, Aedes are 
daytime feeders and their bite is imperceptible; they rest indoors and this 
maximises human-vector contact, and also minimises contact with insecticides 
(Gibbons and Vaughn 2002; Weaver and Barrett 2004). 
 Aedes aegypti probably spread from jungles of Africa throughout the rest of the 
world via slave and trading ships between the seventeenth and the nineteenth 
centuries (Smith 1956; Bosinger et al. 2009). Aedes albopictus is a secondary 
vector of DENV in Southeast Asia, the Western Pacific and, increasingly, in 
Central and South America (Gratz 2004). In recent decades A. albopictus has 
spread in North America, probably from Japan, and its range stretches farther 
North than A. aegypti (Hawley et al. 1987; Gratz 2004). Eggs are resistant to 
subfreezing temperatures and this raises the possibility that A. albopictus could 
mediate a re-emergence of dengue in the United States or in Europe (Hawley et 
al. 1987).  
 30 
DENV replicates in the salivary glands of adult female mosquitoes, reaches the 
blood stream, and through it it gains access to different tissues (nervous system, 
gut, epidermal cells, ovary). Infected mosquitoes transmit the virus to humans by 
biting: since DENV infects organs controlling feeding-associated activities, 
infected mosquitoes take longer to complete a blood meal compared with 
uninfected ones, and as the slightest movement interrupts feeding, several people 
may be bitten in a very short period of time (Platt et al. 1997).  
Once in the human host, DENV replicates efficiently and at very high rate, 
reaching high enough titres to be transmitted to another mosquito through a blood 
meal. 
1.2.2 Target cells of DENV infection in human 
Several cell types have been shown to support DENV replication in vitro, but 
the target of DENV infection in vivo is still a matter of speculation. Mosquito 
vectors release DENV in the skin during a blood meal and several studies have 
shown that dendritic cells in the epidermis and dermis are the first cells 
encountering the virus and able to support viral replication (Wu et al. 2000; 
Libraty et al. 2001). Even though for a long time monocytes and macrophages 
have been suggested to be the main target of DENV infection (Halstead et al. 
1977a), Wu and colleagues showed that at a multiplicity of infection (MOI) of 
0.2, 25-40% of immature monocyte-derived DCs are infected in vitro with 
DENV; in contrast, exposure of macrophages from the same donor resulted in 1-
2% of infected cells, while neither purified B lymphocytes nor T lymphocytes 
were infected (Wu et al. 2000). Immature DCs are highly permissive to DENV 
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infection, whereas mature DCs are relatively resistant (Wu et al. 2000). Different 
expression of DENV receptor DC-SIGN (see section 1.2.3.1) may provide an 
explanation for this, since immature DCs express higher DC-SIGN density on 
their surface than mature DCs.  
After infection by DENV-2 New Guinea C (NGC) strain, monocyte-derived 
DCs provide an efficient replication site for the virus (Ho et al. 2001). 24 hours 
after infection, virus particles can be detected in cytoplasmic vesicles, vacuoles 
and endoplasmic reticulum (ER), where they induce hypertrophy of the rough ER 
(RER), as well as swollen mitochondria. After 48 hours, virus particles are found 
outside the cell (Ho et al. 2001).  
DCs have been called “sentinels” of the immune system, as they capture and 
process microbial products and finally present them to the effector cells of the 
adaptive immune response (Palucka 2000). Several studies suggest that the 
activation of DENV-infected immature DCs is blunted compared with the 
surrounding uninfected cells, with lower expression of maturation markers 
compared with bystander cells (Libraty et al. 2001) and reduced capacity to 
stimulate T-cells in co-culture (Palmer et al. 2005). Impaired activation of 
infected DC suggests a possible mechanism of evasion of the immune system, but 
the exact role of DC in DENV pathogenesis is not clear and further studies are 
required. 
Liver dysfunction in DENV infection has been correlated to DHF severity 
(Wahid et al. 2000) and several lines of evidence show that DENV directly 
invades the liver (Kuo et al. 1992; Hilgard and Stockert 2000). Liver cells have 
been suggested to be one of the major sites of viral replication (Thepparit and 
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Smith 2004), but besides the identification of some moieties involved in DENV 
entry, little information is available on the interaction between DENV and 
hepatocytes. 
1.2.3 DENV life cycle 
The major steps in the DENV life cycle can be briefly summarised as follows 
(Figure 1.1): 
 DENV virions attach to the host surface and enter the cell in endocytic 
vesicles; 
 conformational changes induce fusion between the viral membrane and the 
endocytic vesicle, and the viral genome is released into the cytoplasm;  
 the positive-sense RNA is translated into a polyprotein, which is co- and post-
translationally modified to generate 3 structural and 7 non-structural (NS) viral 
proteins; 
 viral RNA is replicated, providing both new templates for replication and 
genomes for packaging into new virions; 
 virions assemble on the ER surface, mature in the Golgi, and are released via 
exocytosis outside of the cell.  
1.2.3.1 Fusion and entry 
DENV infectious particles consist of an external glycoprotein shell and an 
internal host-derived lipid bilayer, which surrounds the RNA genome and the 
capsid proteins (core). The glycoprotein shell consists of 180 copies each of the 
envelope glycoprotein E, which has been shown to be essential to viral infection 
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Figure 1.1|  
Schematic diagram of DENV replication cycle. After binding, the DENV 
virion is internalised in an endosomal vesicle. Fusion between viral and 
endosomal membranes is followed by release of the RNA genome in the 
cytoplasm. The positive strand RNA can be immediately translated into a 
polyprotein and processed into individual proteins. Some of these proteins are 
involved in virus RNA replication and subsequent production of new virions. 
Structural proteins and RNA assemble in new virion particles in the ER and 
mature in the Golgi network. Mature virions are released via exocytosis (from 
Perera et al. 2008). 
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 (Perera and Kuhn 2008; Yu et al. 2008). 
The cell entry mechanism of DENV is still under investigation. The first contact  
between DENV infectious particles and the cell surface is mediated by the 
interaction between DENV envelope glycoprotein E and cellular proteins or 
carbohydrate molecules on the host surface (Hung et al. 1999). DENV E protein 
is organised in dimers. Each monomer is composed of three -barrel domains 
(Figure 1.2, A-B). Domain I is the central structural domain, domain II contains 
the fusion peptide, critical for the release of DENV nucleocapsid into the 
cytoplasm after endocytosis, and domain III is an immunoglobulin-like domain 
containing putative receptor-binding sites (Crill and Roehrig 2001). 
The literature abounds with descriptions of putative ligands on different host 
cells and for different DENV serotypes and it is possible that DENV exploits 
different molecules/mechanisms to enter different cell types. Heparan sulphates 
(Hilgard and Stockert 2000; Germi et al. 2002), Heat Shock Protein 70 (HSP70) 
and Heat Shock Protein 90 (HSP90) (Reyes-Del Valle et al. 2005; Cabrera-
Hernandez et al. 2007), GRP78/Bip (Jindadamrongwech et al. 2004), CD14 
(Chen et al. 1999), and laminin receptor (Thepparit and Smith 2004) have all been 
implicated in viral entry, but only DC-SIGN and the mannose receptor (MN) have 
been shown to play an active role. The four serotypes of DENV have all been 
shown to bind C-type lectin receptors. DC-SIGN (DC Specific ICAM-3 Grabbing 
Non-integrin) is a membrane protein on DC surface, carrying an external 
mannose-binding C-type lectin domain. DC-SIGN carbohydrate-recognition 
domains (CRD) on DENV E protein bind mannose residues within DC-SIGN on 
DCs (Tassaneetrithep et al. 2003; Navarro-Sanchez et al. 2003) and the 
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interaction is sufficient for viral infection. Lozach and colleagues (Lozach et al. 
2005) showed that internalisation of DC-SIGN is not necessary for DENV 
infectivity and probably DC-SIGN does not function as a specific receptor but 
allows virus attachment on cell surface. A second type of C-type lectin receptor, 
the mannose receptor (MR), is also recognised by all DENV serotypes (Miller et 
al. 2008). Since the MR is constitutively internalised, the authors suggest that, 
differently from DC-SIGN, the MR could work as a proper DENV receptor rather 
than just as an attachment molecule (Miller et al. 2008). 
A different mechanism of viral entry exploits Fc receptors (FcR) on the 
surface of cells of the immune system: this phenomenon, called antibody-
dependent enhancement (ADE) (Halstead et al. 1970) has been suggested to be a 
critical determinant of DHF in secondary infections, and it will be described more 
extensively in section 1.3.2.3. Interestingly, Boonnak et al (Boonnak et al. 2008) 
showed that mature DC infectability is higher in ADE conditions, but when 
sufficient levels of DENV receptors are expressed, ADE-independent mechanisms 
of cell entry are preferentially used.  
Attachment of DENV on the cell surface is followed by endosomal uptake 
(Modis et al. 2004). Recent studies indicate that DENV enters the cell via 
clathrin-mediated endocytosis. A recent study performed on African green 
monkey kidney cells shows that virus particles bind and move along the cell 
surface in a diffusive manner -either as virus-receptor complexes, or rolling over 
multiple receptors along the cell surface- and then associate to clathrin-coated 
pits. Shortly after, the clathrin spot matures into a clathrin vesicle and delivers the  
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Figure 1.2|  
Organisation, membrane fusion and maturation of DENV E 
protein. 
A-B. Diagrams of DENV E protein ectodomains, side (A) and top (B) 
view. E-H1, E-H2 and E-T1, E-T2 (in blue) represent the stem (H) and 
transmembrane (T) helices of the E protein; M-H1, M-H2 and M-T1, 
M-T2 (in orange) represent the stem and transmembrane helices of the 
M protein. C. Rearrangement of DENV virions during membrane 
fusion. The E protein dimers on the mature virion (left) undergo a 
rearrangement to form the fusogenic intermediate structure (right). The 
solid triangle indicates the position of a quasi three-fold axis, while the 
arrows indicate the direction of the E rotation (adapted from 
Mukhopadhyay et al. 2005). D. Maturation process of DENV virion. 
The E proteins, organised in trimers in the immature virion (left) 
rearrange into dimers to form the mature viral particle (right). 
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virus to early endosomes in the cytoplasm (van der Schaar et al. 2008). 
After mediating virus attachment to the cell surface and internalisation, the next 
 major role for DENV E protein is the release of the nucleocapsid into the 
cytoplasm. Low pH in the endosome causes the dissociation of the E dimers into 
monomers, and their irreversible re-association into trimers (Figure 1.2 C). In the 
new conformation, the three fusion peptides, previously buried between domain I 
and III, are finally exposed on the top of the trimer and can penetrate the 
endosomal membrane (Modis et al. 2004).  
Fusion between virion and endosomal membranes results in release of the viral 
nucleocapsid into the cytoplasm. What happens to the nucleocapsid immediately 
after is not known, and the precise mechanism of release of the RNA genome is 
still under investigation. 
1.2.3.2 Genome organisation 
The DENV genome (Figure 1.3, A) consists of a positive single-stranded RNA 
molecule of about 11kb, containing a 5` untranslated region (UTR; ~100 
nucleotides), a single open reading frame (ORF) encoding the viral polyprotein, 
and a 3` UTR (~400 nucleotides). A 7-methyl guanosine cap structure covers the 
5` end but, unlike cellular mRNAs, the DENV genome is not 3` polyadenylated 
(Bartenschlager and Miller 2008). Both the 5`UTR and the 3` terminal region of 
the 3` UTR contain complementary cyclisation sequences which play critical roles 
in the replication of the negative strand mRNA molecule, as described in section 
1.2.3.4 (Henchal and Putnak 1990; Khromykh et al. 2001; Alvarez et al. 2005). 
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Figure 1.3| 
Schematic representation of DENV genome (A) and predicted membrane 
topology of DENV polyprotein (B). The ~11 kb genome of DENV is translated 
into a single polyprotein which traverses the ER membrane at several positions. 
PrM, E, NS1 and part of NS4A and NS4B are thought to localise to the ER lumen 
via hydrophobic signal sequences, whereas the remaining proteins are thought to 
localise on the cytoplasmic side of the ER. Arrows represent the polyprotein 
cleavage sites recognised by viral or host proteases, as indicated by different 
colours. 
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1.2.3.3 Genome translation 
Being positive sense, DENV RNA genome can be directly translated. When the 
RNA-ribosome complex encounters the hydrophobic signal sequence at the C-
terminus of the capsid protein, the polyprotein is directed to the endoplasmic 
reticulum (ER). Signal sequences within the nascent polyprotein translocate NS1 
and the ectodomain of prM and E into the lumen of the ER; the C protein, NS3 
and NS5 localise in the cytoplasm (Figure 1.3, B) and NS2A, NS2B, NS4A and 
NS4B remain predominantly transmembrane. The anchoring process regulates the 
start of the proteolytic processing (Markoff et al. 1994). Processing of the 
polyprotein occurs before the translation is completed and is carried out by both 
host proteases in the lumen of the ER, and the viral protease NS3 and its cofactor 
NS2B (Falgout et al. 1991; Falgout and Markoff 1995). Between C and prM, prM 
and E, and between NS4A and NS4B, the proteolytic cleavage is mediated by host 
enzyme signal peptidases, while the serine protease domain of NS3 cleaves the 
polyprotein between NS2A and NS2B, NS2B and NS3, NS3 and NS4A, NS4B 
and NS5, and some other residues within its own C-terminus domain (Falgout et 
al. 1991; Zhang et al. 1992). 
 
1.2.3.4 Genome replication 
About three hours after infection, RNA replication can be detected in the 
perinuclear region of infected cells, in association with smooth membranes. 
Positive strand RNA viruses replicate in close association with virus-induced 
intracellular membranous structures: these structures provide a scaffold for the 
replication complex and increase the local concentration of all components 
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required (Bartenschlager and Miller 2008). An interesting hypothesis suggests that 
these membranes may also prevent the activation of double strand RNA (dsRNA)-
induced host defence mechanisms and interferon production (Bartenschlager and 
Miller 2008). In DENV infected cells membrane alterations seem to be actively 
induced by the non-structural protein NS4A (Miller et al. 2007), which would also 
anchor the replication complex to such membranes (Lindenbach and Rice 1999). 
The RNA-dependent RNA polymerase (RdRp) of DENV NS5 binds to a stem-
loop structure in the 5` UTR and it is transferred to the transcription initiation site 
at the 3` end of the genome by 5`-3` long range interactions (Filomatori et al. 
2006) (see section 1.2.3.2). Cyclisation of the viral genome is therefore crucial for 
viral replication and it may be a control mechanism to ensure that only full length 
templates are amplified (Bartenschlager and Miller 2008). The replication starts 
with the synthesis of a negative strand RNA. The replicative product, called 
replicative form, is a full-length, double-stranded RNA. The negative strand of the 
replicative form functions as a template for the generation of new positive RNA 
strands; the partially double stranded RNA formed during the elongation of the 
nascent positive strain is called replicative intermediate. The helicase domain of 
DENV NS3 helps the dissociation of the nascent RNA strand from its template 
and the relaxation of RNA secondary structures (Gorbalenya et al. 1989). The 
newly produced positive strand is then released from the replicative intermediate 
and either attaches to ribosomes to undergo a new translation cycle, or assembles 
into new virions in the ER (reviewed in Bartenschlager and Miller 2008).  
DENV proteins NS1, NS2A and NS4B have also been suggested to take part in 
viral replication: NS1 is assumed to act at an early stage of viral replication, but 
its precise function is not known, NS2A has been suggested to anchor the viral 
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replicase to cellular membranes and to recruit the RNA template (Mackenzie et al. 
1998; Bartenschlager and Miller 2008), and NS4B might help the dissociation 
between the viral RNA and the helicase NS3 (Umareddy et al. 2006). The role of 
DENV NS proteins will be further discussed in section 1.2.4. 
Finally, after RNA replication, a cap is added at the 5` terminus of the positive 
strand RNA molecule. The addition of a cap is a three stage process involving 
both NS3 and NS5. The RNA-5`-triphosphatase (RTPase) activity of NS3 is 
responsible for the cleavage of the 5`-triphosphate terminus and for the 
subsequent addition of GMP to the 5`-diphosphate (Bartelma and Padmanabhan 
2002); the methyltransferase domain of NS5 is responsible for the methylation of 
the 5`GMP at the N
7
 position first, and then at the ribose 2`O (Egloff et al. 2002). 
1.2.3.5 Virion assembly and release  
Particle formation is a coordinated process involving the membrane-associated 
capsid proteins C and the prM-E heterodimer in the ER. The membrane-bound 
capsid proteins (C) are organised in dimeric structures which constitute the 
building blocks for the assembly of the nucleocapsid (one molecule of RNA and 
multiple C proteins). The basic, positively charged composition of the 
nucleocapsid suggests that the C proteins may function like histones (Ma et al. 
2004).  
The nucleocapsid and the prM-E heterodimers assemble in the ER, and the 
complex acquires an envelope from the intra-cytoplasmatic membrane (Henchal 
and Putnak 1990; Mukhopadhyay et al. 2005). Immature particles display 60 
prominent and irregular spikes on their surface, each spike consisting of a trimer 
of prM-E heterodimers. The prM proteins cap the fusion peptides on the E 
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proteins and protect the virus from premature fusion before release (Yu et al. 
2008; Li et al. 2008). Depending on the pH of the cellular environment, the 
immature particle can exist reversibly in either “spiky” (pH 7) or “smooth” (pH 6) 
forms. During the maturation process, due to the low pH-conditions in the trans 
Golgi network, the prM proteins expose a furin cleavage site and the pr peptides 
are irreversibly cleaved. As a consequence, the trimer is disrupted and the E 
proteins rearrange in the characteristic and irreversible mature conformation, with 
90 heterodimers lying flat on the viral surface (Figure 1.2, D) (Mukhopadhyay et 
al. 2005). The pr peptides, which are still associated to the M-E complex, 
dissociate only when the virion is released into the neutral pH of cellular 
environment (Yu et al. 2008; Li et al. 2008). Immature virions are highly stable 
and relatively inert, but the final cleavage step makes the virus more labile and 
flexible for the subsequent penetration of the host cell. The dimers formed by the 
E proteins organise in parallel groups of three, with the putative receptor-binding 
domain protruding from the surface, ready for binding cellular receptors.  
Release of virus from infected cells occurs via secretory exocytosis: the vesicles 
fuse with the plasma membrane of the host and mature virions are released 
outside of the cell (Henchal and Putnak 1990). 
1.2.4 DENV non-structural proteins 
The precise function of most of the non-structural proteins of DENV is still 
obscure and many effects of viral infection have not been correlated to specific 
proteins yet. Structural information is available for NS3/NS2B and NS5 only. 
Diverse functions have been attributed to each DENV NS protein, but only few 
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observations have been reproduced and validated. In spite of little information, the 
literature suggests that most NS proteins are able to perform multiple functions, in 
order to sustain efficient proliferation and, at the same time, to successfully evade 
the main cellular mechanisms of antiviral defence. 
1.2.4.1 NS1/NS2A 
NS1 is a glycoprotein of 40-46 kilodalton (kDa). Newly synthesised NS1 
appears in the lumen as a monomer but it dimerises after 20-40 minutes without 
intervention of other proteins (Falgout et al. 1989). The N-terminal of NS1 is 
preceded by a localisation signal of 24 hydrophobic amino acids that leads the 
protein to the endoplasmic reticulum (ER) and is then cleaved. The localisation 
signal is followed by a group of charged residues, and by a second hydrophobic 
sequence of 14 amino acids acting as a stop-transfer (Falgout et al. 1989). The 
correct localisation of NS1 in the ER is critical for the subsequent attachment of 
two N-linked high mannose carbohydrate moieties; in the Golgi one of the two 
carbohydrates is trimmed and processed to a complex form (Jacobs et al. 2000).  
NS1 is found intracellularly, on cell surface and, as soluble form, it is also 
released extracellularly. The role of intracellular NS1 is still unclear: its 
association with the RNA genome (Mackenzie et al. 1996) and with hnRNP 
C1/C2 (human heterogenous nuclear ribonucleoprotein), involved in mRNA 
biogenesis (Noisakran et al. 2008), together with its co-localisation with other 
DENV NS proteins involved in viral replication (Mackenzie et al. 1998), suggests 
a role for NS1 in RNA replication, as mentioned in section 1.2.3.4.  
Transmembrane NS1 has been observed to mimic cellular mechanisms of 
signal transduction. NS1 can be anchored to the host membrane via a glycosyl-
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phosphatidylinositole (GPI) anchor. The N-terminal of NS2A can act as GPI 
anchor signal for NS1, and internal cleavages within NS2A occurring during the 
processing of the viral polyprotein determine whether NS1 will acquire the GPI 
anchor or not (Jacobs et al. 2000). The precise role of GPI anchors remains 
uncertain, but they are implicated in signal transduction and confer on proteins the 
ability to transfer between plasma membranes of different cells. Jacobs and 
colleagues showed that binding of anti-NS1 antibodies to NS1 proteins anchored 
on the cell surface initiates a signal transduction cascade leading to tyrosine 
phosphorylation of a number of cellular proteins. The precise consequences of 
such activation on DENV life cycle are not known, but the authors suggest that 
signal transduction by NS1 could promote cellular activation and in turn increase 
production of viral progeny (Jacobs et al. 2000).  
Up to 10 g/ml of a soluble hexameric form of NS1 can be found in the blood of 
DENV infected people (Alcon-LePoder et al. 2005). Whether extracellular NS1 
has any specific role is not clear, but soluble NS1 can activate to completion the 
complement system, inducing cell damage and vascular leakage in DHF 
(Avirutnan et al. 2006). The role of NS1 and of antibodies elicited against NS1 in 
DENV pathogenesis will be further discussed in section 1.3.3.  
The precise role of NS2A remains unclear. Besides the role mentioned above in 
helping NS1 correct localisation in the ER and the acquisition of a GPI anchor, 
NS2A has been suggested to take part in viral replication (see section 1.2.3.4), but 
its precise function has not be identified. 
1.2.4.2 NS2B/NS3 
NS3 is a 69 kDa multifunctional protein with protease, helicase and capping 
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activities. The protease domain localises at the N-terminus of NS3 and is 
required for the processing of DENV polyprotein. NS2B is required for the 
optimal activity of NS3, as its central region completes the substrate-binding site 
of NS3 (Erbel et al. 2006). The catalytic triad (His-51, Asp-75, Ser-135) is buried 
between -barrel structures and hydrolysis occurs after a pair of basic residues 
(Lys-Arg, Arg-Arg, or Arg-Lys), followed by a small side chain amino acid (Gly, 
Ser, or Ala) (Luo et al. 2008). The substrate specificity of NS2B/NS3 has not 
been extensively studied but Shafee et al (Shafee and AbuBakar 2003) suggest 
that cleavages may occur also on substrates other than the viral polyprotein. In 
this work apoptosis is observed in cells transfected with a functional NS2B/NS3 
complex: this suggested that cleavage of apoptosis initiators or antagonism of 
apoptosis inhibitors by DENV NS3 might activate effector caspases and induce 
apoptosis.  
The C-terminus portion of NS3 (amino acids 170-619) performs different 
related activities, including the NTPase/helicase activity and the RTPase activity 
(section 1.2.3.4). The helicase separates the nascent RNA strands from the 
template and assists replication initiation by unwinding RNA secondary structures 
in the 3`UTR (Gorbalenya et al. 1989). The energy required is provided by the 
nucleotide-triphosphatase (NTPase) activity, which hydrolyse NTP -
phosphates. The RNA-5`-triphosphatase (RTPase) is involved in the first step of 
the RNA capping described in section 1.2.3.4 (Bartelma and Padmanabhan 2002). 
During RNA replication, NS3 interacts with the hypophosphorylated form of 
DENV NS5, and such interaction stimulates both the NTPase and the RTPase 
(Yon et al. 2005). 
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1.2.4.3 NS4A 
NS4A is one of the least characterised proteins of DENV. The last 23 amino 
acids in the C-terminus of NS4A (2K fragment) act as a signal for the 
translocation of NS4B into the ER lumen, and are then removed by a host 
signalase (Miller et al. 2007). NS4A is the smallest of DENV proteins, highly 
hydrophobic and therefore tightly associated with cellular membranes. The first 
49 amino acids at the N-terminus are exposed in the cytoplasm, while four highly 
hydrophobic transmembrane regions anchor NS4A to ER-derived cytoplasmic 
dot-like structures (Miller et al. 2007). As mentioned in section 1.2.3.4, NS4A 
seems to be responsible for the generation of such cytoplasmic membrane 
structures, particularly following removal of the 2K fragment (Miller et al. 2007). 
As outlined in section 1.2.3.4, these same structures also contain dsRNA and 
DENV NS proteins involved in viral replication, suggesting that NS4A might re-
organise cellular membranes in order to create the subcellular structures required 
for DENV replication (Miller et al. 2007). 
1.2.4.4 NS4B 
NS4B is a hydrophobic non-structural protein of 248 amino acids (27 kDa) 
(Miller et al. 2006). Immediately after synthesis, NS4B is found in perinuclear 
regions of the cell in a pattern resembling the ER, and later on large NS4B foci 
are visible all throughout the cytoplasm. NS4B localises in the ER membrane, 
directed by the 2K fragment at the C-terminus of NS4A. The N-terminal region 
lies in the ER lumen while the C terminus is cytoplasmic; the rest of the protein is 
constituted of transmembrane hydrophobic domains (Miller et al. 2007). Yeast 
two-hybrid assays and immunoprecipitation studies have shown the association 
between NS4B and the NS3-NS5 complex (Umareddy et al. 2006). Full length 
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NS4B has been shown to interact with the C-terminal region of NS3 
encompassing the helicase motif. As mentioned in section 1.2.3.4, this 
observation suggests a role for NS4B in viral replication, by helping the 
dissociation of the NS3 helicase from the RNA, and enabling binding of another 
duplex. Alternatively, NS4B might hold the separated RNA strand apart as the 
replication complex moves along the duplex (Umareddy et al. 2006). 
Together with NS4A and NS2A, NS4B has also been suggested to take part in 
IFN antagonism (Munoz-Jordan et al. 2003). Since the evasion of the IFN 
response by DENV constitutes the focus of this thesis, the role of NS4B and other 
non-structural proteins in the inhibition of IFN will be further discussed later. 
1.2.4.5 NS5 
NS5 (104 kDa) is the biggest non structural protein of DENV and the most 
conserved amongst flaviviruses. Across the four DENV serotypes, NS5 shares a 
minimum of 67% amino acid sequence identity (Yap et al. 2007). 
Based on structural and biochemical studies, two functional domains have been 
identified. The N-terminal domain (amino acid residues 1-260) is an S-adenosyl 
methionine methyltransferase (MTase) which takes part in DENV genome 
capping, catalysing the sequential binding of two methyl groups from an S-
adenosyl methionine to the 5’ GMP of any new molecule of viral mRNA (section 
1.2.3.4) (Egloff et al. 2002; Zhou et al. 2007). The C-terminal region is the viral 
RNA-dependent RNA polymerase (RdRp) which synthesises a transient double-
stranded RNA intermediate and then additional plus-strand genomic RNAs. The 
crystal structure of DENV RdRp catalytic domain has been determined (Yap et al. 
2007). The architecture of NS5 RdRp resembles the typical pattern of known 
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polymerases, consisting of fingers, palm and thumb. Between the amino acids 320 
and 405, two nuclear localisation sequences (NLS) have been mapped, both 
recognised by the importin system (Forwood et al. 1999; Johansson et al. 2001; 
Brooks et al. 2002; Pryor et al. 2007). Transport into the nucleus of proteins 
bigger than 45 kDa requires intrinsic targeting signals recognised by the importin 
complex. The importing system starts with the binding of -importin to the 
NLS; this induces the recruitment of importin- and its conformational change. 
-importin binds -NLS and the target protein is translocated into the nucleus 
in a GTP-dependant process (Brooks et al. 2002). While DENV-1 carries only one 
NLS, DENV-2, DENV-3 and DENV-4 have a bipartite NLS (320-368; 369-389): 
the first cluster seems to be critical for the interaction with NS3 (residues 312-332 
are almost completely conserved between all strains) while the second (residues 
369-389) is critical for nuclear localisation and carries the typical pattern of three 
basic clusters of most NLSs (K371-K372; K388-K389; R401-K402) (Brooks et 
al. 2002; Pryor et al. 2007). It has been shown that NS5 contains also a nuclear 
export signal (NES; amino acids 327-343) that uses the cellular CRM1 exportin 
complex to translocate from the nucleus to the cytoplasm (Pryor et al. 2006). Such 
a mechanism seems to prevent nuclear accumulation of NS5 but the consequences 
and the biological significance of this shuttling between nucleus and cytoplasm 
have not been elucidated.  
Cellular localisation of NS5 seems to be dependent on its phosphorylation 
status. A low phosphorylated form localises in the cytoplasm, where it interacts 
with DENV NS3 and takes part in the replication of the viral genome; a high 
phosphorylated form dissociates from NS3 and translocates into the nucleus 
(Kapoor et al. 1995; Johansson et al. 2001). Even though phosphorylation induces 
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NS5 nuclear translocation, protein kinase CK2-mediated phosphorylation of Thr-
395 in the NLS seems to inhibit nuclear targeting, probably through a cytoplasmic 
retaining mechanism (Forwood et al. 1999). NS5 activity in the nuclear 
compartment is not entirely clear, despite some hypotheses suggesting a role for 
nuclear NS5 in regulation of gene expression at different stages of infection. In 
2005 Medin and colleagues (Medin et al. 2005) suggested a role for NS5 in the 
over-expression of IL8. IL8 is a cytokine produced by virtually all cells in 
response to LPS, TNF, and virus infection. Besides neutrophil recruitment, its role 
is controversial as it can both enhance viral infection by antagonising interferon 
and itself act as an antiviral molecule. IL8 concentration is high in the blood of 
DHF patients, and it may be involved in increased endothelial permeability 
(Bosch et al. 2002). Medin`s work shows that in vitro infection of human myeloid 
or endothelial cells by DENV induces secretion of IL8. This effect was attributed 
to the NS5-mediated activation of specific cellular factors, such as the 
CAAT/enhancer binding protein (C/EBP), and to a lesser extent to NF-B. A later 
study suggests that the induction of IL8 observed by Medin and colleagues is 
more likely to be due to the cytoplasmic form of NS5 (Pryor et al. 2007). In this 
work increased IL8 secretion is observed only when nuclear NS5 is reduced. This 
observation suggests that NS5 has dynamic control of IL8 production and after 
initial induction mediated by cytoplasmic NS5, nuclear translocation of NS5 
reduces IL8 production (Pryor et al. 2007; Rawlinson et al. 2009). However, a 
correlation between NS5 regulated production of IL8 and DENV pathogenesis has 
not been proved and the exact role of NS5 in the nucleus has not been elucidated. 
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1.3 DENGUE AND DHF: CLINICAL 
MANIFESTATIONS AND RISK FACTORS 
1.3.1 Dengue clinical manifestations 
DENV infection can either be asymptomatic or induce undifferentiated fever, 
dengue fever (DF), or dengue haemorrhagic fever (DHF) (reviewed in Henchal 
and Putnak 1990). Undifferentiated fever usually follows primary infection and it 
is indistinguishable from other common viral infections. DF may occur during 
primary or secondary infections: symptoms are sudden high fever, headache, 
arthralgia, myalgia, anorexia, abdominal pain and sometimes macular papular 
rash. Recovery is usually uneventful but may be prolonged in adults. DHF 
normally follows secondary DENV infections. DHF in infants may occur also in 
primary infections, and pre-existent maternal non-neutralising antibodies have 
been suggested to be in part responsible for this (see section 1.3.2.3). DHF begins 
with a febrile phase, haemorrhagic phenomena, and generalised constitutional 
symptoms. This first phase can either be followed by full recovery, or progress 
towards a second more severe phase, characterized by plasma leakage, 
tachycardia, hypotension and sometimes pleural effusions and ascites. Bleeding 
may occur from any site and especially from the gastrointestinal tract. Platelet 
count is <100·10
9
/l and a generalised leukopenia as well as abnormal coagulation 
profiles can be observed. Depending on its severity, DHF can be further divided 
into four grades, the last and most severe is characterised by profound shock 
(Dengue Shock Syndrome, DSS). Surviving patients undergo an uneventful and 
short period of convalescence (Henchal and Putnak 1990).  
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1.3.2 Risk factors for DHF 
The reasons for different disease outcomes following viral infection are not 
completely known and more work is required to understand the precise patho-
physiology of dengue disease. In 2000 Vaughn and colleagues (Vaughn et al. 
2000) showed that DENV peak titre is between 100 and 1000-fold higher in DHF 
than in DF patients: this suggests a strong correlation between viral replication 
and disease severity. This observation has been further confirmed by subsequent 
studies (Libraty et al. 2002; Guilarde et al. 2008). Success of viral replication 
early in infection depends upon both viral and host factors. Furthermore, several 
studies have proved the existence of a strong epidemiological correlation between 
DHF and secondary infections (see below), suggesting that pre-existing immunity 
can act as risk factor for DHF. 
1.3.2.1 Viral factors 
Whether some serotypes are more pathogenic than others remains an open 
question, but a correlation has been observed between some DENV serotypes and 
disease severity or increased fitness in the context of host immunity (Kyle and 
Harris 2008). In secondary infections, DHF is most commonly associated with 
DENV-2, followed by DENV-1 and DENV-3 (Sangkawibha et al. 1984; 
Balmaseda et al. 2006); DENV-4 seems to be the least clinically severe, even if it 
can on occasions induce DHF in secondary infection (Nisalak et al. 2003). Also 
the particular sequence of infecting DENV serotypes can influence the severity of 
the disease: DENV-2 and DENV-4 have been associated with increased disease 
severity in secondary infections, while DENV-1 and DENV-3 with more severe 
disease in primary infections (Harris et al. 2000; Vaughn et al. 2000; Nisalak et 
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al. 2003; Balmaseda et al. 2006).  
Southeast Asia seems to be a source of viral diversity, generating a multitude of 
strains which are often more virulent and successful than the existing ones, and 
displacing more benign genotypes (Zanotto et al. 1996). Much evidence suggests 
that DENV-2 strains generated in Southeast Asia are associated with DHF, while 
strains generated in America are not (Rico-Hesse et al. 1997; Diaz et al. 2006). In 
particular it has been reported that the Thai DENV strains of the Asian genotype 
replicate to higher titres in human monocyte-derived macrophages and dendritic 
cells, suggesting that the success of the Southeast Asia DENV-2 strains is due to a 
more efficient replication in human cells, and a more efficient transmission by 
vector mosquitoes (Pryor et al. 2001; Cologna and Rico-Hesse 2003).  
Higher virulence has been shown also for DENV-3 genotype III, which has been 
associated with an increase in DHF: the decisive factor was identified as a clade 
replacement event, suggesting that increased viral diversity is leading to the 
emergence of virus clades associated with DHF (Messer et al. 2003; Kyle and 
Harris 2008). Following the analysis of 11 DENV-2 of the American and 
Southeast Asian genotype, Leitmeyer and colleagues suggest that the amino acid 
390 of the E protein and specific sequences within the 3` NTR and the 5` NTR 
might be determinants of DHF (Leitmeyer et al. 1999); however, genetically 
distinct viruses have not been consistently associated with severe or mild dengue, 
highlighting once again the complexity of dengue disease. 
1.3.2.2 Human factors 
DHF has been correlated to age and ethnicity. Children under 15 years old are 
more at risk of developing DHF, probably because of increased capillary fragility 
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and decreased tolerance for micro vascular damage (Gamble et al. 2000). Certain 
populations and ethnic groups also show increased tendency to develop DHF: 
Africans and people of African descent for instance have been suggested to have 
some genetic polymorphisms that confer partial protection against the most severe 
forms of dengue (Coffey et al. 2009). One hypothesis suggests that the nature and 
magnitude of the immune response generated by HLA-class I presentation of 
DENV antigens could also contribute to immunopathogenesis (Stephens et al. 
2002; Simmons et al. 2005; Mongkolsapaya et al. 2006; Sierra et al. 2007). 
Selected HLA alleles have only been significantly associated with DF or DHF 
caused by certain DENV serotypes (Stephens et al. 2002); however, no single 
allele has been associated with dengue disease and some ethnic groups show no 
consistent HLA association pathway (Coffey et al. 2009). Associations between 
HLA alleles, DENV genotypes and DENV disease are complex and require 
further investigation. 
1.3.2.3 Pre-existing immunity and ADE 
In secondary infections, the presence of non-neutralising pre-existing immunity 
against different DENV serotypes is also recognised as one of the main factors 
contributing toward the development of DHF. In response to primary infection, 
protective immunity to the infecting serotypes is believed to last a lifetime 
(Halstead and O'Rourke 1977; Guzman et al. 2007). Differently, complete cross-
protective immunity against a secondary infection is present for only 1-2 months 
after the primary infection (Sierra et al. 2002). After 9 months, heterologous 
DENV infections represent a risk factor for the development of DHF (SABIN 
1950). This has been attributed to an immunological phenomenon known as 
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antibody-dependant-enhancement (ADE) (Halstead et al. 1970). During second 
infections with a different DENV serotype, antibodies binding to non-neutralising 
viral epitopes or circulating at non-neutralising concentrations fail to clear the 
virus and in fact enhance DENV infections. DENV-antibody complexes bind to 
the Fc receptors (FcR) on cell surface and are efficiently internalised, providing 
an alternative entry route to the cell and contributing to higher viral load (Halstead 
and O'Rourke 1977; Halstead et al. 1977b). The ADE model provides an elegant 
explanation for increased viral burden following secondary infections and it also 
suggests that circulation of maternal antibodies might be responsible for the high 
frequency of cases of DHF in infants. ADE, extensively described in vitro, has 
been reproduced in IFN receptor-deficient mouse models (Williams et al. 2009) 
and suggests that the risk of ADE must be taken into account in the design of 
vaccines against DENV. However, no evidence of ADE has so far been reported 
in DENV infected patients and more studies are required to clarify the importance 
of this phenomenon in DHF pathogenesis.   
1.3.3 Pathogenesis of DHF 
In spite of the strong correlation between virus titre and disease severity, it has 
been observed that the most severe symptoms of DHF do not coincide with viral 
peak, but in fact develop as viraemia is controlled (Halstead 1980a). Furthermore, 
studies on the molecular mechanism of plasma leakage in DHF have shown that 
increased vascular permeability is not induced by the virus directly, but can in part 
be explained by a dysregulated adaptive immune response.  
Vascular endothelial cells, lining the inner lumen of blood vessels, constitute the 
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primary blood-tissue barrier controlling flux of nutrients, microcirculatory 
dynamics, and permeability of micromolecules. TNF-, IFN-, IL6, IL8, and 
several other proinflammatory cytokines control endothelial permeability and 
diapedesis of neutrophils, extravasation of erythrocytes, and infiltration of 
perivascular mononuclear cells. Skin biopsies from patients with DHF show that 
blood vessels are not damaged by DENV infection and the endothelial junctions 
are also intact; in fact, DHF patients display a complex cytokine secretion 
profile, which has been associated with increased capillary permeability and 
plasma leak (reviewed in Chaturvedi et al. 2005; Fink et al. 2006; Basu and 
Chaturvedi 2008).  
In response to DENV infection, both T cells and macrophages are activated and 
they have been shown to contribute to high release of proinflammatory cytokines 
(Kurane et al. 1989; Green et al. 1999); however whether they only help virus 
clearance or they are involved in dengue pathogenesis is still a subject of debate. 
In secondary infections, the reactivation of pre-existing memory T-cells specific 
against a different DENV serotype has also been suggested to contribute towards 
dengue pathogenesis, phenomenon described as “original antigenic sin” 
(Mongkolsapaya et al. 2003). Original antigenic sin occurs when memory T cells 
are highly specific for antigens encountered during the primary infection, but have 
low binding affinity to new antigens from heterologous serotypes. These cells 
proliferate quicker than naïve high-affinity clones, and their faster re-activation 
not only does not undermine virus replication, but may instead contribute to 
immunopathogenesis through cytokine release and tissue damage (Gagnon et al. 
1999; Mongkolsapaya et al. 2003). 
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Further studies are required to assess the role of the complement system in 
dengue disease. Avirutnan and colleagues have observed accelerated complement 
consumption during shock in patients with DHF (Avirutnan et al. 2006; Avirutnan 
et al. 2008). Further investigation has shown a correlation between the amount of 
membrane-associated or soluble NS1, the concentration in the blood of final 
products of complement activation as SC5b-9, and increased vascular 
permeability. The authors suggest that expression of NS1 on infected cells may 
result in binding of heterotypic, non-neutralising antibodies and complement 
attack. Moreover, when associated to the cell membrane, SC5b-9 can trigger 
cellular reactions leading to production of cytokines involved in endothelial 
permeability (Avirutnan et al. 2006).  
Anti-DENV NS1 antibodies have also been suggested to contribute to dengue 
pathogenesis by cross-reacting with cell surface antigens on endothelial cells and 
platelets. This phenomenon is also known as antigenic mimicry. Lin and 
colleagues showed that binding of anti-NS1 antibodies to endothelial cells is 
responsible for NF-B signalling activation and increased levels of cytokines and 
chemokines; furthermore, anti-NS1 stimulation has been correlated to increased 
expression of adhesion molecules on endothelial cells, and therefore increased 
lymphocyte adhesion (Lin et al. 2005). According to Wang and colleagues, anti-
NS1 antibodies would also be responsible for the drop of platelet count observed 
in DF and especially in DHF patients (Wang et al. 1995). Chen and colleagues 
suggest that anti-NS1 antibodies recognise protein disulfide isomerase on platelets 
thereby inhibiting platelet aggregation (Chen et al. 2009). However, the precise 
mechanism is unclear and the importance of anti-NS1 antibodies in determining 
dengue disease outcome has not been established. 
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1.4 PROGRESS AND SETBACKS IN VACCINE AND 
ANTIVIRAL DRUG DEVELOPMENT 
More than sixty years after the isolation of DENV, no effective vaccine is 
commercially available. Theoretically, DENV infections display some 
characteristics that make the development of a vaccine potentially achievable: the 
virus causes only acute infection with a short period of viraemia, and individuals 
who have recovered from DENV infection are immune to second challenges with 
the same serotype. Several immunogenic epitopes have been identified on both 
structural and non-structural proteins and antigen delivery does not present major 
obstacles. However, DHF pathogenesis is not completely clear and every effort to 
design a vaccine has been further compromised by the lack of adequate animal 
models. The main challenge in the design of a vaccine against DENV is to 
separate enhancing and neutralising immunity, since the immune response to 
DENV infection, while protecting from dengue disease, also appears to be a major 
risk factor towards DHF (see above). To prevent antibody enhancement 
phenomena and re-activation of a potentially harmful heterotypic memory 
response, an effective vaccine should provide protection against all four DENV 
serotypes simultaneously, and induce a robust and long-lasting immune response. 
Economic cost-benefit issues must be taken into consideration, and repeated 
dosing should be kept to a minimum. In recent years the number of different 
approaches to develop a vaccine against DENV has been unprecedented, with 
several candidates currently in clinical trial (Chaturvedi et al. 2005; Wilder-Smith 
and Deen 2008).  
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1.4.1 Live vaccines 
1.4.1.1 Live-attenuated vaccines 
Live-attenuated vaccines are promising because of low costs of production and 
because they induce a powerful and long lasting B and T cell immune response, 
even though the possibility of reversion and spread of vaccine strains must be 
carefully taken into consideration. Two live-attenuated vaccines are currently in 
clinical trial. The Mahidol University in Bangkok together with the Sanofi-Pasteur 
developed candidate live-attenuated vaccines by attenuating the four DENV 
serotypes through serial passages in primary dog kidney cells (serotypes 1, 2 and 
4), or primary African green monkey kidney cells (serotype 3), and the four 
monovalent candidates were finally combined in a single tetravalent formulation. 
After a single dose vaccination, seroconversion was observed in all volunteers. 
The main limit was the high reactogenicity of this formulation, variable among 
the four serotypes and particularly high for serotype 3 (Kitchener et al. 2006). A 
different live-attenuated vaccine was formulated by The Walter Reed Army 
Institute of Research together with GlaxoSmithKline, by passaging all four DENV 
serotypes in primary dog kidney cells. After vaccination with the tetravalent 
formulation, high seroconversion and moderate reactogenicity were observed 
(Sun et al. 2003). 
The US National Institute of Allergy and Infectious Diseases have used reverse 
genetic techniques to introduce defined attenuating deletions. Tetravalent 
formulations incorporate a 30 deletion in the 3` UTR in wild-type DENVs 
(Blaney, Jr. et al. 2006). Phase I trials showed low level viraemia and acceptable 
immunogenicity for a live attenuated DENV-4 vaccine candidate (Durbin et al. 
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2005). The same institute is also working on chimaeric viruses expressing the 
prM-E region of DENV-1, DENV-2 or DENV-3 into DENV-430. If needed, the 
level of attenuation of each vaccine can be further increased, introducing 
additional well established attenuating mutations (Blaney, Jr. et al. 2006).  
1.4.1.2 Chimaeric vaccines 
Successful experience with the chimaeric JEV/YFV vaccine raised optimism 
that such a formulation could have been used for DENV as well. ChimeriVax™ 
from Sanofi-Pasteur, currently in phase III of clinical trial, uses YFV 17D 
backbone and replaces the structural protein genes prM and E with the 
homologous proteins from DENVs. RNA transcripts are electroporated into Vero 
cells and progeny viruses are purified to produce the vaccine. Preclinical studies 
on monovalent formulations and on a tetravalent mixture of monovalent chimaeric 
viruses show that the ChimeriVax™ is replication competent, genetically stable 
and not-virulent upon 20 passages in Vero cells (Guirakhoo et al. 2002). The 
vaccine was shown to be attenuated, efficacious, safe and unlikely to be 
transmitted by arthropod vectors (McGee et al. 2008). However, anti-DENV 
immune responses are limited to prM and E, while responses to the NS proteins 
are probably an important component for life-long immunity (Rothman et al. 
1993).  
Chimaeric vaccines are much attenuated formulations and provide strong and 
long-lasting immunity. However, recent evidence has shown vaccine-related 
reactions in response to YF vaccine in some individuals who develop acute 
viscerotropic disease (Monath 2007); in these same individuals high viraemia 
(≥105 pfu/ml) has been documented, suggesting higher risk of recombination 
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events in case of dual infection with wild type flaviviruses (Seligman and Gould 
2004; Seligman and Gould 2008). 
1.4.2 Inactivated vaccines  
After inactivation with formalin, DENV-2 retains its immunogenicity in mice 
and rhesus monkeys, inducing high titres of neutralising antibodies (Putnak et al. 
1996). The main advantage of inactivated vaccines is the impossibility of 
reversion, but multiple doses are required and costs remain the main limit of such 
formulation.  
1.4.3 Recombinant subunit vaccines 
Many B and T cell epitopes have been mapped on DENV structural and non-
structural proteins and these epitopes can be expressed in protein subunit 
vaccines. The extracellular portions of the E protein of each DENV serotype 
expressed in Drosophila cells have been used as a subunit vaccine by Hawaii 
Biotech Inc., showing high immunogenicity in mice and monkeys when 
administered with appropriate adjuvants (Clements et al. 2010). Further attempts 
have been made by fusing the first 395 amino acids of the DENV-2 E protein with 
the HBV (Hepatitis B Virus) surface antigen as a potent adjuvant. This hybrid was 
shown to elicit immune response against both components of the hybrid protein in 
vivo (Bisht et al. 2002). Scaling-up remains the major problem for recombinant 
vaccines, and powerful adjuvants are needed. Attempts have also been made by 
injecting purified recombinant DENV-2 NS1 protein in mice, but antibody 
production is not protective (Feighny et al. 1992).  
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1.4.4 Antiviral treatments  
At present, no antiviral treatment is available against DENV infection. The 
treatment is only to alleviate symptoms and rehydration in case of hypotension is 
the main aid to survival. Corticosteroids or drugs decreasing capillary 
permeability do not reduce mortality in children with DHF/DSS (Leyssen et al. 
2000).  
Rational design of drugs aims at targeting viral mechanisms critical for DENV 
survival, limiting propagation of the infection. Preventing capping, for instance, 
has been shown to destabilise viral progeny, and also compounds able to inhibit 
the viral methyl-transferase have been studied. Pharmaceutical groups are mainly 
working on the RNA-dependent RNA polymerase and the viral protease/helicase, 
but no drug is currently available and not all mechanisms involved in DENV 
replication and pathogenesis are known (reviewed in Leyssen et al. 2000).  
 
Deeper knowledge of viral infection and of the immune system response might 
be the key to identify more specific and effective ways to stop DENV. In 
particular, as outlined above, high viral replication at early stages of infection is 
known to be a determinant of dengue outcome (Vaughn et al. 2000); it is therefore 
logical to think that the rational development of attenuated vaccines or antiviral 
drugs could be greatly helped by better understanding viral and host factors 
involved at this critical stage of infection.  
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1.5 DENV INHIBITION OF INNATE IMMUNITY 
As outlined in the previous chapters, the most severe forms of dengue disease 
are associated with high viral titres. Both host genetic determinants and virus 
characteristics contribute to viral replication, but rapid replication during the short 
viraemic period of acute infection can be achieved only if innate immunity, which 
represents the first line of host defence against pathogens, is delayed or inhibited. 
The more efficient the evasion of innate immunity, the higher will be the viral 
titre, and the more severe the disease outcome.  
Emerging data show that DENV, like many other flaviviruses, has developed 
several mechanisms to inhibit the innate immune system, in order to 
systematically suppress the main components of the early immune response and 
quickly reach high viral titres. Innate immunity seems to have exerted stronger 
selective pressure than adaptive immunity, since adaptive immunity clears the 
virus at later stages of infection, when the viral titre has peaked already, and it has 
probably already been transmitted from human to mosquito.  
DENV efficiently inhibits cellular response to type I IFN, and recent work has 
shown that it also prevents the activation of Natural Killer (NK) cells. Better 
understanding of these mechanisms is the main focus for this thesis, and they will 
be discussed in detail below. 
1.5.1 DENV and NK cells 
NK cells are an important component of the innate immunity, but their role in 
controlling flavivirus infections is not clearly defined. NK recognition of target 
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cells does not require receptor rearrangement or clonal expansion, so NK cells 
respond rapidly to infection (Lodoen and Lanier 2005). Resting mature NK cells 
constitutively express transcripts for inflammatory cytokines, and contain pre-
formed cytolytic mediators like granzymes and perforines stored in intracellular 
granules (Lanier 2008). NK cell activation culminates in the exocytosis of such 
granules, lysis of infected target cells, and release of cytokines, primarily IFN-
(Lodoen and Lanier 2005). NK cells display both activating and inhibitory 
receptors and activation of NK cells depends on the integration of these opposite 
signals. Activating receptors mainly recognise glycoproteins induced by cellular 
stress or pathogen-encoded ligands; inhibitory receptors recognise MHC class I 
molecules. MHC class I are expressed on the surface of all nucleated cells, and 
this prevents NK cytolytic activity on cells recognised as “self” (Lanier 2008). 
Due to the rapid and powerful response of NK cells, the role of inhibitory 
receptors is crucial. 
Following DENV infection in mice, NK cell activity is transiently increased 
(Shresta et al. 2004a), and early activation of NK cells in humans has been 
associated with mild clinical disease, suggesting that high NK cell activation may 
be associated with a more favourable prognosis (Azeredo et al. 2006). According 
to Azeredo and colleagues, the majority of NK cells from DENV infected patients 
display early markers of activation during the acute stage of the disease, and 
intracellular cytotoxic granules are also up-regulated early. A recent study has 
shown that DENV E protein binds the NKp44 activating receptor on NK cells, 
inducing activation (Hershkovitz et al. 2009). Therefore, evasion of NK 
recognition might be critical to the establishment of a successful viral infection. A 
number of studies have shown that flaviviruses up-regulate expression of MHC 
 64 
class I molecules on the cell surface in an IFN-independent manner (reviewed in 
Lobigs et al. 2003). Uncleaved C-prM structural protein has been implicated, 
suggesting that MHC-I up-regulation may be an incidental consequence of virus 
assembly rather than a proper evasion strategy (Lobigs et al. 2004). Differently, 
Hershkovitz et al (Hershkovitz et al. 2008) have shown that expression of DENV 
NS proteins only, in the context of DENV replicon, is sufficient to enhance 
membrane expression of MHC-I and therefore reduce susceptibility to NK lysis. 
These studies suggest that a complex balance exists between DENV-induced 
triggering of NK cell activation and subversion of NK-mediated killing by 
enhanced MHC-I expression on infected cells (Hershkovitz et al. 2008).  
While preventing activation of NK cells, up-regulation of MHC class I 
molecules on the cell surface also increases cell susceptibility to cytotoxic T cells. 
This could provide potential disadvantages to the virus, but while adaptive 
immunity represents a relatively late event in infection, NK activation would 
jeopardise early stages of viral replication. As suggested above, it is likely that 
DENV evolution may have been affected by selective pressure of innate rather 
than adaptive immunity, and therefore that neutralisation of early NK cells rather 
than T cells might have been the priority (Hershkovitz et al. 2008).  
1.5.2 DENV and type I IFN 
The IFN system provides the earliest and most potent line of defence against 
many pathogens. The IFN response induces apoptosis and growth inhibition of 
infected cells, and regulates the immune response. The IFN family is composed of 
two main classes of related cytokines: type I IFN (including IFN-and IFN-) 
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which mounts a robust response against viruses, and type II IFN (IFN-) which 
also exhibits antiviral activity but is mainly regarded as a powerful 
immunomodulatory cytokine (Bonjardim et al. 2009). A third less well-known 
class, type III IFN, regulates the antiviral response and cell proliferation, and it 
has been proposed to be the ancestral antiviral system of vertebrates (Sadler and 
Williams 2008; Bonjardim et al. 2009).  
Experiments with knock-out mice lacking IFN- or IFN- receptors or both 
show that a functional response to IFN- is critical in controlling the early viral 
load in the first stages of DENV infection; in contrast, the IFN- response 
provides partial resistance against DENV-induced disease and limits viral 
spreading in the periphery, but it is less important in controlling viral load 
(Shresta et al. 2004b). Several studies have now shown that DENV is capable of 
inhibiting type I IFN response. This thesis further investigates the molecular 
mechanisms of such inhibition. Therefore the type I IFN system is the main focus 
of the following sections. 
1.5.2.1 The type I IFN system  
1.5.2.1.1 Viral induction of type I IFN  
Recognition of different viral components by specific host receptors, called 
Pattern Recognition Receptors (PRR), activates multiple distinct routes that 
trigger induction of the type I IFN. The importance of each route depends upon 
the specific virus, the infected cell and the stage of infection. IFN production can 
be induced by different viral components, from viral genome (RNA or DNA) or 
replication intermediates (dsRNA), to viral proteins, or simply following viral 
entry (Bonjardim et al. 2009). In response to PRR signalling, cytoplasmic IRF-3 
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(IFN Regulatory Factor-3) is phosphorylated, dimerises and exposes a nuclear 
localisation signal (NLS) which allows its translocation to the nucleus. The NF-
B (Nuclear Factor B) inhibitor IB, which holds NF-B in the cytoplasm, is 
also phosphorylated and this induces dissociation from its substrate and 
subsequent ubiquitination and proteasome-mediated degradation. The NLS on 
NF-B also becomes accessible and NF-B translocates to the nucleus. IRF-3, 
NF-B, and a third component, the c-jun/ATF-2 heterodimer, assemble on the 
IFN- promoter and aid the recruitment of CREB-binding protein (CBP)/p300 
which in turn promotes the assembly of the transcription machinery. The 
assembly of the transcription machinery on the IFN- promoter induces 
transcription of IFN-. Positive feedback models have been proposed in which the 
IFN- produced feeds back onto cells and induces the synthesis of at least three 
other transcription factors, IRF-1, IRF-7 and IRF-9, which in turn, in the presence 
of a continued infection, enhance the transcription of “primary IFN genes” (IFN-
genes) and allow the transcription of “secondary IFN genes” (IFN- genes) 
(reviewed in Randall and Goodbourn 2008). 
1.5.2.1.2 Type I IFN signalling  
In spite of differences in induction, IFN- and IFN- are the main components 
of the type I IFN sub-family and they signal through the same pathway (Figure 
1.4) (reviewed in Stark et al. 1998; Randall and Goodbourn 2008). Interaction of 
IFN- molecules with two different receptor subunits, IFNAR1 and IFNAR2c, 
forces the two subunits together and induces their dimerisation. 
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Figure 1.4|  
Type I and type II IFN signalling cascade. After activation at 
receptor level, phosphorylation of STAT transcription factors induces 
their dimerisation and translocation into the nucleus, where they 
activate transcription of specific IFN-regulated genes. 
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 The two receptor-associated kinases JAK1 (associated with IFNAR2c) and 
Tyk2 (associated with IFNAR1) are now close enough to phosphorylate and 
activate each other (Gauzzi et al. 1996). Once activated, JAK1 and Tyk2 
phosphorylate some critical residues on IFNAR1. STAT2 binds IFNAR2c also 
before IFN induction and it is weakly associated with STAT1, but only IFNAR1 
phosphorylation creates a docking site for STAT2 on IFNAR1. STAT2-IFNAR1 
association brings STAT2 close enough to Tyk2 to allow STAT2 phosphorylation 
on tyrosine 690. Finally, phosphorylated STAT2 provides the docking site that 
orients STAT1 for phosphorylation on tyrosine 701 (Li et al. 1997). Once 
phosphorylated, the two STATs heterodimerise and dissociate from the receptor. 
This creates a novel NLS and, simultaneously, inactivates the constitutive NES of 
STAT2. The heterodimer and the associated transcription factor IRF-9 form the 
transcription complex ISGF3 and translocate into the nucleus by interaction with 
the nuclear importin system (Reich and Liu 2006). A recent study suggests that 
the assembly between the STAT heterodimer and IRF-9 is coordinated at the 
receptor, following acetylation of IFNAR2 after IFN binding (Tang et al. 2007).  
Once in the nucleus, the transcription complex ISGF3 binds to specific DNA 
sequences called ISRE (Interferon-Stimulated Regulatory Elements) and induces 
the expression of more than 300 genes that specify the antiviral state. Amongst 
those genes some encode enzymes that directly block viral replication, such as 
protein kinase R (PKR) which prevents recycling of the eukaryotic translational 
initiation factor 2 (eIF2), halting translation initiation; or the 2`5`-oligo-
adenylate synthetase (OAS), which bind to activate the RNAse L and degrade 
cellular and viral RNA; or the MX GTPases, that recognise virus nucleocapsid 
structures and restrict their localisation within the cell, preventing viral 
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replication. No single gene is pivotal and for any virus a subset of genes is 
probably required to establish an antiviral state and prevent viral replication 
(reviewed in Randall and Goodbourn 2008; Sadler and Williams 2008). 
Besides its potent antiviral effect at early stages of infection, type I IFN is also 
known as an important immunological modulator. Type I IFN bridges innate and 
adaptive immunity by enhancing clonal expansion of CD8+ T cells (Tough et al. 
1996) and B cells (Le Bon et al. 2006), by activating NK cells (Biron and Brossay 
2001), and by regulating differentiation and maturation of DC cells (Luft et al. 
1998).  
Even thought the importance of the type I IFN response in preventing viral 
spreading is well established, recent works are showing that rapid and efficient 
control of the IFN signalling is as critical as its activation. Prolonged activation of 
IFN- can exert deleterious effects on the host immune system through several 
mechanisms, including elevated serum levels of pro-inflammatory cytokines 
(Stacey et al. 2009), apoptosis of uninfected cells, and generalised immune 
activation due to defects in the T cell selection and thymopoiesis (Bosinger et al. 
2009). Recent work has shown that SIV-infected sooty mangabeys, a monkey 
species that is a natural SIV host, do not develop pathogenesis. Differently, 
infected rhesus macaques, in spite of similar levels of viral replication and early 
immune response activation, develop pathogenic infection (Bosinger et al. 2009). 
The difference can be explained by the presence in sooty mangabeys of lower 
levels of immune activation during the chronic phase of infection, and by reduced 
production of IFN- (Bosinger et al. 2009; Jacquelin et al. 2009). Also, by using 
lymphocyte-deficient hosts, Kim and colleagues (Kim et al. 2007) also suggest 
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that in the absence of T cells the innate immune response can be a direct cause of 
death due to uncontrolled release of proinflammatory cytokines. This suggests 
that, while the type I IFN response is critical to activate T cells, the presence of 
active mechanisms of immune regulation exerted by T cells is also crucial to 
temper the initial innate response (Kim et al. 2007). 
1.5.2.1.3 Viral evasion of type I IFN  
Millions of years of co-evolution between hosts and pathogens have resulted in 
the acquisition by most viruses of mechanisms to evade the host immune system. 
Different viruses inhibit different steps of the IFN pathway, either by interfering 
with host-cell gene expression and/or protein synthesis, or by inhibiting IFN 
production, signalling, or IFN-regulated antiviral pathways (Levy and Garcia-
Sastre 2001). To circumvent the antiviral response, viruses often use a 
combination of these strategies, such as inhibition of both IFN production and 
signalling (Randall and Goodbourn 2008). 
Inhibition of IFN production allows viruses to spread to non-infected cells 
before full establishment of an antiviral state. Viruses can minimise production of 
IFN by using replication strategies that limit generation of pathogen-associated 
molecular patterns (PAMPs) recognised by PRRs, by inhibiting PRRs, or by 
interference with specific critical points in the IFN-induction cascade (Randall 
and Goodbourn 2008). 
Since IFN can still be produced by uninfected cells, inhibition of IFN signalling 
can be even more efficient than inhibition of IFN production. Several viruses have 
developed different strategies to block IFN signalling, and there are examples of 
viral proteins blocking each step of the IFN signalling cascade, as exemplified in 
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Table 1.1.  
 
Virus Target 
HCMV JAK1/IRF-9 reduction (Miller 1998) (Miller et al. 1999) 
STAT1/STAT2 sequester (Paulus et al. 2006) 
HSV-1 JAK1/STAT2 reduction (Chee and Roizman 2004) 
SOCS3 up-regulation (Yokota et al. 2004) 
PIV-2 STAT2 degradation (Andrejeva et al. 2002) 
Nipah virus, STAT1/STAT2 sequester (Rodriguez et al. 2003; 
Rodriguez et al. 2004) Hendra virus 
RSV STAT2 degradation (Elliott et al. 2007) 
Adenovirus STAT1/IRF-1 reduction (Look et al. 1998) 
CBP/p300 sequester (Look et al. 1998) 
Ebola virus Inhibition of STAT import (Reid et al. 2007) 
1.5.2.1.4 Flavivirus inhibition of type I IFN 
 Most (or possibly all) flaviviruses have evolved mechanisms to inhibit IFN-
mediated signal transduction (Best et al. 2005), but the exact mechanisms remain 
elusive. Besides differences between flaviviruses, the picture is further 
complicated by the employment of different cell lines and expression systems by 
different investigators. The literature abounds in contradictory reports and very 
few observations have been reproduced and validated. West Nile virus (WNV) 
has been reported to inhibit the phosphorylation of STAT1, STAT2, Tyk2 and 
JAK1; four non-structural proteins (NS2A, NS3, NS4A and NS4B) have been 
implicated (Guo et al. 2005), but no mechanism has been described. Differently, 
Laurent-Rolle and colleagues, have recently identified NS5 of the virulent strain 
WNV NY99 as a potent antagonist of type I IFN signalling (Laurent-Rolle et al. 
Table 1.1|  
Mechanisms of inhibition of type I IFN signalling by different 
viruses. 
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2010). Japanese encephalitis virus (JEV) blocks Tyk2 phosphorylation and this 
has been attributed to the non-structural protein NS5 (Lin et al. 2004; Lin et al. 
2006). Langat virus (LGTV) NS5 has also been shown to be involved in IFN 
inhibition and specific regions have been mapped. Best and colleagues suggest 
that the IFN inhibition by LGTV may be the consequence of a direct interaction 
between LGTV NS5 and the IFN receptor, but the mechanism remains unclear 
(Best et al. 2005; Park et al. 2007). The methyltransferase domain of tick borne 
encephalitis virus (TBEV) NS5 has also been reported to be critical to IFN 
inhibition: Werme and colleagues suggest that it allows NS5 localisation at cell 
membrane, where the block of the IFN signalling seems to take place (Werme et 
al. 2008). 
All these studies suggest that IFN inhibition occurs at early stages of the 
signalling cascade, and that different viruses within the same genus may have 
developed different mechanisms to antagonise the IFN response. However, 
several questions remain unanswered and more studies are required for a clear 
understanding of flavivirus mechanisms of evasion. 
1.5.2.2 DENV inhibition of type I IFN 
Inhibition of type I IFN response in infected cells by DENV has been observed 
in several circumstances. However, not only is the mechanism unclear, but also 
conflicting and dubious observations have been reported. Different studies 
disagree both on the steps of the signalling cascade antagonised by DENV 
(STAT1 (Munoz-Jordan et al. 2003), STAT2 (Jones et al. 2005), Tyk2 (Ho et al. 
2005)) and on the viral proteins involved (NS4A, NS4B, NS2A (Munoz-Jordan et 
al. 2003; Munoz-Jordan et al. 2005)), and only few observations have been 
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reproduced by different investigators. Even though it is possible that DENVs have 
developed more than one strategy to evade the IFN response at different stages of 
the signalling cascade, the lack of reproducibility and consistency suggests that 
such diversity in the literature is more likely to be due to experimental variability.  
The pathogenicity of DENV despite high concentrations of circulating IFN in 
patients was reported many years ago (Kurane et al. 1993), suggesting some 
malfunction in the IFN system. The first study addressing the possibility that 
DENV might escape cellular responses to IFN was published by Diamond and 
Harris in 2001 (Diamond and Harris 2001). The work mainly investigated how 
IFN prevents DENV-2 replication, but the authors observed that such inhibitory 
effect occurred only when IFN treatment preceded viral infection; differently, 
when cells were treated only a few hours after infection, a significant percentage 
of the IFN antiviral effect was lost. Even though the existence of an active 
mechanism of inhibition was considered, Diamond and Harris proposed an 
alternative hypothesis. According to this model, as soon as a short polypeptide is 
synthesised from DENV RNA, membrane-anchor signals in the C protein recruit 
the ribosome-RNA complexes to the ER: if cells are treated with IFN before the 
infection, some unidentified IFN-induced molecules prevent RNA translation 
before the translocation to the ER; conversely, if IFN treatment follows infection, 
the complexes, protected by the ER, become inaccessible to the IFN-induced 
molecules (Diamond and Harris 2001). This hypothesis could explain the 
inefficacy of late IFN administration, but has never been demonstrated 
experimentally; instead, there is growing evidence that DENV actively 
antagonises the IFN response. In 2003, Muñoz-Jordan and colleagues showed that 
the IFN response was inhibited in DENV infected cells and by measuring the 
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replication of the IFN-sensitive virus NDV (Newcastle Disease Virus)-GFP after 
IFN- treatment in different cell lines expressing individual protein/s of DENV-2, 
the group suggested that DENV NS2A, NS4A and NS4B are all IFN antagonists 
(Munoz-Jordan et al. 2003). NS4B in particular demonstrated the strongest 
inhibitory properties, but the effect was further magnified by the co-expression of 
NS2A and NS4A. In this work, inhibition of STAT1 phosphorylation in response 
to both IFN- and IFN- was reported in cells expressing NS4B and the authors 
suggested that DENV NS4B inhibits IFN signalling by preventing STAT1 
activation. In 2005, the same group reported the importance of the N-terminal 
sequence of NS4B and of the proteolytic cleavage between NS4A and NS4B for 
IFN inhibition (Munoz-Jordan et al. 2005). Moreover, the authors suggested that 
the same inhibitory function of NS4B is conserved in WNV and YFV (Munoz-
Jordan et al. 2005). This is the only preceding work investigating the role of 
specific DENV proteins in IFN antagonism, and it is widely cited in the literature. 
However, the phenotype described in these studies has been contradicted by 
others, potentially questioning the validity of the observations: even though 
inhibition of STAT1 phosphorylation has been observed by others (Ho et al. 
2005; Jones et al. 2005), inhibition of type II IFN has never been reproduced, 
suggesting that inhibition of STAT1 phosphorylation is more likely to be the 
consequence of upstream blocks rather than direct effect of DENV antagonism.  
DENV-2 inhibition of IFN signalling was investigated in primary monocyte-
derived DC by Ho and colleagues (Ho et al. 2005). This study does not address 
the role of individual DENV proteins in IFN antagonism, but investigates which 
step of the signalling cascade pathway is targeted by DENV. According to this 
work, up to 24 hours post-infection, the basal levels of all proteins involved in 
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type I IFN signalling are unaltered and DENV-2 is reported to block the 
phosphorylation of Tyk2.  
Jones and colleagues used both DENV-2 infected and replicon containing cells: 
since the replicon expresses only NS proteins, the role of structural components or 
viral entry in the phenomena observed can be excluded. The most interesting 
observation in this study is that in both DENV infected and replicon containing 
cells, cellular levels of STAT2 are greatly reduced; this suggests that STAT2 
reduction could be the mechanism by which DENV inhibits the IFN response 
(Jones et al. 2005). Even though in Ho`s work no STAT2 reduction could be 
observed, later studies by Umareddy and colleagues reproduced Jones` 
observation (Umareddy et al. 2008). It is possible that reduced STAT2 expression 
was not observed in Ho’s study because the analysis was performed at a relatively 
early time-point (24 hours). 
 
In spite of several inconsistencies, taken together these studies have made some 
steps forward toward the understanding of DENV inhibition of type I IFN. These 
studies show that DENV actively inhibits IFN signalling and the inhibitory effect 
is probably specific for type I IFN. The focus of the work in this thesis was to 
elucidate the precise mechanism of inhibition of type I IFN signal 
transduction by DENV-2 and to identify the non-structural protein/s that 
mediate/s this effect. A precise link between IFN antagonism and dengue 
pathogenesis has not been proved, but a relationship between IFN response, virus 
replication and viral pathogenesis has been shown for WNV.  In particular WNV 
virulence has been linked to control of JAK-STAT signalling pathway and to 
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overall resistance to IFN response (Keller et al. 2006; Tobler et al. 2008). 
Therefore, as outlined above, evasion of the innate immunity seems critical to 
high viral replication and therefore severe disease. Better understanding of how 
DENV evades the IFN response would therefore represent a crucial advance in 
understanding dengue pathogenesis. 
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Chapter 2.  
                MATERIALS AND    
    METHODS 
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2.1 MOLECULAR CLONING 
2.1.1 High-Fidelity Polymerase Chain Reaction (PCR) 
Amplification of long templates for successive cloning requires high accuracy 
and speed. Phusion High-Fidelity DNA Polymerase (Finnzymes, New England 
BioLabs) incorporates a processivity-enhancing domain to a Pyrococcus-like 
enzyme, which possesses a 5`-3` DNA polymerase activity and a 3`-5` 
exonuclease (“proofreading”) activity: such a combination allows an error rate of 
4.410-7 in HF Buffer (50-fold lower than Thermus aquaticus DNA polymerase, 
and 6-fold lower than Pyrococcus furiosus DNA polymerase), and it is suitable for 
amplification of long amplicons such as 7.5 kb.  
In this work we employed High-Fidelity PCR whenever high accuracy in 
template amplification was required, i.e. any time we amplified an insert from the 
replicon or other plasmid for subsequent cloning into the lentiviral vector. 
2.1.1.1 Primer design 
When possible, depending on the specific sequence to amplify, primers were 
designed in order not to be complementary to each other and with roughly similar 
annealing temperatures. 
To aid with the primer design, primer sequences were checked on the web-based 
program Primer3, available at http://frodo.wi.mit.edu/primer3.  
Primers used for cloning are listed in Table 2.1. Primers Lentivector Forward 
(F) and Lentivector Reverse (R) were exclusively used for sequencing. 
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Primer name Primer sequence 
NS1/NS2A For AGGATCCCACCATGAGCACCTCACTGTCTGTGTCA 
NS1/NS2A Rev GCGCGGCCGCTTACCTTTTCTTGTTGGTTCTTGAAAG 
NS2B/NS3 For TAGGATCCCACCATGAGCTGGCCACTAAATGAGG 
NS2B/NS3 Rev GCGCGGCCGCTTACTTTCTTCCAGCTGCAAACTC 
NS4A For TAGGATCCCACCATGTCCCTGACCCTGAACCTAAT 
NS4A Rev TAGCGGCCGCTTATCTCTGCTTTTCTGGTTCTGG 
NS4B For AGGATCCCACCATGACACCCCAAGATAACCAATTG 
NS4B Rev TAGCGGCCGCTTACCTTCTCGTGTTGGTTGTGT 
NS5 For AGGATCCCACCATGGGAACTGGCAACATAGGAGAG 
NS5 Rev TAGCGGCCGCCTACCACAGGACTCCTGCCT 
NS5-FLAG Rev 
Reverse 
TAGCGGCCGCCTACCCTTTGTCATCGTCGTC 
MTase 260 Rev 
Reverse 
TAGCGGCCGCCTAGCTTCCGAGGTCTACATCTGG 
Pol 270 For AGGATCCCACCATGGAGATACCAAACCTAGACATAA
TC Pol 405 For AGGATCCCACCATGAATGCAGCCTTGGGGGCC 
NLS 320 For AGGATCCCACCATGAATGCCTCCGGGAACATAGTG 
NLS 405 Rev TAGCGGCCGCCTAGCTTCTCACCTTTCTTGT 
Lentivector F 
FForward 
AAAGAGCTCACAACCCCTCA 
Lentivector R 
Reverse 
CAAATTTTGTAATCCAGAGGTTGA 
2.1.1.2 High-Fidelity PCR 
To avoid DNA contamination, PCR reactions were set up in a separate 
designated area. Separate micro-pipettes, reagents, equipment, laboratory coats 
and sterilized pipette tips were used.  
Negative PCR controls in which the DNA template had been replaced by ddH2O 
were included: should these give positive results, then the experiment and the 
current batch of reagent aliquots were discarded.   
Table 2.1|  
Primers employed for PCR amplification of DENV NS cassettes and for 
sequencing. The nucleotide sequences recognised by restriction enzymes are 
underlined; the Kozak sequence+start codon (forward primers, For) and the stop 
codons (reverse primers, Rev) are in bold. Lentivector F and Lentivector R map 
within the lentiviral vector, upstream and downstream of the cloning site 
respectively, and were used for DNA sequencing. 
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Accordingly to manufacturer`s instructions, the following reagents were mixed 
as in Table 2.2: 
Component Volume Final Concentration 
ddH2O Up to 50 l   
5X Phusion GC Buffer 10 l 1X 
10 mM dNTPs 1 l 200 M each 
25 M Primer Forward 1 l 0.5 M 
25 M Primer Reverse 1 l 0.5 M 
DNA template X (10-50 ng)   
Phusion DNA 
polymerase 0.5 l 0.02 U/ml 
PCR reactions were performed in the thermal cycler I-cycler (BIO-RAD), 
preheated to 95˚C, as described in Table 2.3. 
Cycle step Temperature Time 
Number 
of 
cycles 
Initial 
denaturation 
98˚C 30 seconds 1 
Denaturation 98˚C 10 seconds 
30 Annealing* X˚C 30 seconds 
Extension 72˚C 30 sec/kb 
Final 
Extension 
72˚C 10 minutes 
1 
4˚C hold 
Table 2.2|  
Reagent mix for High Fidelity Phusion PCR  
Table 2.3|  
Cycling conditions for High Fidelity Phusion PCR.  
*An annealing temperature equal to the melting 
temperature (Tm) of the lower Tm primer has been used. 
The Tm of each primer has been calculated using the 
nearest-neighbor method on the Finnzymes` website 
(www.finnzymes.com). When necessary, a temperature 
gradient has been used in order to find the optimal 
annealing temperature. 
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2.1.2 Agarose gel 
PCR products, amplified plasmids, and DNA digestions were analysed on 
agarose gel in order to test the presence and the correct size of the DNA of 
interest.  
All gels were prepared dissolving 1 g of agarose (Melford) in 100 ml of 1X TAE 
buffer, diluted from 50X TAE stock [1L: 242 g Tris base (Trizma), 57.1 ml 
glacial acetic acid and 100 ml 0.5M EDTA, pH 8.0], and adding 5 l of 10 mg/ml 
Ethidium Bromide (Sigma).  
1X loading dye [0.25% (w/v) bromophenol blue, 0.25% (w/v) xylene cyanol FF 
in 40% (w/v) sucrose solution] was added to 50-200 ng of DNA before loading. 
0.5 g of molecular ladder (1 kb or 100 bp, NEB) were loaded as reference. 
Gels were run at 5 V/cm until the bromophenol blue front in the loading dye had 
migrated at a sufficient distance. Gels were then visualized using a UV trans-
illuminator (Epi Chemi II darkroom, UVP Laboratory Products) and 
photographed if required (Software: Labwork 4.6). 
2.1.3 Subcloning in pGEM®-T Easy Vector System 
The pGEM®-T Easy Vector System is a convenient system for cloning PCR 
products. DNA amplified by PCR has flat extremities that make particularly 
difficult the cloning into a vector; even when the DNA template is flanked by 
restriction sites, enzymatic digest of linear fragments is particularly difficult, 
especially close to the DNA extremities. Inserting the PCR product into a 
subcloning vector is a common strategy to facilitate the activity of restriction 
 82 
enzymes, and sometimes to insert or substitute restriction sites in the subcloned 
DNA.  
The pGEM®-T Easy Vector (Figure 2.1) carries 3`-T overhangs at both ends of 
the linearised vector: 3`-Ts at the insertion site prevent re-circularisation of the 
vector and provide compatible overhangs for PCR products flanked by 
deoxiadenosines (dATP), improving the efficiency of ligation. 
The multiple cloning region is located within the -peptide coding region of the 
enzyme -galactosidase: insertional inactivation of the -peptide allows 
recombinant clones to be immediately identified by colour screening in indicator 
plates. In this work, subcloning in pGEM®-T Easy vector has been used every 
time we amplified a construct by PCR, for following cloning into the lentiviral 
Figure 2.1|  
Map of the pGEM®-T Easy Vector and sequence 
reference points. 
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vector.  
2.1.3.1 A-tailing 
In order to match the 3`-T overhangs of the pGEM®-T Easy Vector cloning site, 
PCR products must carry A-overhangs. Thermostable DNA polymerase with 
proofreading activity generates blunt ends during PCR amplification, but these 
fragments can be modified by insertion of an A-tail at both sides of the fragment 
by incubating for 30 minutes at 70˚C the purified (see section 2.1.3.2) PCR 
products with a Taq DNA polymerase in excess of dATP.  
The A-tailing reaction mix was prepared as in Table 2.4. 
Component Volume 
10X Taq Polymerase Buffer 1 l 
dATP (1 mM) 2 l 
MgCl2 (25 mM) 0.6 l 
GoTaq Flexi DNA Polymerase 1 l 
Purified PCR product 5.4 l 
2.1.3.2 PCR purification 
The addition of a poly-A tail would be prevented by the proof-reading activity 
of the High Fidelity DNA polymerase in the reaction. Therefore, all products were 
purified from PCR reagent by using the QIAquick® PCR purification kit 
(Qiagen), following manufacturer`s instructions.  
Briefly, each PCR sample were mixed with Binding Buffer and loaded in a 
small silica column: the high salt concentration provided by the Binding Buffer 
allows DNA products between 100 bp and 10 kb to absorb to the column, while 
Table 2.4|  
Reagent mix for A-tailing reaction. 
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contaminants pass through. Impurities were washed away by an ethanol 
containing buffer, and pure DNA was eluted with water.  
2.1.3.3 Ligation in pGEM®-T Easy Vector 
Ligations were performed following manufacturer`s instructions; reagents were 
mixed as shown in Table 2.5. 
Reaction 
Component 
Standard 
reaction 
Positive 
control 
Background 
control 
2X rapid ligation 
buffer 
5 l 5 l 5 l 
pGEM®-T Easy 
Vector (50ng) 1 l 1 l 1 l 
PCR product X l* - - 
Control insert DNA - 2 l - 
T4 DNA ligase 
1 l 1 l 1 l (3 Weiss units/ml) 
Nuclease free water Up to 10 l Up to 10 l Up to 10 l 
The reactions were incubated at 4˚C overnight to increase the number of 
transformants. 
2.1.3.4 Transformation 
Max Efficiency® DH5™ competent cells have been used for transformations 
with pGEM®-T Easy Vector, following manufacturer`s instructions. Briefly, 50 
l of competent cells were aliquoted into pre-chilled tubes and 1 l of the ligation 
reaction was added. Cells were incubated 30 minutes on ice, heat-shocked 30 
Table 2.5|  
Reagent mix for cloning into pGEM®-T Easy vector.  
*A volume corresponding to 1:1 or 3:1 insert:vector ratio has 
normally been used. To calculate the appropriate amount of insert 
to include in the ligation reaction we used the following equation: 
[(ng of vectors x kb size of insert)/kb size of vector] x 
insert:vector molar ratio = ng of insert. 
Size of vector pGEM®-T Easy = ~3 kb. 
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seconds in a 37˚C water bath, and placed back on ice for 2 minutes.  
450 l of room temperature LB medium were added and the samples were 
incubated at 37˚C, 225 rpm for 1 hour. Half the volume was spread onto LB plates 
containing 100 g/ml ampicillin and prepared by adding 15 l of 50 g/ml X-gal, 
and 3 l of 1 mM IPTG onto the plates 1 hour before using. Plates were incubated 
at 37˚C overnight. As successful insertion into pGEM®-T Easy Vector interrupts 
the coding sequence of -galactosidase, recombinant clones can be identified by 
colour screening, with clones containing PCR products generating white colonies.  
2.1.4 DNA preparation 
2.1.4.1 Mini-DNA preparations (minipreps) 
Minipreps were employed when only a small amount of DNA was required, i.e. 
for screening of positive colonies after transformation. On average, 5 white 
colonies per plate where selected and grown overnight at 37˚C, 225 rpm, in 5 ml 
of LB medium containing 100 g/ml of ampicillin. The following day DNA was 
isolated using Promega Wizard® Plus SV Minipreps DNA Purification System, 
according to manufacturer`s instructions. Briefly, 3 ml of bacteria culture were 
harvested by centrifugation at maximum speed in a tabletop centrifuge. Pellet was 
resuspended in Cell Resuspension Solution and lysed by Cell Lysis Solution. 
After short incubation, Alkaline Protease Solution was added to inactivate 
endonucleases and other proteins released during the lysis. Lysis was stopped by 
adding Neutralisation Solution. Bacteria lysate was centrifuged at maximum 
speed in a microcentrifuge for 10 minutes, and the cleared lysate transferred to a 
silica-membrane column. The column was washed with a Column Wash solution 
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containing ethanol and the DNA eluted in nuclease-free water. Eluted DNA was 
quantified and assessed for purity by NanoDrop (ND-1000 NanoDrop® 
Spectrophotometer; software: ND-1000 V3.2.1). 
2.1.4.2 Midi-DNA preparation (midipreps) 
When higher amounts of DNA were required, Promega PureYield™ Plasmid 
Midiprep System were used, following manufacturer`s instructions. The main 
differences compared with the miniprep system are the possibility of processing 
larger volume of bacteria culture (50-100 ml), and therefore obtaining larger 
amounts of purified DNA. Eluted DNA was quantified and tested as described 
above.  
2.1.5 Enzymatic Digestions 
Enzymatic digestions are used in order to generate compatible ends in vectors 
and inserts before ligation, or to check the correct size of the selected clones.  
In this work restriction digests were used: 
 to extract the inserts from the pGEM®-T Easy Vector; 
 to linearised the lentiviral backbone; 
 to test the presence and the correct size of the insert, after cloning in pGEM®-T 
easy or in the lentiviral vector. 
 
Restriction endonucleases employed in this study: 
 BamHI (NEB, Buffer BamHI, BSA): cloning site 
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 NotI (NEB, Buffer 3, BSA): cloning site 
 AscI (NEB, Buffer 4): cloning site for the MESV “leader sequence” (see chapter 
3, section 3.3.3.1) 
 ScaI (NEB, Buffer 3): to break the pGEM®-T Easy backbone when the insert 
had a similar size to the pGEM®-T Easy itself, in order to help the separation on 
gel. 
 
1 unit (U) of enzyme is defined as the amount of enzyme required to digest 1 g 
of DNA in 1 hour at 37˚C. The required amount of DNA was mixed with the 
appropriate dilution of the specific 10X Restriction Buffer recommended, the 
appropriate dilution of 100X BSA when required, and with sufficient amount of 
enzyme.  
To generate compatible ends for cloning, between 5 and 10 g of DNA from a 
midiprep were digested in a final volume of 100 l. To check the correct size of 
the inserts only 1 g of DNA was digested, in a final volume of 50 l. When 
double digestion was required, but no restriction buffer was compatible with both 
enzymes at the same time, restrictions were performed subsequently, heat 
inactivating the first enzyme (when possible) and substituting the restriction 
buffer by ethanol precipitation of the DNA (see below). 
2.1.6 Ethanol precipitation of DNA 
Ethanol precipitation of DNA was used to replace the restriction buffer in 
sequential digestions, when the efficiency of the second restriction enzyme was 
suboptimal in the buffer used for the first restriction digestion. 
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To precipitate DNA, 1/10 volumes of 3 M sodium acetate (pH 4.8) were added, 
followed by 2.5 volumes of cold ethanol. The solution was mixed thoroughly and 
placed at –80ºC for at least 30 minutes. The tube was then spun at 12,000 g for 15 
minutes at 4ºC. The supernatant was aspirated and the pellet washed once with 
70% ethanol, air-dried and resuspended in the desired buffer.  
2.1.7 Insert preparation 
Inserts were extracted by double digestion from the pGEM®-T Easy Vector. 
Digested DNA was run on agarose gel in order to separate the linearised 
fragments. All digested DNA volume was loaded on 1% agarose gel and run until 
the loading dye has reached the bottom end of the gel. The gel was then exposed 
to UV light for the shortest time possible in order not to damage the DNA and a 
thin slice of gel containing the fragment of interest was cut and carefully trimmed. 
DNA was purified from agarose as described in section 2.1.9. 
2.1.8 Backbone preparation 
2.1.8.1 Dephosphorylation of linearised DNA fragments 
During a ligation reaction the 5’ end phospho-group and the 3’ hydroxyl-group 
become the substrate for the T4 DNA ligase resulting in a phosphodiester bond. 
This could generate recircularisation of the vector, preventing the insertion of the 
transgene of interest. Therefore, especially when the extremities of the vector are 
blunt, or when high background is observed in the absence of the insert, 
dephosphorylation of the vector is required. By using the calf intestinal alkaline 
phosphotase (CIP, NEB), the 5’ phosphate ends of the DNA vector are removed, 
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and the vector is unable to self-ligate.  
After double digestion, the reaction was performed resuspending the DNA in 1X 
NEB buffer 3 at a concentration of 0.5g/10l, and adding 0.5U of enzyme per 1 
g of DNA. The reaction was incubated at 37ºC for 1 hour. 
2.1.9 Isolation of DNA from agarose gel 
The procedure to purify DNA from gel depends on the size of the fragment: for 
fragments longer than 10 kb we used QIAEX II Agarose Gel Extraction kit 
(Qiagen), while for shorter fragments we used QIAquick Gel Extraction kit 
(Qiagen), following manufacturer`s instruction. Both kits are based on 
solubilisation of the agarose and selective absorption of the DNA onto silica gel in 
the presence of high salt, but the QIAEX II Agarose Gel extraction kit, optimised 
for larger DNA fragments (up to 50 kb), employs silica gel particles, while the 
QIAquick Gel Extraction kit, optimised for fragments up to 10 kb, employs silica 
gel membranes. Washing steps remove impurities and DNA is eluted in water.  
2.1.10 Cloning in lentiviral vector 
2.1.10.1 Ligation 
Ligation between the BamHI-NotI linearised, dephosphorylated, and gel 
purified lentiviral vector, and the genes excised from pGEM®-T Easy were 
performed following the instruction for the Rapid DNA Ligation Kit (Roche). 
Briefly, 50 ng of lentiviral backbone and a 3:1 insert:vector ratio were diluted in 
1X DNA Dilution Buffer, in a final volume of 10 l. 10 l of T4 DNA Ligation 
Buffer were added to the DNA mix, followed by 1 l of T4 DNA Ligase. The 
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reaction was incubated 10 minutes at room temperature. 
2.1.10.2 Transformation 
Transformation of DH5 cells was performed as described above (see section 
2.1.3.4), using 1-2 l of ligation mix. 
Colonies were screened by miniprep (section 2.1.4.1) followed by double 
digestion BamHI-NotI (section 2.1.5), and correct clones were amplified by 
midiprep (section 2.1.4.2). 
2.1.11 DNA sequencing 
DNA from selected clones was sequenced by The Sequencing Service of the 
University of Dundee. 
Primers mapping shortly upstream (Lentivector F, see table 2.1) and 
downstream (Lentivector R, see table 2.1) of the cloning site were used to check 
the correct insertion of sequences into the lentiviral vector. 
2.2 PRODUCTION OF LENTIVIRAL VECTORS 
2.2.1 Virus production 
Generation of lentiviral vectors was performed by triple transfection of 293T 
cells with three different plasmids: the lentiviral vector containing the gene of 
interest, a second plasmid coding for the VSV-G envelope, and a third plasmid 
(pCMVR8.91) coding for viral enzymes required for reverse transcription and 
integration. Supernatant containing virus particles was collected and cleared after 
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48 and 72 hours and concentrated by ultracentrifugation. Each virusprep 
correspond to the supernatant collected from four 10 cm tissue culture dishes; 
virus preparations were scaled up as needed, taking into consideration the amount 
of virus required and the average yield of the specific lentivirus, often depending 
on the size of the transgene. 
2.2.1.1 Cell plating 
On the first day, 293T cells were washed, trypsinised, counted and 1.3·10
6
 
cells/plate were seeded in 10 ml of complete DMEM (10% FCS, 1% Gln). Cells 
were incubated at 37˚C, 10% CO2 till the following day.  
On the following day media was replaced (10 ml) 2 hours before transfection.  
2.2.1.2 Transfection 
Transfections of 293T cells were performed using FuGENE®6 Transfection 
Reagent (Roche). FuGENE is a blend of lipids and other components that forms 
complexes with DNA and transports it into animal cells. Benefits of FuGENE 
over other transfection systems are the high transfection efficiency of 293T and no 
cytotoxicity. 
200 l of OPTIMEM were aliquoted into 4 eppendorf tubes and 18 l of 
FuGENE were added to each tube, without allowing the transfection reagent to 
touch the side or the bottom of the tubes. The liposomes were left for 15 minutes 
at room temperature. In the meantime, the DNA mix was prepared as follows 
(Table 2.6): 
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Component Volume 
pCMVR8.91 plasmid 6 g 
VSV-G plasmid 6 g 
Lentiviral vector 9.2 g 
Water Up to 200 l 
50 l of DNA mix were added to each eppendorf containing FuGENE, and the 
mix was incubated at room temperature to allow the formation of the DNA-
liposome complexes. After at least 30 minutes, the complexes were added to the 
cells and incubated at 37˚C, 10% CO2 overnight.  
The following day the media was replaced.  
2.2.1.3 Supernatant collection 
The supernatant was collected at 48 and 72 hours, and cleared from detached 
cells and cell debris by low speed centrifugation (5 minutes, 300 g), followed by 
filtration (0.45 m filter). Cleared supernatant was kept in the fridge at 4˚C until 
ready to be concentrated.  
2.2.1.4 Virus concentration 
After the last collection, the supernatant was pooled together and kept cold. 
Maintaining the temperature low is critical along all the procedure. Therefore viral 
supernatant, tubes, rotor, centrifuge, buckets must be kept refrigerated all the time. 
The supernatant was aliquoted into sterile pre-chilled centrifuge tubes and 
ultracentrifuged (Sorvall Discovery 100SE) at 4˚C for 2 hours, at 25,000 rpm.  
Table 2.6|  
DNA mix for triple transfection of 
293T cells. 
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After centrifugation, the supernatant is removed by inversion and the tubes kept 
upside-down to drain all the media from the walls. 50 l of complete media 
(DMEM, 10% FCS) were added to each tube and the virus resuspended by 
pipetting. The tubes were left on ice for 10 minutes to allow complete 
resuspension of the virus and finally all volumes were pooled together in a pre-
chilled eppendorf tube. The eppendorf was spun in a table top microcentrifuge 
(13,000 rpm for 1.5 min) to remove bubbles, and the virus aliquoted in 20 l 
aliquots in sterile pre-chilled eppendorf tubes. 
Viruses were stored at -80˚C. 
2.2.2 Virus titration 
Each virusprep was quantified by measuring the efficiency of transduction of 
different amounts of virus on 293T cells. 293T cells are known for their high 
permissivity to viral infection, allowing the approximation that 1 cell is infected 
by 1 viral particle. 200,000 293T cells/well were seeded into six wells of a 24-
well plate in a volume of 400 l. One aliquot of virus was defrosted on ice and in 
the meantime 100 l of complete media were aliquoted into 6 eppendorf tubes. To 
each tube the following volumes of virus were added: 0 l; 0.3 l, 0.5 l; 1 l; 2 
l; 5 l, and the content of each tube was transferred onto the cells. Cells were 
incubate at 37˚C for 72 hours and GFP expression was measured by flow 
cytometry, calculating the percentage of positive cells compared to the 
untransduced cells.Virus concentration was calculated by using the following 
equation: 
Virus particles/l = [200,000 · ( % positive cells / 100)] / volume of virus added 
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2.2.3 Transduction 
10·10
5
 cells were washed, resuspended in 400 l of complete media, and seeded 
in a 24 well plate. The volume of virus needed to transduce the desired number of 
cells was calculated using the following equation: 
[10·10
5
 (= number of cells to transduce) · MOI] / virus titre 
where MOI (Multiplicity Of Infection), represent the number of infecting 
particles per cell.  
The corresponding number of vials was defrosted on ice and the calculated 
volume of virus was added to 100 l of complete media previously aliquoted in an 
eppendorf tube. The diluted virus was added onto the cells and the plate incubated 
at 37˚C for 72 hours. After 24 hours more media was added to the cells. 
Efficiency of transduction was measured by flow cytometry by comparison with 
untransduced cells. 
2.3 REVERSE TRANSCRIPTION AND REAL TIME 
PCR 
2.3.1 RNA extraction 
RNA was extracted from 2·10
6
 cells for each sample. Cells were lysed in 
Trizol® (Invitrogen), a mono-phasic solution of phenol red and guanidine 
isothiocyanate, which maintains the integrity of RNA while disrupting cells and 
dissolving cell components. RNA extraction was performed following 
manufacturer`s instructions; briefly, after resuspension of cell pellet in Trizol®, 
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chloroform was added, followed by centrifugation, in order to separate the 
solution into an aqueous phase, containing exclusively RNA, and an organic 
phase containing DNA and proteins. RNA is recovered from the aqueous phase by 
precipitation with isopropyl alcohol, and resuspended in RNAse free water. 
RNA was quantified by Nanodrop and stored at -80˚C. 
2.3.2 DNAse treatment 
3 g of RNA were treated with DNAse, in order to ensure the complete removal 
of any DNA contamination: 1 l of 10X DNAse buffer and 3 l of DNAse (FPLC 
pure Dnase I, 5000U, Amersham Pharmacia Biotech Inc.) corresponding to 3 
units were added to the RNA. RNAse free water was added up to 10 l and the 
sample incubated at 37˚C for 30 minutes. The reaction was stopped by adding 1 l 
of STOP buffer and incubating at 65˚C for 10 minutes. 
2.3.3 cDNA reverse transcription 
2 g of RNA were mixed to 1 l of Random Primers (Promega), 1 l of RNAse 
inhibitor (Promega), and incubated at 70 ˚C for 3 minutes to melt secondary 
structures within the template, and then immediately on ice to prevent secondary 
structure re-formation. The following components were then added: 5 l of 
dNTPs (40 mM), 5 l of 5X MLV buffer (Promega), 5.3 l of RNAse free water, 
and 1 l of M-MLV reverse transcriptase enzyme (Promega). The mix was 
incubated 1 hour at 37 ˚C. 
The remaining RNA was used as a negative control, to exclude the presence of 
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DNA contaminants, and was therefore treated according to the same procedure, 
but in the absence of M-MLV. 
For qualitative experiments aiming at testing the presence of a transcript, both 
the samples and the corresponding negative controls were amplified by PCR and 
separated on an agarose gel. 
2.3.4 Taq Polymerase Chain Reaction 
For PCR screening and control PCRs high fidelity was not required and we 
employed GoTaq® Flexi DNA Polymerase (Promega). The enzyme is a modified 
form of Taq DNA polymerase that lacks 5`→3` exonuclease activity. 
I this work, Taq PCR was employed in order to confirm the presence of the 
transcript in K562 after transduction with lentiviruses encoding different DENV 
NS proteins. For NS1/NS2A, NS4A, and NS4B the same primers used for cloning 
were employed; for NS2B/NS3 and NS5 internal primers amplifying a shorter 
region were specifically designed (Table 2.7) 
Primer Sequence 
NS2B/NS3 RT Forward AGGCTGGAAGCTAGAAGGAG 
NS2B/NS3 RT Reverse GTCGATGATTGGAGATCCTG 
NS5 RT Forward ACAAACCACATGGAAGGAGA 
NS5 RT Reverse GTCAGGTGCTGAATGCTTTT 
PCR were performed following manufacturer`s instructions, carefully mixing 
the following components (Table 2.8): 
Table 2.7|  
Primers for amplification from cDNA of NS2B/NS3 and 
NS5. 
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Component Volume 
Final 
Concentration 
ddH2O Up to 50 l   
5X GoTaq® Flexi Buffer 10 l 1X 
MgCl2 Solution, 25 mM 5 l 2.5mM 
10 mM dNTPs 1 l 200 M each 
25 M Primer Forward 1 l 0.5 M 
25 M Primer Reverse 1 l 0.5 M 
DNA template X (10-50 ng)   
GoTaq® DNA Polymerase 0.25 l 1.25 U 
and using the following conditions (Table 2.9)  
Cycle step Temperature Time 
Number 
of 
cycles 
Initial 
denaturation 95˚C 2 minutes 1 
Denaturation 95˚C 1 minute 
30 Annealing* X˚C 1 minute 
Extension 72˚C 1 minute/kb 
Final Extension 
72˚C 5 minutes 
1 
4˚C hold 
2.3.5 Real time PCR 
In this work real-time PCR (RT-PCR) were performed to measure the induction 
of the type I IFN sensitive genes (ISG) MX1 and OAS1 in response to stimulation 
Table 2.8|  
Reagent mix for PCR from cDNA. 
Table 2.9|  
Cycling conditions for PCR from cDNA.  
*The annealing temperature was normally 5°C below the 
calculated melting temperature (Tm) of the primers. The Tm 
of each primer has been calculated using the nearest-neighbor 
method on the Finnzymes` website (www.finnzymes.com).  
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with IFN-. 
Cells were stimulated with 100 IU/ml of IFN-and the RNA extracted, DNAse 
treated and reverse transcribed as described above. SYBR® Green is a DNA-
binding dye that incorporates into dsDNA and emits fluorescence only when 
bound to dsDNA. Maximal excitation and emission are, respectively, at 494 nm 
and 521 nm. As the fluorescent signal increases proportionally with the increasing 
amount of amplicon generated in each cycle, the techniques can be used for 
accurate quantification. 
Primers were designed following the same criteria described above but, 
differently from ordinary primers, RT-PCR primers were specifically designed to 
amplify internal regions of the genes of interest no longer that 100-200 bp, and 
having both a melting temperature between 50 and 60˚C. The primers used are 
listed in Table 2.10 below: 
Primer name Primer sequence 
MX1 Forward AACAACCTGTGCAGCCAGTA 
MX1 Reverse AAGGGCAACTCCTGAGAGTG 
OAS1 Forward ACAGGCAGAAGAGGACTGGA 
OAS1 Reverse GCCAGGAGTCAGGAGACTTG 
GAPDH Forward ACAGTCCATGCCATCACTGCC 
GAPDH Reverse GCCTGCTTCACCACCTTCTTG 
2 l of template were added to a mix constituted of 12.5 l of SYBR® Green 
(Qiagen), 9.5 l of water and 1 l of primers (10 M). A sample in which the 
template had been replaced with water has been used as a negative control, to 
exclude the presence of contaminants. All samples were analysed in duplicate.  
Table 2.10|  
Primers employed for real time PCR. 
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Samples were run in a Rotor-Gene (RG-3000, Corbett Research; software: 
Rotor-Gene 6), using the following cycling conditions (Table 2.11): 
Cycle step Temperature Time 
Number 
of cycles 
Initial 
denaturation 
95˚C 15 minutes 1 
Denaturation 94˚C 15 seconds 
35 Annealing 50-60˚C 20-30 seconds 
Extension 72˚C 10-30 seconds 
To correct experimental variation the experiments were normalised to the 
constitutively expressed gene GAPDH, coding for an abundant glycolytic enzyme 
and present in most cells. GAPDH was chosen because its expression is constant 
among different tissues and because it is not influenced by the experimental 
treatment. Differences in the expression of GAPDH indicate that the expression of 
the normaliser is either up or down-regulated, and therefore the experiment must 
be discharged. 
Data analysis 
After the run was completed, the threshold cycle (CT) value (cycle at which a 
significant increase with an exponential growth of PCR product is first detected) 
was manually set. The Ct value is inversely proportional to the amount of product 
present. The threshold should be placed above any baseline activity and within the 
exponential increase phase (which looks linear in the log transformation).  
The Ct of the gene of interest was normalised to the housekeeping gene 
GAPDH, using the algorithm: 
Table 2.11|  
Cycling condition for real time PCR. 
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Relative expression=2
(Ct GAPDH – Ct Gene of interest) 
2.4 IMMUNOCHEMISTRY TECHNIQUES 
2.4.1 SDS-Polyacrylamide gel electrophoresis (SDS-PAGE)  
2.4.1.1 Sample preparation 
Pellet from 3-10·10
5
 cells was washed twice in PBS before adding 100 l of 
whole cell lysis buffer (2 ml HEPES KOH [1 M], 5 ml NaCl [1 M], 2 ml NP40, 
0.5 g Sodium Deoxycholate, 0.2 g SDS, 1 ml Sodium Orthovanadate [100 mM], 1 
ml EGTA [100 mM], 10 ml Sodium Fluoride [100 mM], made up to 100 ml with 
deionised H2O) containing 10 l Sigma protease inhibitor cocktail, and 10 l 
PMSF [100 mM] freshly dissolved in DMSO. Cell lysate was centrifuged at 
13,000 rpm at 4°C for 15 min to remove the nucleic acid pellet. To 20 l of lysate, 
2.5 l DTT [1 M] and 7.5 l of gel loading buffer (Invitrogen) were added, and 
the sample was heated at 70 °C for 10 min, to allow reduction of disulphide 
bonds.  
2.4.1.2 Electrophoresis  
 Samples were loaded onto BIO-RAD minigels (for 15 ml of 10% acrylamide 
running gel: 6.15 ml H2O; 5 ml 30% acrylamide, 3.75 ml 0.5 M Tris-HCl pH8.8, 
150 l 10% SDS, 75 l 10% APS, 15 l TEMED; for 10 ml of stacking gel: 6.1 
ml H2O, 1.3 ml 30% acrylamide, 2.5 ml 0.5M Tris-HCl pH6.8; 100 l 10% SDS, 
50 l 10% APS, 20 l TEMED), using the following running buffer: 3 g Tris 
base, 14.5 g Glycine, 1 g SDS, in 1 litre of deionised H2O.  
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Gels were run at 200 V until the front of the dye reached the bottom of the gel. 
2.4.2 Western blotting 
2.4.2.1 Protein transfer 
After separation by SDS-PAGE the stacking was gel removed and the running 
gel was soaked in protein transfer buffer (9 g Tris, 1.46 g Glycine, 100 ml 
Methanol, for 500 ml of deionised H2O) for 10 minutes for equilibration, in order 
to prevent any distortion during the transfer process. A sheet of Hybond PVDF 
membrane or nitrocellulose membrane (Amersham) was cut to size and 
equilibrated briefly in transfer buffer. Before equilibration in transfer buffer, 
PVDF membranes only were activated in methanol. The transfer process was 
carried out at 15 V for 45 minutes-1 hour in a BioRad Transblot®SD Semy-Dry 
Transfer cell.  
2.4.2.2 Blocking 
Following transfer, the membrane was rinsed briefly in TBS. Non-specific 
binding sites were blocked by immersing the membrane in blocking solution 
(TBS-Tween 0.2% with 5% PVP and 0.5% FBS; or TBS-Tween 0.2% with 5% 
non-fat dry milk, depending on the primary antibody) at 4˚C overnight, or at room 
temperature for 1 hour.  
2.4.2.3 Blotting 
Blocking is followed by incubation with the appropriate dilution of the primary 
antibody in blocking solution for an hour at room temperature, or at 4 ºC 
overnight. After incubation the membrane was rinsed five times in washing buffer 
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(TBS-Tween 0.2%), alternating quick rinses with longer washings (5 minutes), 
and then incubated again for 1 hour at room temperature with an appropriate 
dilution of secondary antibody in blocking solution. The washing steps were 
repeated as above in TBS without Tween.  
Primary antibodies employed in this study:  
 anti NS1 (5H5.4): mouse monoclonal (from Paul Young) 
 anti NS5: rabbit polyclonal (from Andrew Davidson) 
 anti-FLAG M2: mouse monoclonal (Sigma) 
 anti-human STAT1: mouse monoclonal (Zymed) 
 anti-human phospho-STAT1: mouse monoclonal (Zymed) 
 anti-human STAT2: mouse monoclonal (BD Transduction Laboratories) 
 anti-human phospho-STAT2: rabbit polyclonal (Upstate Technology) 
 anti-phospho Tyk2: rabbit polyclonal (Cell Signaling Technology) 
 anti-human phospho-Tyk2: rabbit polyclonal (Cell Signaling Technology) 
 anti-human -actin: rabbit polyclonal (Sigma) 
Secondary antibodies employed in this study: 
 HRP-conjugated goat anti-mouse (Dako Cytomation) 
 HRP-conjugated goat anti-rabbit (Dako Cytomation) 
2.4.2.4 Development 
The membrane was covered by a mix of ECL or ECL-Plus reagents 
(Amersham) following manufacturer`s instructions and incubated for 1-5 minutes. 
The membrane was then carefully drained on tissue, wrapped in clingfilm, and 
exposed to a sheet of autoradiography film for 2seconds-5minutes before 
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development (Developer Xograph imaging system CompactX4). 
2.4.3 NS5-FLAG Immunoprecipitation 
Immunoprecipitation (IP) of tagged proteins is a well established procedure 
which has been standardised for different tags. FLAG is a short peptide (N-Asp-
Tyr-Lys-Asp-Asp-Asp-Asp-Lys-C), which allows fusion proteins to retain their 
original conformation and function. Its hydrophilic character increases the 
likelihood that it will be located on the surface of the protein, where it is 
accessible to the antibody.  
To immunoprecipitate NS5-FLAG, we employed the FLAGIPT1 FLAG® 
Immunoprecipitation Kit from SIGMA, following manufacturer`s instructions. 
The IP is performed with anti-FLAG® -M2 affinity gel, which is a highly specific 
monoclonal antibody covalently attached to agarose resin. The high 
standardisation of this procedure allows efficient binding of FLAG-tagged 
proteins without need for preliminary steps and calibration. 
Briefly, 10
7 
cells were washed twice in PBS and then lysed in 1 ml of Lysis 
Buffer, containing 10 l of Sigma protease inhibitor cocktail, for 30 minutes at 
4˚C, in a roller shaker. The lysate was centrifuged 10 minutes, at 12,000 g, 4˚C, 
and the supernatant transferred into a chilled test tube.  
40 l of resuspended gel were used for each reaction and washed 3 times with 
0.5 ml of 1X Washing Buffer, once with 0.5 ml of Elution Buffer to remove traces 
of unbound anti-FLAG antibodies, and 3 more times with 0.5 ml of 1X Washing 
Buffer. 900 l of cell lysate were added to the resin and the final volume was 
brought to 1 ml with Lysis Buffer. The remaining 100 l of whole lysate were 
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kept as control for following immunoblots.  
Two control reactions were performed: a positive control consisting of the 
immunoprecipitation of a FLAG-BAP fusion protein, and a negative control 
consisting of blank reagents, without proteins. For the positive control, 1 ml of 1X 
Wash Buffer and 4 l of 50 ng/l (= 200 ng) of FLAG-BAP fusion protein were 
added to the resin; for the negative control only 1 ml of Lysis Buffer with no 
proteins was added to the resin. 
Samples and controls were gently agitated on a roller shaker for at least 2 hours. 
After incubation the resin was centrifuged for 30 minutes at 8,200 g and the 
supernatant, containing all the unbound proteins, was removed. The resin was 
washed 3 times with 1X Washing Buffer. 
Elution was performed with 3X FLAG™ peptide, which provides efficient and 
gentle elution through direct competition. 3 l of 5 mg/ml 3X FLAG peptide were 
added to 100 l of 1X Washing Buffer. After 30 minutes of gentle shaking at 4˚C, 
the resin was centrifugated and the supernatant, containing the eluted NS5-FLAG 
was collected and stored at -20 ˚C, and then used for immunoblots as described 
above. 
2.4.4 NS1 ELISA 
A 96 well plate was coated overnight at 4 C with 50 l of Coating Buffer (1.59 
g Sodium Carbonate; 2.93 g Sodium Bicarbonate; 0.2 g Sodium Azide; 900 ml 
deionised H2O. Adjust to pH 9.6 with HCl and make up to 1 L), containing -NS1 
antibody (1:1500). The plate was washed 3 times with PBS Tween20, and each 
well blocked with 150 l of 1% gelatin in PBS, 0.1% Sodium Azide for 1 hour at 
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room temperature. The plate was then emptied and washed again 3 times with 
PBS Tween20.  
The samples were serially diluted in PBS Tween20 containing 0.25% gelatin, 
and together with a standard curve of Dengue NS1 (100-5 ng/ml), left to incubate 
for 1 hour at 37C, before washing 3 times with PBS-Tween20. 100 l of 1H7.4 
-NS1 antibody diluted to 1/1000 in PBS Tween20-0.25% gelatin were added to 
each well and incubated for 1 hour at 37°C, before washing 3 times with PBS 
Tween20. 100 l of 1/1000 dilution of goat -mouse IgG/Peroxidase conjugate 
were added to each well and again incubated for 1 hour at 37°C. The plate was 
then washed three times and 100 l of TMB substrate solution were added for 15 
minutes at room temperature in the dark. The incubation was stopped with 100 l 
of 1 M H2SO4 and the plate mixed with swirling for 15 seconds. The absorbance 
at 450 nm was measured in a microplate reader (Tropix TR 717 microplate 
Luminometer PE applied Biosystems) within 5 minutes after the addition of the 
stop solution.   
2.4.5 Surface Staining and Flow Cytometry 
In this work, surface staining was employed whenever we wanted to test the 
presence of a specific antigen, or alteration on its expression on cell surface. In 
this work surface staining was used: 
-to measure expression of the IFN sensitive antigen HLA-ABC in response to 
both IFN- and IFN- in different K562 based cell line 
-to measure the expression of the type I IFN receptor IFNAR2c 
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Primary antibodies employed in this study: 
 anti-human HLA-ABC (clone W6/32): mouse monoclonal (Dako 
Cytomation) 
 anti-human IFNAR2c: mouse monoclonal (CalbioChem) 
Secondary antibodies employed in this study:  
 APC-conjugated goat anti-mouse immunoglobulins (Jackson 
Immunoresearch) 
 PE-conjugated goat anti-mouse immunoglobulins (Jackson Immunoresearch) 
 
All stainings were performed on 1-3·10
5
 cells. Cells were washed once in HBSS 
and incubated in 50 μl of blocking buffer (HBSS, 0.1% sodium azide, 5% serum 
from the same species of the secondary antibody) for 1 hour at 4 ˚C. After 
incubation, 50 μl of primary antibody at the appropriate dilution in blocking 
buffer were added, and the sample was incubated 30-45 minutes at 4 ˚C. Negative 
and isotype controls were incubated without primary antibody. Cells were washed 
3 times with blocking buffer in order to remove the unbound primary antibody, 
and 50 l of the secondary antibody at the appropriate dilution in blocking buffer 
were added; the samples were incubated for 20-30 minutes at 4˚C in the dark. 
Negative staining controls only were incubated without secondary antibody. After 
incubation, cells were washed 3 times with HBSS to remove unbound secondary 
antibody, and finally resuspended in 100 l of 3.8% formaldehyde. Samples were 
kept at 4˚C in the dark until ready to be analysed by flow cytometry, normally no 
later than 12 hours.  
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Controls 
Negative control: cells incubated in the absence of primary and secondary 
antibodies, to test the specificity of the staining and check autofluorescence of 
cells. 
Isotype control: cells incubated in the absence of primary antibody but in the 
presence of the secondary antibody, to test the specificity of the secondary 
antibody. 
2.5 TRANS-RESCUE ASSAY 
2·10
6
 non-adherent cells were treated overnight with 100 IU/ml of IFN-2a. The 
following day 1x10
6
 cells were counted and 0.5 pfu/cell of EMCV added in 
DMEM containing 2% serum for 1 hour at 37C. Cells were washed and seeded 
in 6-well plates in DMEM containing 10% serum. After 18 hours, the cells were 
centrifuged at 6000 rpm for 2 minutes and the supernatants collected. The 
supernatants were added as a serial dilution onto an A549 monolayer (2·10
5
 cells 
plated the night before) in a 96-well plate for 1 hour, before being replaced with 
DMEM containing 10% serum and incubated overnight. The following day, cell 
viability was determined by staining with methyl violet and reading the 
absorbance at 570 nm in a plate reader (Tropix TR 717 microplate Luminometer 
PE applied Biosystems). The OD measured was plotted against the serial dilution 
of the EMCV: low optical density is index of cell death, while high optical density 
suggests high viability.  
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2.6 CELL MAINTENANCE 
K562: RPMI 10% foetal bovine serum 
   Passaged 1:10 every 3-4 days 
K562_Replicon: RPMI 10% foetal bovine serum, with 3 ng/ml of puromycin 
    Passaged 1:10 every 3-4 days 
293T: DMEM 10% foetal bovine serum 
           Passaged 1:10 every 3-4 days 
 
All cells derived from K562 following lentivirus transduction have been 
cultured as parental K562.
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Chapter 3.  
DEVELOPMENT OF K562 
CELL LINES EXPRESSING 
INDIVIDUAL DENV NON-
STRUCTURAL PROTEINS 
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3.1 INTRODUCTION 
The inhibition of the type I IFN response in DENV infection has been 
extensively described (see chapter 1, section 1.5.2.2). Our group and others have 
reported reduced intracellular levels of STAT2, a key component of the type I IFN 
signalling pathway, in DENV infected cells (Jones et al. 2005; Umareddy et al. 
2008). This suggests that STAT2 reduction is at least one of the mechanisms 
responsible for the inhibition of the IFN response.  
In work published in 2005, our group reported inhibition of type I IFN and 
reduction of cellular STAT2 levels in human cell lines stably expressing the 
DENV replicon CprMEPAC2A, a self-replicating RNA-based DENV-2 (New 
Guinea C strain, NGC) sub-genome in which the genes coding for the structural 
proteins have been removed (Jones et al. 2005). The absence of viral entry and the 
lack of structural components imply that both IFN inhibition and STAT2 
reduction must involve one or more DENV non-structural proteins.  
The initial question that we wanted to address in this project was which of the 
DENV non-structural protein/s was/were responsible for the inhibition of IFN- 
and for the reduction of STAT2 levels. 
 
 In order to test the roles of the individual DENV non-structural components in 
the subversion of the type I IFN response, in the first part of this work we aimed 
to establish five K562 cell lines, each one expressing a different DENV NS 
protein cassette. K562 are a human chronic myeloid leukaemia cell line, originally 
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established from a patient in blast crisis (Klein et al. 1976). Similarly to 
monocytes, macrophages and dendritic cells, K562 are cells of myeloid 
haematopoietic origin, and therefore related to DENV target cells in vivo (chapter 
1, section 1.2.2). K562 have been extensively used by our group since they 
efficiently support the replication of the DENV replicon CprMEPAC2A; 
moreover, since they are incapable of producing type I IFN (Diaz et al. 1988), 
their response to viral infection can be studied in the absence of a complicating 
IFN autocrine loop.  
One potential disadvantage of using K562 cells is that, in common with many 
other cells of myeloid hematopoietic origin, they are difficult to transfect using 
conventional mammalian expression vectors and standard molecular biology 
techniques. In order to overcome the refractoriness of K562 cells to the most 
common transfection methods, we decided to express DENV NS proteins in the 
context of a lentiviral vector. The lentiviral vector used in this work is the dual 
promoter self-inactivating vector pHRSIN-CSGWdINotI_pUb_Em (Figure 3.1), 
described by Rowe (Rowe et al. 2006) and Escors (Escors et al. 2008) and kindly 
given to us by Professor Mary Collins. In order to diminish the risk of vector 
mobilisation and recombination, the 5` LTR (Long Terminal Repeat) are replaced 
by heterologous promoting sequences, while the U3 region of the 3` LTR is 
partially deleted to abolish promoter activity (Zufferey et al. 1998). The 
sequences Ψ/RRE (Rev Response Element) is preserved in order to improve RNA 
packaging efficiency and nucleocytoplasmic transport, and the 178 base pair 
fragment cPPT (central PolyPurine Tract) is a cis-acting sequence enhancing the 
nuclear translocation of the pre-integration complex (Demaison et al. 2002). The 
WPRE (Woodchuck hepatitis virus Post-transcriptional Regulatory Element) was 
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added to increase the expression of the transgene by increasing the levels of 
nuclear transcripts and facilitating RNA nuclear export (Zufferey et al. 1999; 
Schambach et al. 2000).  
The expression of the transgene is regulated by the SFFV (Spleen Focus 
Forming Virus) promoter, chosen for its high activity in human dendritic cells 
(Rowe et al. 2006), and to overcome the relative inefficiency of the HIV long 
terminal repeat (LTR) in the absence of Tat protein (Demaison et al. 2002), while 
the Ubi (Ubiquitin) promoter regulates the expression of the reporter gene 
emerald GFP (Em). The employment of a dual promoter system allows the 
expression of a fluorescent marker with less likelihood of interference with the 
transgene. 
 
3.2 
Figure 3.1|  
Schematic representation of the lentiviral vector pHRSIN-
CSGWdINotI_pUb_Em. LTR: long terminal repeats; RRE: rev response 
element; cPPT: central poly-purine tract; SFFV: spleen focus forming virus; 
WPRE: woodchuck hepatitis virus post-transcriptional regulatory element; 
Ub: ubiquitin. U3: 400-nucleotide deletion in the 3`LTR that abolishes 
promoter activity. 
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OBJECTIVES 
 To clone separate DENV NS protein cassettes into the dual promoter 
lentiviral vector pHRSIN-CSGWdINotI_pUb_Em 
 to generate five different K562 cell lines, each one stably expressing an 
individual DENV NS protein cassette, by transducing K562 cells with the 
corresponding lentiviral vectors 
 to validate and optimise the expression of DENV NS proteins in K562 cells. 
3.3 RESULTS 
3.3.1 Generation of lentiviruses encoding individual DENV NS 
proteins 
3.3.1.1 Design of DENV NS cassettes 
In designing the separate NS cassettes to be cloned into the lentiviral vector, we 
took into account what is known about the functions and localisation of the 
individual NS proteins in the context of DENV infection. NS2A has been shown 
to act as a GPI anchor for NS1 signal and to allow the correct localisation of NS1 
in the ER (chapter 1, section 1.2.4.1) (Falgout et al. 1989; Jacobs et al. 2000), and 
therefore NS1 and NS2A were expressed together. The proteolytic site between 
NS1 and NS2A in DENV polyprotein is recognised and cleaved by an ER 
protease (see section 1.2.4.1), generating two individual proteins. NS3 and its co-
factor NS2B were also expressed together (chapter 1, section 1.2.4.2) (Erbel et al. 
2006) and the proteolytic site between the two is cleaved by the proteolytic 
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complex NS2B/NS3 in an autoproteolytic event. The short 2K fragment localised 
between NS4A and NS4B was cloned at the N-terminal of NS4B, to allow correct 
localisation of NS4B in the ER (chapter 1, section 1.2.4.4) (Miller et al. 2007), 
and because this sequence has been reported to play a role the IFN antagonism 
attributed to NS4B (Munoz-Jordan et al. 2003). This short sequence is also known 
to be cleaved by host proteases. Therefore, all the NS protein cassettes were 
engineered in order to be finally expressed as individual proteins. 
Each cassette (NS1/NS2A, NS2B/NS3, NS4A, NS4B, and NS5) was amplified 
by PCR from the DNA genome of the DENV replicon CprMEPAC2A: forward 
and reverse primers were designed in order to incorporate BamHI and NotI 
restriction sites at the 5` and 3` termini respectively, necessary for subsequent 
cloning into the lentiviral vector. A Kozak sequence (CACCATG), required for 
optimal transcription in eukaryotic systems, was inserted immediately 
downstream of the restriction site in all the forward primers, and a stop codon was 
incorporated before the restriction site in all the reverse primers (see chapter 2, 
Table 2.1). 
3.3.1.2 Cloning of DENV NS protein cassettes into the lentiviral vector 
pHRSIN CSGWdINotI_pUb_Em 
After high-fidelity PCR amplification, the correct size of each PCR product was 
confirmed by DNA electrophoresis (Figure 3.2, A). Restriction digest of linear, 
amplified fragments is inefficient, and therefore each blunt-ended PCR product 
was first subcloned into the vector pGEM®-T Easy, and then sequentially 
digested by the restriction enzymes BamHI and NotI. Inserts were separated by 
DNA electrophoresis, isolated by gel extraction and purification, and finally 
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cloned into the linearised and dephosphorylated lentiviral vector, as described in 
chapter 2, section 2.1. Correct sequences and insertions were checked by double 
digestion BamHI-NotI (Figure 3.2, B) and by DNA sequencing.  
For generation of lentiviruses, all lentivector constructs were amplified by DNA 
midi-preparations. 
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Figure 3.2|  
A. Gel electrophoresis of PCR products amplified from the DNA replicon 
CprMEPAC2A Each cassette (NS1/NS2A, NS2B/NS3, NS4A, NS4B, and 
NS5) was amplified by High-Fidelity DNA polymerase from the DNA replicon 
CprMEPAC2A, and the PCR products were analysed by gel electrophoresis. 
The gel shows the correct size of each fragment and the absence of unspecific 
bands.  
B. Gel electrophoresis of lentiviral vectors containing individual DENV NS 
protein cassettes, before and after double digestion BamHI-NotI. Each 
cassette amplified by PCR was subcloned into the pGEM®-T Easy vector, 
extracted by double digestion BamHI-NotI and cloned into the lentiviral vector 
pHRSIN-CSGWdINotI_pUb_Em. In order to verify the presence and correct 
insertion of each cassette, 1 g of each vector was digested by the restriction 
enzymes BamHI and NotI and loaded on agarose gel. The picture shows each 
construct before and after double digestion. 
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3.3.1.3 Virus preparation 
Each virus was prepared by transient transfection of 293T cells with the 
lentiviral vectors described above and two more plasmids: a multi-deleted 
packaging plasmid coding for HIV gag and pol genes, required for vector particle 
production and efficient transduction of target cells, and the envelope plasmid 
VSV-G. VSV-G envelope protein binds to target cells via a receptor-independent 
mechanism, interacting with common phospholipids on the membrane of the 
target cell. VSV-G confers on the virus a broad tropism and makes the virus 
particles resistant to ultracentrifugation and long-term storage; furthermore, it 
directs lentiviral vector entry to an endocytic pathway, which reduces the 
requirements for viral accessory proteins for infectivity (reviewed in Cockrell and 
Kafri 2007). Viruses were prepared as described in chapter 2, section 2.2. 
Viruses were titrated by infecting 293T cells with sequential dilutions of virus 
and measuring GFP expression by flow cytometry after 72 hours: depending on 
size and characteristics of the transgene, virus titres were 10
7
-10
8
 infecting 
units/ml. 
3.3.2 Development of K562 cell lines expressing individual 
DENV NS proteins 
3.3.2.1 Transduction of K562 
The lentiviruses described above were employed to transduce K562 cells. 
Transduction of K562 was carried out at a multiplicity of infection (MOI) that 
ensured at least 50% transduced cells and at the same time minimised the number 
of vector integrating copies, in order to minimise the risk of experimental artefacts 
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from disruption of host cell genes. In order to assess the optimal MOI to employ, 
we transduced K562 cells at MOI 1, 4, and 7 with the lentivirus containing the 
NS1/NS2A cassette. After 72 hours, GFP expression was measured by flow 
cytometry. As shown in Figure 3.3, at MOI 4 more than 50% of the cells (74%) 
were GFP positive, and therefore we chose MOI 4 for all the other transductions.  
K562 cells were transduced at MOI 4 with each lentivirus (NS2B/NS3, NS4A, 
NS4B, and NS5) and the expression of the reporter GFP was measured 72 hours 
later by flow cytometry (Figure 3.4). GFP positive cells were then separated by 
FACS sorting. 
3.3.2.2 Protein expression 
Viral integration could be assessed by detection of the reporter transgene GFP, 
but direct assessment of DENV protein expression was possible by immunoblot 
only for NS1/NS2A, as no other specific antibodies were available at the time of 
the experiment. As described in chapter 1 (section 1.2.4.1), DENV NS1 localises 
both intracellularly and on the cell surface, but it is also secreted from the cell 
(Mackenzie et al. 1996; Jacobs et al. 2000; Alcon-LePoder et al. 2005). In order 
to assess whether the protein was correctly expressed, processed and secreted, we 
tested NS1 expression both by immunoblotting and by ELISA.  
For immunoblotting, 5·10
5
 K562_NS1/NS2A cells were lysed and proteins were 
separated by SDS-PAGE. Immunoblot was performed using an antibody specific 
for NS1. Surprisingly, we could not detect any signal for NS1 from K562 cells 
transduced with NS1/NS2A lentivirus, despite a strong signal from dengue 
replicon containing cells, included as a positive control (data not shown). We next 
tested the presence of NS1 in the supernatant of the same cells by ELISA: only 
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low levels of extracellular NS1 were detectable (about 200 ng/ml). Taken 
together, these results suggested that in our lentiviral system DENV NS1 is 
correctly expressed and processed, but expression levels are low.  
3.3.2.3 Transgene expression is diminished over time  
High levels of GFP expression were sustained over time, suggesting that the low 
NS1 transgene expression does not depend on low efficiency of transduction or on 
insufficient number of integrated copies. We therefore hypothesised that either (a) 
the SFFV promoter might not have been efficient enough to sustain sufficient 
levels of protein expression in K562, or (b) that other translational/post-
translational mechanisms, such as transcriptional silencing, could intervene and 
compromise protein production. In order to test the efficiency of the SFFV 
promoter, we checked the expression of NS1 by immunoblot shortly after 
transduction, and we also tested whether integration of more copies of the 
transgene could overcome poor expression efficiency. We therefore transduced 
K562 cells at MOI 4, 10, and 20. After 72 hours, we measured GFP expression by 
flow cytometry. Transduction efficiency was higher than 96% at all MOI (Figure 
3.5, A). At higher MOI, the mean fluorescence intensities of GFP were slightly 
increased (55 at MOI 4, 68 at MOI 10, and 103 at MOI 20), presumably reflecting 
more lentivector copies integrated in the cell genome. Three days later, cells were 
lysed and proteins were separated by SDS-PAGE. NS1 expression was tested by 
immunoblot: as shown in Figure 3.5 B, similar levels of NS1 were detectable in 
all samples, suggesting that, shortly after transduction, the transgene is expressed 
and the SFFV promoter is functional in K562 cells. 
Finally, to test whether progressive silencing was occurring over time, we 
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transduced K562 cells at MOI 25 to ensure that all cells were GFP positive and no 
preferential expansion of un-transduced cells occurred. We then measured both 
GFP (flow cytometry) and NS1 expression (immunoblot) 72/96 hours after 
transduction and 1 month later. As shown in Figure 3.6, GFP expression levels 
were maintained over time (Figure 3.6, A); in contrast, we observed that one 
month after transduction NS1expression was reduced (Figure 3.6, B). 
3.3.3 Enhancement of protein expression over time: cloning of 
the MESV leader sequence into lentiviral constructs 
We therefore hypothesised that long-term stable protein expression could have 
been impaired by some post-transcriptional mechanism. In order to overcome loss 
of protein expression over time, we introduced an enhancer element (“leader 
sequence”; GeneBank accession number: AJ132037) (Hildinger et al. 1999) 
immediately downstream of the SFFV promoter into all the lentivirus constructs 
containing the NS protein cassettes. The leader sequence, originally isolated from 
murine embryonic stem cell virus (MESV), constitutes the upstream untranslated 
region that in retroviruses controls translation of gag. The introduction of an 
intron in the 5` untranslated sequence, containing a minimal splice acceptor 
oligonucleotide, reduces silencing of eukaryotic genes; moreover, all the aberrant 
AUG starting codons have been removed in order to abrogate the expression of 
aberrant proteins (Hildinger et al. 1999).  
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Figure 3.3|  
Transduction efficiency of the lentivirus NS1/NS2A at MOI 1, 4, and 7. K562 
cells were transduced at MOI 1, 4, and 7. GFP expression (x axes) in transduced 
cells (black line histograms) was measured by flow cytometry 72 hours after 
transduction. Untransduced cells (plain gray histograms) were used as a negative 
control. The percentage of GFP positive cells is calculated by comparison with the 
negative control. 
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Figure 3.4| 
Transduction efficiency of K562 cells, transduced by different lentiviral 
vectors. K562 cells were transduced at MOI 4 with the lentiviruses NS1/NS2A, 
NS2B/NS3, NS4A, NS4B, or NS5. GFP expression (x axes) in transduced cells 
(black line histograms) was measured by flow cytometry 72 hours after 
transduction. Untransduced cells (plain gray histograms) were used as a negative 
control. The percentage of GFP positive cells is calculated by comparison with 
the negative control. 
 123 
 
Figure 3.5|  
NS1 expression in K562 cells transduced at different 
MOI of the lentivirus NS1/NS2A. Cells were transduced at 
MOI 5, 10, and 20 with the lentivirus containing the 
NS1/NS2A cassette. Expression of GFP (A) was measured 
by flow cytometry 72 hours later (black line histograms). 
Untransduced cells were used as a negative control (plain 
gray histograms). Expression of NS1 (B) was measured by 
immunoblot 96 hours later, using an antibody specific for 
NS1. Parental cells were included as a negative control. 
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Figure 3.6|  
Expression of GFP and NS1 in K562_NS1/NS2A over 
time. Cells were transduced at MOI 25. GFP expression 
was measured by flow cytometry 72 hours (left panel) 
and 1 month (right panel) after transduction.   The 
percentage of transduced cells (~100%) (black line) was 
calculated by comparison with untransduced parental 
cells (plain grey histograms) (A). 96 hours and 1 month 
after transduction, transduced cells were lysed and 
protein separated by SDS-PAGE. NS1 expression was 
measured by immunoblot using a specific antibody.  
Untransduced parental cells were included as control 
(B). 
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3.3.3.1 Cloning of the “leader sequence” into the lentiviral vectors encoding 
DENV NS protein cassettes 
The leader sequence was isolated from the lentiviral vector GFPLV (kindly 
provided by Professor Mary Collins) by double digestion with the restriction 
enzymes AscI and BamHI, and cloned into all the vectors containing the 
individual DENV NS protein cassettes, following linearisation and 
dephosphorylation. The sequence (about 700 bp) localises between the SFFV 
promoter and the transgene (Figure 3.7).       
Correct insertions into each construct were checked by AscI-BamHI double 
digestion, followed by DNA sequencing. The selected constructs were amplified 
by midi DNA preparation and used to prepare the lentiviruses as previously 
described. We observed that the insertion of the leader sequence did not affect 
virus titres, which remained at 10
7
-10
8
 infecting units/ml. 
3.3.3.2 Transduction of K562 
To assess the efficiency of transduction of the lentiviral vector containing the 
Figure 3.7|  
Insertion of MESV Leader sequence into the lentiviral vector pHRSIN-
CSGWdINotI_pUb_Em. LTR: long terminal repeats; RRE: rev response 
element; cPPT: central poly-purine tract; SFFV pro: spleen focus forming virus 
promoter; WPRE: woodchuck hepatitis virus post-transcriptional regulatory 
element; Ub: ubiquitin. U3: 400-nucleotide deletion in the 3`LTR that 
abolishes promoter activity. 
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leader sequence, we transduced K562 cells at MOI 1, 4, and 10. At 72 hours post-
transduction, we measured the expression of GFP by flow cytometry. As shown in 
Figure 3.8 A, the percentage of GFP positive cells is higher than in cells 
transduced with the same lentivirus without leader sequence (Figure 3.3), 
suggesting either higher transduction or, more likely, higher expression efficiency. 
At 96 hours post-infection cells were lysed and proteins separated by SDS-PAGE, 
in order to assess by immunoblot the expression of NS1. As shown in Figure 3.8 
B, high levels of NS1 are detectable in all samples, with higher expression in cells 
transduced with higher MOI of the leader sequence lentivector, in keeping with 
the higher percentage of transduced cells.  
In spite of the higher expression efficiency in the presence of the leader 
sequence, we decided to maintain MOI 4 to transduce K562 cells with all other 
constructs. GFP expression was measured 72 hours later (Figure 3.9). As already 
noticed for NS1/NS2A, higher percentage of GFP positive cells was observed 
when cells were transduced with lentiviruses containing the leader sequence. A 
further cell line was generated by transduction with an “empty” control, without 
any transgene after the SFFV promoter (Empty Vector). We did not observe any 
significant alterations of cell phenotype or viability following lentivirus 
transduction. 
3.3.3.3  DENV NS message and protein expression 
Due to the lack of available antibodies specific for each DENV NS protein, we 
could only assess the presence and transcription of some genes by reverse-
transcription PCR (RT-PCR). RNA from transduced cells was extracted, DNAse 
treated and reverse transcribed, and the cDNA was amplified by PCR using the 
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same primers employed during the cloning stage for NS1/NS2A, NS4A and 
NS4B; due to the length of the NS2B/NS3 and NS5 genes, and in order to 
optimise the efficiency of the reverse transcription process, we employed primers 
mapping inside the genes, amplifying a smaller internal portion (see chapter 2, 
section 2.3.4). All the PCR products were analyzed by gel electrophoresis. Figure 
3.10 shows that all genes are present and efficiently transcribed. The absence of 
bands in samples in which the reverse transcription step has been omitted 
excludes artefacts from DNA contamination and amplification of the integrated 
DNA gene. 
Protein expression could be assessed by immunoblot for NS1/NS2A (as 
discussed above) and also for NS5, as a new polyclonal antibody had become 
available. Both proteins were detectable and the expression levels were 
comparable to those of cells stably expressing the DENV replicon 
CprMEPAC2A (Figure 3.11). Expression of both proteins was tested by 
immunoblot at different times after transduction and, in the presence of the leader 
sequence, we did not observe any significant decreases of protein level over time 
(data not shown).  
GFP positive cells were isolated by FACS sorting. The isolation of a mixed 
population overcomes the limits of clonal selection, mitigating the risk of 
experimental artefacts from isolation of an aberrant cell phenotype.      
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Figure 3.8|  
Transduction efficiency of the lentivirus NS1/NS2A containing the leader 
sequence at different MOI. K562 cells were transduced at MOI 1, 4 and 10. GFP 
expression (x axes) in transduced cells (black line histograms) was measured by 
flow cytometry 72 hours after transduction. Untransduced cells (plain gray 
histograms) were used as a negative control. The percentage of GFP positive cells is 
calculated by comparison with the negative control (A). 96 hours after transduction, 
transduced cells were lysed and protein separated by SDS-PAGE. NS1 expression 
was measured by immunoblot using a specific antibody. Untransduced parental cells 
and cells containing the DENV replicon were included as a control (B). 
 129 
 
 
Figure 3.9| 
Transduction efficiency of K562 cells transduced by different lentiviral vectors 
containing the MESV leader sequence. K562 cells were transduced at MOI 4 with 
the lentiviruses NS1/NS2A, NS2B/NS3, NS4A, NS4B, and NS5, containing the 
MESV leader sequence. GFP expression (x axes) in transduced cells (black line 
histograms) was measured by flow cytometry 72 hours after transduction. 
Untransduced cells (plain gray histograms) were used as a negative control. The 
percentage of GFP positive cells is calculated by comparison with the negative 
control. 
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Figure 3.10|  
Presence of the NS gene transcripts in K562 cells transduced with 
the lentiviral vectors NS1/NS2A, NS2B/NS3, NS4A, NS4B and NS5. 
RNA was extracted from stably transduced cells, treated with DNAse 
and reverse transcribed (RT, left samples) or not (No RT, right samples) 
by the MLV enzyme. cDNA was amplified by PCR using the same 
primers employed for cloning for NS1/NS2A, NS4A, and NS4B, and 
primers mapping internal regions for NS2B/NS3 and NS5 (expected 
sizes, respectively, 220 and 247 bp). 
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Figure 3.11| 
Comparison of NS1 and NS5 protein 
levels in DENV replicon containing 
cells and in K562 transduced with the 
corresponding lentiviral vectors. Equal 
numbers of cells were lysed and proteins 
were separated by SDS-PAGE. NS1 and 
NS5 were detected by immunoblotting 
using specific antibodies Parental cells 
were included as a negative control.  
 
 132 
3.4 DISCUSSION 
Identifying the role of individual viral proteins in the subversion of innate 
immunity is crucial to understanding DENV pathogenesis. In order to investigate 
the effects of DENV NS proteins on the type I IFN system, the first part of this 
project was directed towards the development of five cell lines, based on the 
human chronic myeloid leukaemia cell line K562, each one individually 
expressing a different non-structural protein cassette of DENV. We elected the 
use of a lentiviral vector system in order to overcome the well-known 
refractoriness of K562 cells to traditional transfection methods, and in anticipation 
of further experiments in human primary dendritic cells. Mainly because of their 
efficient mechanisms of cell entry, viral vectors represent the first choice in gene 
delivery for cells refractory to other transfection systems. Retroviruses are 
particularly appealing because the DNA is integrated into the genome of target 
cells, enabling stable and long term expression of the transgene, but cells must be 
in active proliferation at the time of infection, as the pre-integration complex 
needs the disruption of the nuclear membrane to translocate into the nucleus. 
Lentiviral vectors overcome this limitation because the karyophilic lentiviral pre-
integration complex is recognised by the cell nuclear import machine. Therefore, 
lentiviral vectors are capable of efficiently transducing growth-arrested cell lines, 
terminally differentiated cells, or haematopoietic stem cells (reviewed in Cockrell 
and Kafri 2007).  
The main safety concern about the employment of retroviral vectors is the 
possibility that the parental pathogenic virus may be reconstituted. Removal or 
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replacement of structural, accessory and regulatory genes considerably reduces 
the risk of homologous recombinations, and splitting the structural genes and the 
gag-pol packaging constructs into separate plasmids is one of the most common 
strategies to maximise the number of recombination events required to 
reconstitute a replication competent virus. Replication defective lentiviral vectors 
are commonly generated by transient transfection of a producer cell line with 
three different plasmids expressing respectively: 1) the proteins of the core and 
the enzymes required for viral replication, reverse transcription and integration; 2) 
the envelope protein, usually from a different virus with the required tropism; 3) 
the gene of interest with the cis-acting sequences required for the optimisation of 
packaging, reverse transcription and integration of the transgene into the genome 
(reviewed in Delenda 2004; Cockrell and Kafri 2007). This is the strategy that we 
employed in this work. In the lentiviral vector used in this study, the SFFV 
promoter regulates the expression of the transgene, while a second promoter 
controls the expression of the transduction marker GFP: this allows indirect 
assessment of transgene integration without altering conformation, function and 
localisation of the protein of interest. 
Successful cloning of all individual NS proteins into the lentiviral vector 
pHRSIN-CSGWdINotI_pUb_Em was confirmed by DNA sequencing, but in spite 
of high efficiency of transduction, we could only detect protein expression in 
freshly transduced K562; a dramatic reduction of transgene expression was 
observed over time. Such a phenomenon would compromise consistency and 
reliability of subsequent studies on the transduced cell lines. Information about 
stability of gene expression after lentiviral vector integration is limited, but it is 
known that in wild type HIV infection a proportion of integrated viruses becomes 
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latent. In particular, long term expression seems to be compromised in primary 
cells and in haematopoietic stem cells due to their high level of cytidine 
methylation, a general mechanism used by cells to silence foreign DNA and 
defend against transposable elements (Cherry et al. 2000; Pannell and Ellis 2001). 
Studies have been carried out on the murine leukaemia virus (MLV) and its 
derived vectors and they showed that proviral gene expression does not persist, 
mainly because of epigenetic changes such as de novo DNA methylation of CpG 
sequences and local histone deacetylation, which form repressive chromatin 
configurations (reviewed in Pannell and Ellis 2001). Mok and colleagues (Mok et 
al. 2007) suggest that there are two forms of vector silencing: immediately after 
infection, probably dependent on the site of integration, or after long term, due to 
late epigenetic changes. Besides gene silencing, the literature describes two more 
factors that can contribute to impaired expression efficiency in retroviral vectors: 
first, the majority of transcribed RNA is not efficiently processed and licensed for 
nuclear export (Schambach et al. 2000); second, the presence of several aberrant 
AUG starting codons may start the translation of polypeptides with unknown 
function that may be toxic for the cells, or simply prevent the transcription of the 
entire gene (Hildinger et al. 1999).  
Several studies suggest that expression efficiency can be enhanced by 
manipulating promoter and enhancer elements. In particular, Hildinger (Hildinger 
et al. 1999) developed a 5` untranslated leader sequence that results in a reduction 
of silencing and consequent improvement in gene expression. In this work, 
Hildinger and colleagues examined the architecture of specific retroviruses 
selected for their high level of protein expression, such as the murine embryonic 
stem cell virus (MESV): in simple retroviruses, the upstream untranslated region 
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mimics the translational control of Gag, and therefore the sequence upstream of 
the gag-pol genes was selected as enhancer. Subsequent deletion of all the 
aberrant AUG starting codons abrogated the expression of aberrant proteins or 
peptides and optimised the specificity of translation, since no transcripts are lost 
by recruitment of aberrant reading frames. Further, the introduction of an intron in 
5` prevented transcriptional silencing due to cytosine methylation and induced 
higher levels of transgene mRNA over time. The effect is not dependent on the 
transgene or on the number of integrated copies of the vector, but can still depend 
on the cell line.  
We therefore decided to insert the same leader sequence described by Hildinger 
into all lentiviral constructs expressing each individual NS protein of DENV. The 
presence of the leader sequence, confirmed by DNA sequencing, did not affect 
viral titre, but ensured higher and more uniform efficiency of transduction and, 
most important, high and prolonged expression of the transgene over time. 
3.5 CONCLUSIONS 
In this preliminary part of our work, we developed five K562 cell lines 
expressing individual DENV NS protein cassettes: K562_NS1/NS2A, 
K562_NS2B/NS3, K562_NS4A, K562_NS4B, and K562_NS5. We incorporated 
a leader sequence from MESV into the lentiviral vector, a strategy that resulted in 
high level and stable expression of DENV NS proteins. Each cell line also 
expressed the fluorescent marker GFP under control of a separate promoter, 
enabling positive cells to be sorted by flow cytometry to generate non-clonal 
populations of cells all expressing the NS protein/s of interest.  
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Chapter 4.  
IDENTIFICATION OF NS5 AS 
A POTENT IFN- 
ANTAGONIST 
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4.1 INTRODUCTION 
DENV is known to inhibit the type I IFN response. As previously discussed 
(chapter 1, section 1.5.2.2), DENV prevents STAT1 phosphorylation in infected 
cells, but neither the precise mechanism of inhibition nor the viral proteins 
involved are clear. In work published in 2005, our group observed reduced levels 
of STAT2 both in DENV infected cells and in replicon containing cells, and 
suggested that reduced STAT2 expression explains the inhibition of the IFN 
signalling (Jones et al. 2005). Follow-on work in replicon containing cells has 
shown that STAT2 reduction is probably due to proteasome-mediated 
degradation: STAT2 mRNA levels were unaffected in the presence of the 
replicon, and treatment with the proteasome inhibitor bortezomib restored STAT2 
levels in DENV replicon containing cells (Mazzon et al. 2009). As noted 
previously in chapter 3, these observations in DENV replicon containing cells, 
rule out the possibility that STAT2 degradation might be caused by expression of 
DENV structural proteins or by virus assembly, and instead imply a role for one 
or more DENV non-structural protein/s. By expressing individual NS protein 
cassettes of DENV in K562 cells (chapter 3), we were able to test the role of each 
non-structural component in the inhibition of type I IFN and in STAT2 
degradation. 
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4.2 OBJECTIVES 
 To test the role of separate DENV NS protein/s in reducing cellular 
expression of STAT2 
 to test the role of separate DENV NS protein/s in inhibiting the type I IFN 
response 
 to investigate the selectivity of the inhibitory effect on the type I IFN, 
especially in relation to the type II IFN response  
 to test whether NS5 from a different strain of DENV-2 has the same 
inhibitory effect. 
4.3 RESULTS 
4.3.1 DENV NS proteins expressed separately do not induce 
STAT2 degradation 
In order to test the hypothesis that one or more DENV NS proteins target/s 
STAT2 for proteasomal degradation, we tested by immunoblotting intracellular 
levels of STAT2 in all K562 cell lines described in chapter 3 (K562_NS1/NS2A, 
K562_NS2B/NS3, K562_NS4A, K562_NS4B, and K562_NS5). As shown in 
Figure 4.1, in all these cell lines STAT2 is expressed at the same level as in 
parental cells and cells transduced with empty lentiviral vector. As anticipated, 
STAT2 levels are markedly reduced in DENV replicon containing cells, which 
express all the NS proteins together. These results imply that DENV NS proteins 
expressed separately are incapable of inducing STAT2 degradation. 
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Figure 4.1| 
STAT2 is degraded in the presence of DENV NS 
proteins expressed together but not separately. 
Comparison of STAT2 levels in K562 cells expressing 
DENV non-structural protein cassettes. Equal numbers 
of cells stably transduced with lentiviral vectors as 
indicated were lysed and proteins separated by SDS-
PAGE. Cellular levels of STAT2 were analysed by 
immunoblotting. Parental K562 cells and K562 cells 
containing DENV replicons were included as controls.  
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4.3.2 NS5 inhibits the type I IFN response  
The observation that none of the NS protein cassettes expressed separately was 
sufficient to induce degradation of STAT2 does not exclude the possibility that 
they may mediate other inhibitory effects on the type I IFN response: it is possible 
that STAT2 degradation might be the final outcome of a more complex process, 
or that other completely different mechanisms are involved. 
We therefore examined the response to IFN- in the same cell lines. Cells were 
stimulated with IFN- for 6 hours, and then RNA was extracted and induction of 
the IFN--sensitive gene MX1 was measured by quantitative RT-PCR. Figure 4.2 
shows the percentage induction of MX1 compared with parental cells: MX1 
induction was significantly inhibited only in cells expressing NS5. This inhibition 
was similar to that observed in replicon containing cells, included as a positive 
control. 
4.3.2.1 NS5 inhibits the dose-dependent induction of ISGs. 
Figure 4.2 shows the mean of three independent experiments; high standard 
deviations associated with some NS proteins suggest biological variability within 
the system. Therefore, in order to further validate our observations, we measured 
the activation of MX1 and of a second IFN sensitive gene, OAS1, in response to 
different concentrations of IFN- (0, 10, 100, and 1000 IU/ml). After 6 hours 
from IFN stimulation, we extracted the RNA and measured by RT-PCR the up-
regulation of MX1 and OAS1. As shown in Figure 4.3, while both negative 
controls -parental cells and cells transduced with empty lentiviral vector- respond 
to IFN- in a dose-dependent manner, in cells expressing NS5 the up-regulation 
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of both MX1 and OAS1 is inhibited, as it is in replicon containing cells. At the 
highest concentration of IFN- (1000 IU/ml), the antagonistic effect is still 
significant in cells expressing NS5.  
4.3.2.2 The antiviral effect of IFN- is suppressed in NS5 expressing cells 
Inhibition of type I IFN response was also tested at protein level, by measuring 
the expression of the IFN-inducible molecules HLA-ABC in response to IFN-. 
24 hours after IFN stimulation, we measured HLA-ABC expression on cell 
surface by flow cytometry. Figure 4.4 shows that, differently from parental cells 
and cells transduced with empty lentiviral vector, cells containing NS5, as well as 
cells containing the replicon, do not up-regulate HLA-ABC in response to IFN. 
 
In previous work, a trans-rescue assay was performed in order to test whether 
the presence of DENV replicon affected the general antiviral effect of type I IFN 
(Jones et al. 2005). In order to assess the biological consequences of NS5 
inhibition of IFN-, we compared the antiviral activity of IFN- in K562 cells 
expressing NS5 and in K562 cells transduced with empty lentiviral vector. After 
24 hour treatment with or without 100 IU/ml of IFN-, both cell lines were 
infected by the IFN-sensitive virus ECMV (encephalomyocarditis virus). Viral 
replication in infected cells was measured by titrating cell supernatant on indicator 
A549 cells, as described in chapter 2 (section 2.5). Since IFN treatment prevents 
ECMV replication, persistent viral replication reflects inhibition of the IFN 
response. As shown in Figure 4.5, pre-treatment with IFN of cells transduced 
with empty vector inhibits ECMV replication; in contrast, when NS5 is expressed, 
ECMV replication is higher, reflecting reduced antiviral response.  
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Finally we examined the effect of NS5 and of all other DENV NS proteins on 
the IFN- signalling by immunoblotting. After 15 minute stimulation, cells were 
lysed and proteins separated by SDS-PAGE; immunoblotting was performed with 
a specific antibody recognising phosphorylated STAT1, a key downstream 
signalling component of the IFN pathway, which is known to be inhibited in 
DENV infection. As shown in Figure 4.6, reduction of STAT1 phosphorylation is 
observed only in cells expressing NS5 and in cells expressing the replicon. Total 
cellular levels of STAT1 did not significantly differ between the different K562 
lines. 
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Figure 4.2|  
NS5 inhibits the induction of the IFN stimulated gene MX1. K562 
cells expressing individual DENV NS proteins as indicated were treated 
with 100 IU/ml of IFN-α for 6 hours before RNA extraction. MX1 
induction was measured by quantitative RT-PCR and normalised to the 
housekeeping gene GAPDH. The percentage induction of MX1 was 
compared with parental K562 cells (100%) and the figure shows the 
mean (+SD) of three independent experiments, each performed in 
duplicate. Replicon containing K562 were included for comparison. 
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Figure 4.3|  
NS5 inhibits the dose-dependent induction of ISGs. Parental K562 cells, replicon-
containing K562 cells, K562 cells transduced with empty lentiviral vector and K562 
cells expressing NS5 were treated with different concentrations of IFN-α as shown 
for 6 hours before RNA extraction. MX1 (left panel) and OAS1 (right panel) 
induction was measured by real time PCR and normalised to the housekeeping gene 
GAPDH using the formula 2
(GAPDH-GENE OF INTEREST)
. 
Figure 4.4| 
NS5 inhibits cellular responses to IFN-. NS5 expressing cells and controls as 
indicated were treated for 24 hours with (open histogram) or without (grey 
histogram) 100 IU/ml of IFN- and cell surface expression of the IFN inducible 
antigen HLA-ABC was measured by flow cytometry. 
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Figure 4.5| 
The antiviral effect of IFN- is suppressed in NS5 expressing cells. K562 
transduced with NS5 (solid line) or with empty lentiviral vector (broken line) 
were treated with 100 IU/ml of IFN- for 24 hours. The cells were then infected 
with ECMV and after further 24 hours the supernatants were harvested and 
serially diluted on confluent A549 cells (x axes). 24 hours later the A549 cells 
were fixed and stained with methyl violet. The optical density (O.D., y axes) of 
each well was measured at 570 nm. More ECMV replication results in increased 
cell death and lower optical density reading. 
 146 
 
 
Figure 4.6| 
NS5 reduces STAT1 phosphorylation. K562 cells expressing individual 
DENV NS proteins as indicated were treated with 100 IU/ml of IFN-for 15 
minutes. Equal number of cells were lysed and proteins separated by SDS-
PAGE. STAT1 levels and STAT1 phosphorylation were analysed by 
immunoblotting. Parental K562 were included as a control. 
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4.3.3 NS5 does not inhibit cellular responses to IFN-  
Previous work reported that DENV replicon expression specifically blocked 
IFN- but not IFN- signalling (Jones et al. 2005). In order to test the response to 
IFN-in cells containing NS5, we first looked at phosphorylation of the 
transcription factor STAT1. STAT1 is common to both type I and type II IFN 
signal transduction pathways, and we show above that its phosphorylation in 
response to IFN- is reduced in the presence of DENV NS5 (Figure 4.6). Cells 
were incubated with or without 100 IU/ml of IFN- for 15 minutes. Cells were 
then lysed, proteins separated by SDS-PAGE and analysed by immunoblotting. 
As expected, the presence of DENV replicon did not inhibit STAT1 
phosphorylation in response to IFN- (Figure 4.7, A). Similarly, expression of 
NS5 alone did not affect STAT1 phosphorylation. 
We also confirmed the functionality of IFN- response by measuring the 
expression of the surface molecules HLA-ABC (Figure 4.7, B). Cells were 
stimulated with or without 100 IU/ml of IFN- and 24 hours later the expression 
of HLA-ABC molecules was measured by flow cytometry. As shown in Figure 
4.7 B, and in contrast to the HLA response to type I IFN, up-regulation of HLA-
ABC is equivalent in all cell lines, further confirming the specificity of 
NS5/DENV replicon inhibitory effect on type I IFN. Taken together, these results 
suggest that DENV antagonism of type I IFN signalling involves components of 
the signal transduction pathway that are not shared with the type II IFN signalling 
pathway. 
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Figure 4.7| 
NS5 does not inhibit cellular response to IFN-.  
A. NS5 does not inhibit STAT1 phosphorylation in response to IFN-. NS5 expressing 
cells were treated with or without 100 IU/ml of IFN- for 15 minutes before lysis. 
Proteins were separated by SDS-PAGE and cellular levels of STAT1 and 
phosphorylated STAT1 were analysed by immunoblotting. B. NS5 does not inhibit up-
regulation of HLA-ABC in response to IFN-. NS5 expressing cells and controls were 
treated for 24 hours with (open histogram) or without (grey histogram) 100 IU/ml of 
IFN- and cell surface expression of the IFN inducible antigen HLA-ABC was 
measured by flow cytometry. 
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4.3.4 DENV-2 TSV01 NS5 also inhibits type I IFN response  
In recent work, Umareddy and colleagues (Umareddy et al. 2008) suggested that 
DENV inhibits type I IFN signalling in a strain-dependent manner. They 
compared the response to IFN in cells infected with two closely related DENV-2 
strains, NGC and TSV01 (Gene Bank AY037116). Phosphorylation of STAT1 
and STAT2, as well as the induction of the IFN response element ISG, were all 
found to be inhibited by NGC but not TSV01 infection.  
NGC and TSV01 NS5 proteins differ in only 17 residues across the gene, of 
which 9 are conservative substitutions. A differential effect of the two NS5 
proteins on the cellular response to IFN- might therefore help identify those 
residues in NGC NS5 that are critical for IFN subversion. We therefore decided to 
investigate the effects of TSV01 NS5 on the IFN-response.  
TSV01 NS5 was cloned into our lentiviral vector, following the procedure 
described in chapter 3. Briefly, TSV01 NS5 was amplified by High-Fidelity PCR 
from the TSV01 cDNA genome (kindly provided by M. Johansson, Stockholm 
University), inserting the restriction sites for BamHI and NotI in 5` and 3` 
respectively, and the amplified product was cloned in the pGEM®-T Easy vector. 
The insert was finally cloned into the dual promoter lentiviral vector containing 
the leader sequence described in chapter 3. Correct sequences and insertions were 
checked by double digestion BamHI-NotI and by DNA sequencing. The construct 
was used to generate lentivirus and transduce K562 cells. TSV01 NS5 expression 
was tested by immunoblotting, showing expression levels similar to NGC NS5 
(Figure 4.8, A). Positive cells were not FACS sorted because cellular response to 
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IFN- was tested by flow cytometry, which allows gating on the GFP positive 
cells only; cells not expressing GFP (not transduced) were used as an internal 
control. 
Cells were treated with 100 IU/ml of IFN-for 24 hours and then cell surface 
expression of HLA-ABC was measured by flow cytometry. K562 expressing 
NGC-NS5 and K562 transduced with empty lentiviral vector were included as 
control. As shown in Figure 4.8, differently from cells containing the empty 
vector, which respond to IFN- by up-regulating HLA-ABC, IFN- mediated up-
regulation of HLA-ABC in cells expressing TSV01 NS5 was inhibited to a similar 
extent as in cells expressing NGC NS5.  
 151 
 
 
 
 
Figure 4.8|  
TSV01_NS5 inhibits cellular response to IFN-  
A. NGC_NS5 and TSV01_NS5 are expressed at similar levels in K562 transduced 
with the correspondent lentiviruses. Equal numbers of cells were lysed and proteins 
contained in the lysates separated by SDS-PAGE. NS5 was detected by 
immunoblotting using an anti-NS5 antibody. B. TSV01_NS5 expressing cells, 
NGC_NS5 expressing cells and empty control were treated for 24 hours with (open 
histogram) or without (grey histogram) 100 IU/ml of IFN- and cell surface 
expression of the IFN inducible antigen HLA-ABC was measured by flow 
cytometry. 
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4.4 DISCUSSION 
Having developed human cell lines stably expressing DENV NS protein/s 
separately (chapter 3), we investigated which NS protein/s is/are responsible for 
STAT2 degradation. STAT2 expression was consistently reduced in replicon 
containing cells, in which all NS proteins are expressed together, but this effect 
was not replicated in cells expressing individual DENV NS protein cassettes. One 
possibility is that when expressed in a context other than the replicon, some NS 
proteins might be differently processed, orientated or compartmentalised, and this 
might compromise some of their functions. In chapter 3 we have shown that 
expression levels of NS1 and NS5 in our lentiviral system are comparable to the 
expression level of the same proteins in cells containing the replicon; however, 
since we could not test any other NS protein, we cannot exclude the possibility 
that absence of STAT2 degradation might be due to inadequate levels of protein 
expression. Another possible explanation is that an untested combination of NS 
proteins might be required to reduce cellular STAT2 expression, and this 
possibility will be further investigated in chapter 5. We therefore examined 
whether NS proteins expressed separately have the capacity to inhibit the IFN 
response, either through an interaction with STAT2 that is not sufficient to lead to 
its degradation, or via a completely different mechanism. 
 
Using the cell lines established in chapter 3, we first measured the induction of 
type I IFN sensitive genes (ISG) in response to IFN- by RT-PCR. Despite 
observing some variability between repeated experiments, we observed consistent 
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inhibition of ISG induction in cells expressing NS5. In view of the biological 
variability in this experimental system, we performed a series of further 
experiments to test whether or not NS5 is an IFN antagonist. Dose-response 
experiments measuring the induction of different ISG in cells treated with 
increasing concentrations of IFN- consistently showed that the response to IFN 
is suppressed in the presence of NS5. Also, pre-treatment of NS5 cells with IFN- 
does not prevent replication of the IFN-sensitive virus ECMV, failing to establish 
an IFN-induced antiviral state. Finally, immunoblot measuring phosphorylation of 
STAT1, a key component of IFN signalling, showed reduced STAT1 
phosphorylation in cells containing NS5. Since in the presence of other DENV NS 
proteins STAT1 phosphorylation levels were comparable to parental cells and to 
cells transduced with empty lentiviral vector, this observation further highlights 
the unique activity of NS5 on the IFN signalling pathway. Taken together, these 
experiments provide compelling evidence that NS5 is a potent inhibitor of type I 
IFN and blocks IFN- mediated signal transduction. 
In all our experiments we observed that in the presence of the replicon, IFN 
inhibition is slightly stronger than in the presence of NS5 only. This might suggest 
that other mechanisms or more NS proteins may be required to completely block 
the IFN response. Furthermore, even if a role for the UTRs in DENV protein 
synthesis has not been shown, we cannot exclude that they might play a role in 
helping the correct localisation or processing of the DENV polyprotein. In this 
case, the presence of the UTRs in the replicon might concur to explain the 
phenotypic differences between NS5 in the context of the lentiviral vector and in 
the replicon. Degradation of STAT2 observed in the presence of the replicon 
might itself contribute to a more complete inhibition of IFN signalling, allowing 
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NS5 recycling and binding of newly synthesised STAT2 proteins. 
 
Potent inhibitory activity is paired with tight selectivity, as the type II IFN 
signalling pathway, which shares with type I IFN some components of the 
transduction cascade, is not affected by NS5. Our observations are in 
disagreement with Muñoz-Jordan`s work (Munoz-Jordan et al. 2003), but are in 
agreement with several other reports (Ho et al. 2005; Jones et al. 2005; 
Dejnirattisai et al. 2008) showing that DENV infected/replicon containing cells 
efficiently respond to IFN- stimulation.  
 
In two different works, Muñoz-Jordan and colleagues (Munoz-Jordan et al. 
2003; Munoz-Jordan et al. 2005) report that DENV NS2A, NS4A and NS4B are 
all involved in the inhibition of type I IFN. Although we do not definitively rule 
out the involvement of these and/or other NS proteins, we could not observe any 
significant or consistent inhibition of the IFN- response in cells expressing 
proteins other than NS5. Our findings bring DENV in line with studies of other 
flaviviruses, in which NS5 has been reported to be involved in the evasion of 
innate immunity (JEV, TBEV, LGTV, WNV, see chapter 1, section 1.5.2.1.4). 
Discrepancies with Muñoz-Jordan`s data may be due to the experimental settings. 
In our work we have tried to maximise the biological significance of our system in 
several ways. First, aware of the high species specificity of the IFN response, we 
chose to employ human cell lines; also, K562 are cells of haematopoietic origin 
and therefore closer to DENV target in vivo (dendritic cells, monocytes, 
macrophages, see chapter 1, section 1.2.2). Next, when appropriate, we chose to 
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express some NS proteins in combination, in order to reproduce their function 
(NS2B+NS3) and their correct localisation/orientation (NS1+NS2A). Finally, we 
optimised our protein expression system in order to achieve expression levels 
comparable to the replicon and stable over time.  
 
Inter-strain variability in DENV serotypes could also be responsible for the 
discrepancies observed in IFN antagonism in different reports. The possibility that 
there are strain-dependent differences in IFN sensitivity is supported by 
Umareddy and colleagues (Umareddy et al. 2008), who report that, differently 
from the NGC strain, the DENV-2 strain TSV01 is unable to subvert the IFN 
response. However, when we expressed TSV01 NS5 using our lentivirus delivery 
model, we observed the same inhibition of the IFN response that we observed for 
NGC NS5. Marked suppression of the IFN response by NS5 from a strain that is 
apparently sensitive to IFN is a puzzling observation: even hypothesising the 
existence of redundant IFN inhibitory mechanisms in the NGC strain that could be 
absent from the TSV01 strain, the strong inhibition observed in Figure 4.8 
suggests that the presence of NS5 should be sufficient to block the IFN-induced 
antiviral activity. One critical element could be the level of expression of NS5 
required for effective antagonism of the IFN- mediated antiviral response. In 
Umareddy`s work (Umareddy et al. 2008) supernatant from A549 cells infected 
with TSV01 was shown to contain fewer viruses than supernatant from cells 
infected with NGC, suggesting lower levels of virus production. This implies 
lower levels of protein expression, and indeed Umareddy and colleagues show 
much lower levels of NS5 expression in cells infected with TSV01 than in cells 
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infected with NGC. Two opposite hypotheses could explain these observations: 
either lower viral replication is due to ineffective inhibition of the IFN response, 
or the ineffective inhibition of the IFN response is due to lower replication 
efficiency. Since from our work TSV01 NS5 inhibits IFN to the same extent as 
NGC NS5, it is tempting to hypothesise that the incapability of the TSV01 strain 
to inhibit the IFN response might be related to its less efficient replication and to 
lower NS5 expression levels, rather than to specific characteristics of NS5 itself. 
This hypothesis is supported by our own observations that lower NS5 levels 
correlate with a lower IFN inhibitory effect: on several occasions, we used 
constructs which gave low levels of protein expression, and in all these cases we 
also observed a reduced ability to inhibit the IFN response (data not shown). 
Conversely, when we tested by immunoblotting cellular levels of NS5 in cells 
transduced with TSV01 NS5 lentivirus, we showed expression levels comparable 
to NS5 expressed in the replicon. The lentiviral vector system that we established 
guarantees high levels of TSV01 NS5 expression, levelling out the expression 
differences observed in infection. As shown in chapter 3, NS5 expression in cells 
transduced with the lentivirus are comparable to NS5 levels in the replicon. 
Expression levels in BHK containing the replicon are in turn slightly lower than in 
BHK infected with DENV-2 NGC (A. Davidson, personal communications). 
Lentiviral transductions can therefore be employed as an invaluable tool to dissect 
the effects due to structural properties and expression levels.  
Taken together these observations suggest that high expression levels of NS5 are 
required in order to inhibit the IFN response, but the hypothesis that a threshold 
level of NS5 could be required to inhibit the type I IFN has not been further tested 
in this work. To explore the correlation between DENV pathogenesis, the 
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inhibition of the IFN response, and NS5 expression levels would be of great 
interest, but it was beyond the objectives of this project.  
4.5 CONCLUSIONS 
In this part of the work we investigated the capacity of DENV-2 NS proteins 
expressed separately both to degrade STAT2 and to inhibit type I IFN. We 
showed that NS proteins expressed separately are not sufficient to induce STAT2 
degradation. Reduced STAT2 levels are observed only in the presence of the 
replicon, where all DENV NS proteins are expressed together.  
Despite its inability to reduce STAT2 expression, NS5 alone is a potent and 
specific type I IFN antagonist. NS5 prevents induction of type I IFN sensitive 
genes and inhibits the activation of an antiviral state by blocking IFN- mediated 
signal transduction. We demonstrated the same inhibitory activity for NS5 from 
two different strains of the DENV-2, NGC and TSV01. The inhibition is specific 
for the type I IFN pathway, and the type II IFN response is not affected.  
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Chapter 5.  
NS5 BINDS STAT2 AND 
PREVENTS ITS 
PHOSPHORYLATION 
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5.1 INTRODUCTION 
Taken together, the data presented in chapter 4 demonstrate that DENV NS5 is a 
potent antagonist of the type I IFN that specifically blocks IFN- mediated 
signal transduction. As described in chapter 1 (section 1.2.4.5), NS5 is a large 
multifunctional protein that includes both polymerase and methyltransferase 
domains. The observation that the same protein is responsible for such critical 
functions in virus replication and in the inhibition of IFN suggests a tight 
evolutionary relationship between viral replication and the evasion of innate 
immunity. 
DENV NS5 has not previously been implicated as an IFN antagonist, but several 
papers have reported that NS5 proteins of other flaviviruses are involved in the 
inhibition of type I IFN (TBEV and LGTV (Best et al. 2005; Park et al. 2007; 
Werme et al. 2008); JEV (Lin et al. 2004; Lin et al. 2006); WNV (Laurent-Rolle 
et al. 2010)), however, the precise mechanisms of inhibition and the cellular 
components of the signalling cascade involved appear to be different for different 
flaviviruses. In cells infected by JEV, viral NS5 was reported to block Tyk2 
phosphorylation in response to IFN (Lin et al. 2006). In contrast, direct interaction 
between LGTV NS5 and IFN receptors has been suggested (Best et al. 2005). The 
reported variations might suggest the existence of different mechanisms 
developed during parallel flavivirus evolution, but alternatively they may simply 
reflect differences in the experimental models. In keeping with this, inconsistent 
observations about the mechanisms of IFN inhibition have been reported for 
individual viruses: as discussed earlier in chapter 1 (section 1.5.2.2), for DENV 
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Muñoz-Jordan and colleagues suggest a block at STAT1 level (Munoz-Jordan et 
al. 2003), Ho et al propose inhibition of Tyk2 activation (Ho et al. 2005), while 
Jones et al show degradation of STAT2 (Jones et al. 2005).  
Having identified DENV NS5 as a potent type I IFN antagonist, we next 
investigated the precise step/s of the IFN- signalling pathway targeted by NS5, 
and explored the molecular mechanism of IFN inhibition. The major conclusion 
emerging from the first part of this chapter is that NS5 inhibits IFN- signalling 
by binding the transcription factor STAT2, key component of the type I IFN 
transduction cascade, therefore preventing its phosphorylation. Inhibition of 
STAT2 phosphorylation following IFN treatment is also observed in cells 
expressing the DENV replicon; however, while in the presence of the replicon 
STAT2 is degraded via proteasome (Mazzon et al. 2009), we did not observe 
reduction of STAT2 levels in cells expressing NS5 alone.  
Cells have developed sophisticated systems to dispose of proteins that are no 
longer required and degradation via proteasome of ubiquitinated targets is one of 
the most commonly employed. Ubiquitination is a reversible post-translational 
modification that results in the conjugation of ubiquitin -a small protein of 76 
amino acids- to the target protein, usually on a lysine residue (reviewed in Leon 
and Haguenauer-Tsapis 2009). Different ubiquitination systems can be composed 
of different elements, depending on the different proteins and pathways involved, 
but the general mechanism requires three basic components: E1, the ubiquitin 
activating enzyme; E2, the ubiquitin conjugating enzyme; and E3, the ubiquitin 
ligase. The E3 ligase is normally a multifunctional complex itself, composed of 
one protein that specifically recognises the target and is in charge of the 
 161 
specificity to the substrate, and one more complex/es of proteins recruiting E2. 
The ECS (Elongin C-Cullin-SOCS-box) E3 ubiquitin ligases, one of the most 
characterised E3 complexes, include the SOCS (suppressor of cytokine signalling) 
family of proteins, which are involved in feedback inhibition of JAK/STAT 
signalling pathways. In this E3 ubiquitin system, the protein responsible for the 
recognition of the target is usually responsible also for the assembly of the 
complex/es that binds E2, as it carries a “BC-box”, i.e. a short consensus sequence 
responsible for the recruitment of the Elongin B/C complex (Figure 5.1). The 
Elongin B/C complex is in turn responsible for binding a further complex of 
proteins, which finally bridges to E2 through a RING domain. Figure 5.1 shows 
one of the best characterised of these complexes, composed of Cullin 2 or Cullin 
5, and Rbx 1 or Rbx 2, the latter containing the RING domain (Yasukawa et al. 
2008; Leon and Haguenauer-Tsapis 2009). 
Figure 5.1|  
Schematic representation of the 
ubiquitination complex. A BC-box motif in 
the protein that recognises the target recruits 
the E3 ligase complex which in turn recruits 
the ubiquitin activation enzyme (E1) and the 
ubiquitin conjugating enzyme (E2) (see text). 
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E3 ubiquitin ligases are also encoded by several viruses, in order to induce 
polyubiquitination and degradation of a variety of proteins, sometimes involved in 
apoptosis and cell cycle inhibition, or in the activation of the immune response 
(Ulane et al. 2005; Elliott et al. 2007; Isaacson and Ploegh 2009). Viruses are 
known that can induce ubiquitination and proteasome-mediated degradation of 
STAT proteins. Rubulavirus V protein assembles an E3 ubiquitin ligase by using 
cellular components, including the UV-damaged DNA binding protein 1 
(DDBP1), Cullin 4A and STAT (Ulane et al. 2005). Respiratory Syncytial virus 
(RSV) NS1 and NS2 proteins also assemble ubiquitin ligase E3 complexes: in 
particular, NS1 has been shown to contain a BC-box and a Cullin 2 binding 
consensus sequence, and to interact with Elongin C and Cullin 2 in vitro (Elliott et 
al. 2007). In the second part of this chapter, we tested whether STAT2 
degradation might be dependent on the assembly of a similar complex, with NS5 
representing the component of the E3 ubiquitin ligase responsible for binding the 
target (STAT2), and some other DENV NS proteins responsible for the 
recruitment of other components of the E3 complex. 
5.2 OBJECTIVES 
 To identify which cellular component of the IFN- signalling pathway is 
targeted by NS5 
 to clarify the molecular mechanism by which NS5 antagonises the IFN 
response 
 to test whether a combination of NS5 and other DENV NS proteins is 
responsible for STAT2 degradation. 
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5.3 RESULTS 
5.3.1 NS5 inhibits type I IFN signalling downstream of STAT2 
phosphorylation 
The data presented in chapter 4 (Figure 4.6) show that expression of NS5 
reduces STAT1 phosphorylation in response to IFN-. It follows that NS5 
inhibits the type I IFN signal transduction cascade at or before STAT1 
phosphorylation. In order to investigate which step of the cascade is inhibited by 
NS5, we treated NS5 expressing cells with or without 100 IU/ml of IFN- for 15 
minutes. Cells transduced with empty lentiviral vector, replicon-expressing, and 
parental K562 cells were included as controls. Equal number of cells were lysed 
and proteins separated by SDS-PAGE. Immunoblots were performed using 
antibodies specific for different components of the type I IFN signalling cascade.  
5.3.1.1 NS5 inhibits STAT2 phosphorylation in response to IFN- 
 As expected, expression of either NS5 alone or DENV replicon reduced 
phosphorylation of STAT1 in response to IFN- without affecting the levels of 
cellular STAT1 expression (Figure 5.2, A). In the classic type I IFN signal 
transduction pathway, the phosphorylation of STAT1 follows and is dependent on 
STAT2 phosphorylation. As described in Chapter 1, only STAT2 phosphorylation 
provides the docking site that orients STAT1 for phosphorylation and subsequent 
heterodimerisation with STAT2 (Li et al. 1997). Therefore, we next examined 
STAT2 phosphorylation in the presence and absence of NS5. As shown in Figure 
5.2 B, STAT2 phosphorylation was markedly reduced in both NS5 and replicon 
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expressing cells. As expected, STAT2 levels were also greatly reduced in DENV 
replicon containing cells, in keeping with our previous data (Jones et al. 2005). In 
contrast, STAT2 levels were unaltered in cells expressing NS5 alone, indicating 
that expression of NS5 alone does not completely replicate the phenotype of 
replicon expressing cells (in which all the non-structural proteins are expressed 
together). 
5.3.1.2 NS5 does not inhibit the IFN- signalling cascade upstream of 
STAT2 phosphorylation 
As described in chapter 1, early components of the IFN- signalling pathway 
have been suggested to be antagonised by both DENV (Ho et al. 2005) and TBEV 
(Best et al. 2005; Werme et al. 2008). To test whether DENV NS5 targets IFN- 
signal components upstream of STAT2 phosphorylation, we next tested the 
activation of the receptor associated kinase Tyk2. Activation of Tyk2 directly 
precedes phosphorylation of STAT2. Being a very early event in the signalling 
cascade, Tyk2 phosphorylation was assessed after stimulation with IFN- for only 
5 minutes. Lysate separation and immunoblotting were performed as above. In 
both replicon and NS5 containing cells, total and phosphorylated levels of Tyk2 
were not reduced (Figure 5.2, C), suggesting that the signalling pathway upstream 
of STAT2 phosphorylation is intact. To further confirm that early components of 
the IFN- signalling pathway are unaffected by DENV NS5, we also measured 
the expression of the type I IFN receptor IFNAR2c on the surface of cells 
containing NS5 by flow cytometry. As shown in Figure 5.3, expression levels of 
IFNAR2c in the presence of both NS5 and the replicon are comparable to parental 
K562 and cells transduced with empty lentiviral vector. 
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Figure 5.2|  
NS5 blocks STAT2 phosphorylation. IFN- signalling 
downstream of Tyk2 activation is inhibited in cells expressing 
NS5. K562 cells expressing NS5 and K562 cells containing 
DENV replicons were treated with and without 100 IU/ml of 
IFN-α for 15 minutes. Parental K562 and K562 cells transduced 
with an empty lentiviral vector were included as controls. 
Proteins in the cell lysates were separated by SDS-PAGE and 
total and phosphorylated levels of STAT1 (A), STAT2 (B), and 
Tyk2 (C) were analysed by immunoblotting. The expression of 
NS5 was tested with an antibody specific for NS5 (D). 
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Figure 5.3| 
NS5 does not alter IFN- receptor levels on the cell surface. NS5 expressing cells and 
control cells were stained for the surface receptor IFNAR2c and analysed by flow 
cytometry. Cells stained with the secondary antibody alone (grey histograms) were 
included as negative staining controls. 
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5.3.2 NS5 binds STAT2 
Taken together our data show that STAT2 phosphorylation in response to IFN- 
is inhibited in both NS5 and replicon containing cells. While in replicon 
containing cells this could be explained simply by reduced levels of STAT2, this 
was not observed in NS5 containing cells. This was the only apparent difference 
between the phenotype of cells expressing NS5 and the phenotype of cells 
expressing all the non-structural proteins together (i.e. the replicon). We therefore 
hypothesised that NS5 expressed in isolation binds STAT2 and thus inhibits its 
phosphorylation and all downstream events in the signalling cascade, but 
additional factors, most likely other DENV NS proteins, are required to target 
STAT2 for degradation. In order to test whether NS5 binds STAT2, we 
investigated whether NS5 and STAT2 could be co-immunoprecipitated. 
Preliminary attempts at immunoprecipitation using commercially available 
STAT2 antibodies or a polyclonal anti-NS5 antibody (kindly provided by Dr 
Andrew Davidson) failed due to non-specific binding. We therefore decided to 
introduce a FLAG-tag at the C-terminus of NS5 (NS5-FLAG), enabling us to use 
an anti-FLAG antibody for immunoprecipitation. 
5.3.2.1 Expression of NS5-FLAG 
The NS5-FLAG gene was amplified by high-fidelity PCR from the plasmid 
pcDNA-3.1_NS5-FLAG (kindly provided by Dr Andrew Davidson) and the 
restrictions sites for BamHI and NotI, necessary for cloning into the lentiviral 
vector, were introduced in 5` and 3` ends respectively. The NS5-FLAG sequence 
was cloned into the lentiviral vector as described in chapter 2, and correct 
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sequences and insertions were confirmed by restriction analysis and DNA 
sequencing. K562 cells were transduced with NS5-FLAG lentiviruses, and GFP 
positive cells were isolated by FACS sorting (K562_NS5-FLAG). Expression of 
NS5-FLAG was confirmed by immunoblotting using both anti-NS5 and anti-
FLAG antibodies.  
5.3.2.2 NS5 specifically binds STAT2, but not STAT1 or Tyk2 
The method used for immunoprecipitation is described in more detail in chapter 
2 (section 2.4.3). Briefly, the lysate from 10 million cells was incubated with anti-
FLAG affinity gel to allow NS5-FLAG binding to the anti-FLAG antibodies on 
the gel. Unbound proteins were washed away and NS5-FLAG was eluted by 
competition with 3X FLAG peptide: as we did not know the chemical 
characteristics of the putative interaction, we chose a gentler elution compared 
with other systems available (elution in lysis buffer or elution buffer). K562 cells 
expressing NS5 without FLAG were included as a negative control.   
Immunoprecipitated samples were loaded onto an SDS-PAGE gel and 
immunoblotted with specific antibodies, as described in Figure 5.4. The whole 
lysates were also included as controls. Specificity of binding to the gel was 
confirmed by detection of NS5 and FLAG only in correspondence of the eluted 
sample NS5-FLAG (Figure 5.4, first and second immunoblots), suggesting no 
aspecific binding of NS5 to the affinity gel. We next tested whether NS5 bound to 
STAT2. As shown in Figure 5.4 (fourth immunoblot), we observed that STAT2, 
which was detected in the whole lysate of both NS5 and NS5-FLAG cells, after 
immunoprecipitation was detectable only in the presence of NS5-FLAG. This 
shows that STAT2 is co-immunoprecipitated in the presence of NS5-FLAG and 
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does not aspecifically bind to the affinity gel. In contrast, as shown in Figure 5.4 
(third and fifth immunoblots), both STAT1 and Tyk2 were detected in the whole 
lysate of both cell lines, but neither STAT1 nor Tyk2 co-immunoprecipitated with 
NS5-FLAG.  
This suggests that NS5 -directly or indirectly- specifically binds STAT2. 
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Figure 5.4|  
NS5 specifically binds the transcription factor STAT2. Lysates from K562 cells 
expressing either NS5 or NS5 tagged at the C-terminus with the FLAG-peptide (NS5-
FLAG) were immunoprecipitated with anti-FLAG antibodies. Proteins contained in the 
immunoprecipitates were separated by SDS-PAGE and analysed by immunoblotting 
using specific antibodies against NS5, FLAG, Tyk2, STAT2 and STAT1. Whole cell 
lysates were included for comparison. One representative experiment of four is shown. 
IP: Immuno-precipitated samples 
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5.3.3 Co-transduction of NS5 and other NS proteins is not 
sufficient to induce STAT2 degradation 
The interaction between NS5 and STAT2, the same component of the IFN- 
signalling cascade that is degraded in the presence of the DENV replicon, 
suggests that NS5, binding STAT2, might be one of the NS proteins required for 
targeting the transcription factor for degradation. However, since STAT2 is 
degraded only in the presence of the replicon, but not when NS5 is expressed 
alone, it is possible that some other DENV NS proteins are involved. In the next 
section, we investigate the possibility that, together with NS5, some other DENV 
NS protein/s are required to induce STAT2 degradation. 
5.3.3.1 DENV NS4B contains a BC-box consensus sequence 
As described in the introduction to this chapter (section 5.1), proteasome 
mediated degradation of target proteins requires the assembly of the ubiquitination 
complex. This is possible if the scaffold protein that specifically binds the target is 
also able to recruit other components of the proteolytic pathway. In the model 
described above, the link between the scaffold protein and the ubiquitination 
complex is provided by a BC-box motif on the scaffold protein, which recognises 
and binds the two cellular proteins Elongin B and Elongin C. The BC-box motif is 
a short consensus sequence composed of the following conserved residues: 
(TSP)LXXXCXXX, where X can be any amino acid and  is a hydrophobic 
residue. The same motif has been recognised also in NS1 protein of RSV (Elliott 
et al. 2007), and it has been shown to recruit the complex of proteins required to 
induce proteasome-mediated degradation of STAT2. We therefore tried to identify 
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the same motif in some other DENV NS proteins by bioinformatic alignments. 
ScanProsite is a program that identifies specific motifs in amino acid sequences of 
interest. When we scanned DENV-2 polyprotein against the BC-box motif, 
amongst all DENV NS proteins we identified a BC-box sequence only in NS4B, 
between amino acids 88-99 (DENV-2). This suggests the presence of a site which 
can potentially bind Elongin and induce the assembly of the E3 ligase. We did not 
find the same sequence in DENV NS5, supporting the observation that NS5 alone 
is not sufficient to induce STAT2 degradation. As shown in Figure 5.5, the BC-
box domain of NS4B is conserved in all four DENV strains. 
Protein alignments described in the literature have also identified a different 
consensus sequence, downstream of the BC-box, which seems to be involved in 
the interaction with Cullin (Elliott et al. 2007). Such sequence, 
XXXXXXXXXXis more generic and therefore is found several time 
along the polyprotein. 
5.3.3.2 Co-expression of NS5 and NS4B does not reduce cellular levels of 
STAT2 
To test whether NS4B is involved in the recruitment of the ubiquitination 
complex, we transduced K562 cells already expressing NS5 with the lentivirus 
encoding NS4B (K562_NS5+NS4B). A prerequisite condition for this experiment 
is that all cells, or at least the large majority, express both NS5 and NS4B. Since 
cells containing NS5 already express GFP, in order to assess the efficiency of 
transduction with the lentivirus NS4B, we transduced in parallel parental K562 
cells and assumed that the percentage of K562_NS5 transduced by the lentivirus 
NS4B was the same as transduced (i.e. GFP positive) parental cells (Figure 5.6, 
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A). To test whether the combination of NS5 and NS4B induced STAT2 
degradation, cells were lysed, proteins separated by SDS-PAGE and 
immunoblotted with an antibody specific for STAT2. Replicon-expressing and 
parental K562 cells, and cells transduced with empty vector, NS5 alone, and 
NS4B alone were included as controls. As expected (Figure 5.6, B) STAT2 levels 
in cells expressing either NS5 alone or NS4B alone were unchanged and 
comparable to parental cells and cells transduced with empty lentiviral vector, 
while reduced level of STAT2 were detected in the presence of the replicon. In 
contrast, we did not observe reduction of STAT2 levels in cells expressing NS5 
and NS4B together, suggesting that co-expression of these two proteins is not 
sufficient to induce STAT2 degradation. 
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Figure 5.5|  
NS4B “BC-box” motif is conserved between the four serotypes of DENV. 
CLUSTAL 2.0.11 multiple sequence alignment of the amino acid sequence of NS4B of 
DENV-1, DENV-2, DENV-3, and DENV-4. The conserved BC-box motif is shown in 
blue.  
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Figure 5.6|  
STAT2 is not degraded in cells tranduced with DENV 
NS4B+NS5.  
A. Transduction efficiency of the lentivirus NS4B. K562 cells 
were transduced at MOI 10. GFP expression (x axes) in 
transduced cells (black line) was measured by flow cytometry 
72 hours after transduction. Untransduced cells (plain grey 
histogram) were employed as negative control. The 
percentage of GFP positive cells is calculated by comparison 
with the negative control. B. Comparison of STAT2 levels in 
K562 cells expressing DENV non-structural protein cassettes. 
Equal numbers of cells stably transduced with lentiviral 
vectors as indicated were lysed and proteins separated by 
SDS-PAGE. Cellular levels of STAT2 were analysed by 
immunoblotting. Parental K562 cells, K562 cells containing 
DENV replicons, and K562 transduced with an empty 
lentiviral vector, NS5 and NS4B were included as controls.  
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5.3.3.3 Combination of NS5 with other DENV NS proteins is not sufficient 
to induce STAT2 degradation 
All DENV NS proteins have been suggested to take part in viral replication and 
to localise in close proximity to subcellular membranes (chapter 1, section 
1.2.3.4). Therefore, each one of them could potentially interact or be in close 
proximity to NS5, to take part in STAT2 degradation. In order to test this 
possibility, we transduced NS5 expressing K562 cells with different lentiviral 
vectors, each one encoding a different NS protein cassette. Moreover, since the 
cytoplasmic form of NS5 has been shown to directly interact with NS3 (chapter 1, 
sections 1.2.3.4, 1.2.4.2, and 1.2.4.5), and in turn NS3 has been shown to interact 
with NS4B (chapter 1, section 1.2.4.4), we also super-transduced 
K562_NS5+NS4B cells (section 5.3.3.2) with the lentivirus encoding NS2B/NS3. 
All combinations tested are summarised in Table 5.1. Next, we tested cellular 
levels of STAT2 by immunoblotting in all cell lines. As above, equal numbers of 
cells were lysed, proteins separated by SDS-PAGE, and immunoblotted with an 
antibody specific for STAT2. Once again, no reduction of STAT2 levels could be 
observed for any of the combination tested (data not shown).  
Two proteins 
NS5+ 
NS1/NS2A 
NS5+ 
NS2B/NS3 
NS5+ 
NS4A 
NS5+ 
NS4B 
Three proteins 
NS5+ 
NS4B+ 
NS2B/NS3       
Table 5.1| 
Combinations of NS proteins tested in order to study STAT2 
degradation. Efficiency of transduction was tested by transducing parental 
K562 in parallel and measuring the percentage of cells expressing GFP. In all 
cases, efficiency of transduction was higher than 80% (data not shown). 
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5.4 DISCUSSION 
As covered in chapter 1, evasion of the innate immunity and in particular of the 
type I IFN is critical for the establishment of any viral infection. DENV 
replication is extremely sensitive to type I IFN, as IFN treatment before infection 
prevents viral replication (Diamond and Harris 2001). Under selective pressure 
from the innate immunity, DENV has evolved mechanisms to evade the IFN 
response. In chapter 4 we showed that DENV NS5 is a potent and specific IFN-
 antagonist; in this chapter we elucidated the mechanism at the basis of such 
inhibition. 
We first focussed on the step of the signalling cascade antagonised by NS5. 
After stimulation with IFN-, we observed that, in the presence of NS5, both 
STAT1 and STAT2 phosphorylation are inhibited. In contrast, neither surface 
expression of the IFN- receptor IFNAR2c nor Tyk2 phosphorylation are 
affected by NS5. This suggests that NS5 antagonises the IFN-signalling 
pathway downstream of Tyk2 phosphorylation and upstream of STAT2 
phosphorylation. The same phenotype is observed in replicon containing cells, 
but, differently from cells expressing NS5 alone, only in the presence of the 
replicon, i.e. all the NS proteins expressed together, we observed reduced levels of 
STAT2. We therefore hypothesised that NS5 blocked STAT2 phosphorylation by 
direct or indirect binding to the transcription factor, preventing its interaction with 
the kinase Tyk2. We also speculated that when other NS proteins are expressed, 
as in replicon containing cells, NS5 might immobilise STAT2 and other NS 
proteins concur to its degradation. In order to test whether NS5 binds STAT2, we 
generated a K562 cell line expressing a FLAG-tagged NS5, and 
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immunoprecipitated NS5-FLAG. By immunoblot we showed that STAT2 co-
immunoprecipitates with NS5. The binding STAT2-NS5 is highly specific since 
neither STAT1 nor Tyk2 co-immunoprecipitate with NS5.  
The possibility that STAT2 degradation might be induced by a combination of 
NS proteins was strengthened by the identification in DENV NS4B of a short 
consensus sequence (BC-box), which is known to be involved in the recruitment 
of the ubiquitination complex. The presence and function of a BC-box motif in 
DENV NS4B had never been described before and its capability of binding 
Elongin B/C has not been proved. However, when we tested whether the co-
expression of NS4B and NS5 induced STAT2 degradation, we did not detect any 
reduction in cellular STAT2 levels. No degradation was observed even after 
super-transduction with the lentivector containing NS2B/NS3, which has been 
shown to interact with both NS5 and NS4B during viral RNA replication. 
Combinations of NS5 with the other NS proteins were also tested, but none had 
any effect on STAT2 levels. Even though it is possible that more than two NS 
proteins are required to induce STAT2 degradation, it is likely that simple co-
expression of individual proteins is not sufficient to reproduce this phenomenon. 
However, the approach that we employed has several limitations and therefore, 
any observation is only speculative. Once again, as mentioned in chapter 4, we 
could not test the expression of each individual NS protein, and we do not have 
information about relative expression levels of each NS protein in cells already 
expressing NS5. Furthermore, it is possible that correct protein conformation, 
localisation, or interaction is obtained only following proteolytic processing of the 
polyprotein. While this work was in progress, a study by Ashour and colleagues 
(Ashour et al. 2009) also reported that DENV NS5 is a type I IFN antagonist. 
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Consistent with our observations, this work showed that the expression of NS5 
alone is not sufficient to induce degradation of STAT2. Furthermore, STAT2 
reduction is not observed even when NS5 is transfected into cells already 
expressing the polyprotein NS1-NS4B. In fact, according to Ashour and 
colleagues, NS5 is indeed sufficient to induce STAT2 degradation, but only if the 
N-terminal cleavage of NS5 is reproduced, mimicking the maturation process in 
the context of the DENV polyprotein. It is possible that the initial cleavage of 
NS5 is critical to correctly fold the N-terminal domain of NS, and this in turn 
might be critical for the recruitment of other cellular or viral proteins involved in 
STAT2 degradation.  
Further experiments would be required to understand the role of the N-terminal 
domain of NS5 in STAT2 degradation, and the role of STAT2 degradation in 
DENV infection, but this was beyond the objectives of this thesis. We decided 
instead to further characterise the region of NS5 involved in STAT2 binding, and 
the role of NS5 nuclear localisation in the inhibition of the type I IFN. This will 
be the subject of the next chapter.  
5.5 CONCLUSIONS 
In this chapter we identified the mechanism by which NS5 inhibits cellular 
response to type I IFN. We showed that NS5 binds STAT2 and prevents its 
phosphorylation, and therefore any downstream event of the transduction 
signalling cascade. Differently from the replicon, which induces proteasome-
mediated degradation of STAT2, NS5 does not affect cellular levels of any 
component of the signalling cascade. We hypothesised that in the presence of the 
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replicon other viral component, together with NS5, might be responsible for 
STAT2 degradation; however co-transduction with NS5 and other individual 
DENV NS proteins was not sufficient to reproduce this phenomenon. This 
suggests that NS protein expression in the context of the polyprotein might be 
critical to confer to the NS proteins the correct conformation, localisation or 
regulation. 
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6.1 INTRODUCTION 
In the previous chapters, we have demonstrated that DENV NS5 binds to 
STAT2 and inhibits its phosphorylation, thereby inhibiting downstream events in 
the type I IFN signalling cascade. As outlined in chapter 1, section 1.2.4.5, 
DENV-2 NS5 is a complex multifunctional protein of 900 amino acids (104 kDa), 
composed of a methyltransferase domain (MTase) and an RNA-dependent RNA 
polymerase (RdRp). At the N-terminal of the RdRp domain there is a region 
containing a bipartite nuclear localisation signal (NLS) and a nuclear export signal 
(NES). Both the MTase and the RdRp domains have been crystallised and the 
structures provide useful insights on their molecular functions.  
The MTase domain (Figure 6.1) is composed of three subdomains: the core 
(amino acids 55-222, yellow in the figure) is the proper catalytic domain, while 
the N-terminal “appendage” (amino acids 7-54, red in the figure) provides a GTP-
binding site, and the C-terminal “appendage” (amino acids 223-267, cyan in the 
figure), packed against the N-terminal one, works as stabiliser (Egloff et al. 2002).              
The RdRp has the same structure of many other viral polymerases, with the 
typical pattern fingers, palm, and thumb (Figure 6.2). The finger subdomains 
(amino acids 273-315; 416-496; 543-600, blue in the figure) are very mobile 
regions; the palm (amino acids 497-542 and 601-705, green in the figure) contains 
the catalytic active site and is highly conserved amongst flaviviruses; and the 
thumb (amino acids 706-900, red in the figure) is the most structurally variable 
(Yap et al. 2007). The NLS region (amino acids 316-404) has been crystallised in 
complex with the RdRp, as it seems to be crucial in stabilising the RdRp. It 
localises between the fingers and the palm (Figure 6.2, in yellow), probably 
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modulating the open-close conformations of the enzyme (Yap et al. 2007).  
Defining the region/s of NS5 that bind/s STAT2 and prevent/s its 
phosphorylation would add to our understanding of the role of NS5 in the evasion 
of the innate immunity, and might in future help the design of antiviral drugs able 
to prevent NS5 binding to its substrate, or of rationally designed live-attenuated 
vaccines unable to antagonise the IFN signalling.  
6.2 OBJECTIVES 
 To identify which domain -the MTase or the RdRp- of NS5 is responsible for 
IFN- inhibition 
 to investigate whether the region encompassing the NLS of NS5 has a role in 
IFN- inhibition 
 to test whether NS5 nuclear trafficking has a role in IFN-  inhibition. 
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Figure 6.1|  
Ribbon representation of DENV-2 NS5 MTase domain. The N-terminal 
domain (amino acids 7-54) is shown in red, the core domain (amino acids 
55-222) in yellow, and the C-terminal subdomain (amino acids 223-267) in 
cyan. The structure is shown in complex with an S-Adenosylhomocystein 
(AdoHcy, sticks and balls representation), a co-product of the 
methyltransferase reaction (from Egloff et al. 2002). 
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Figure 6.2|  
Ribbon representation of DENV-3 NS5 RdRp (amino acids 273-900). The 
finger domains are shown in blue, the NLS in yellow, the palm in green, and 
the thumb in red (Yap et al. 2007) 
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6.3 RESULTS 
6.3.1 Expression of the DENV NS5 RdRp domain alone is 
sufficient to inhibit the type I IFN response 
6.3.1.1 Cloning strategy 
In order to identify the domain of NS5 responsible for the inhibition of type I 
IFN, we separately cloned the MTase domain and the RdRp domain into the 
lentiviral vector described in chapter 3. Based on the published crystal structure 
(Malet et al. 2007), we aimed to expressed the MTase domain from amino acid 1 
to 260 (MTase1-260), and the RdRp domain from amino acid 270 to 900 (RdRp270-
900). A schematic representation of both constructs is shown in Figure 6.3 B. In 
brief, both domains were amplified by High-Fidelity PCR from the lentiviral 
vector containing the NS5 gene, and the restrictions sites for BamHI and NotI 
were introduced in 5` and 3` ends respectively. The sequences were first 
subcloned into the vector pGEM®-T Easy, then digested by BamHI and NotI 
restriction enzymes, and finally cloned into the lentiviral vector as described in 
chapter 2. Correct sequences and insertions were checked by double digestion 
(BamHI-NotI) and by DNA sequencing.  
6.3.1.2 Development of K562 cell lines expressing the MTase1-260 domain 
and the RdRP223-900 domain 
We used the constructs above to generate lentiviruses as described previously. 
This was successful for the construct MTase1-260, but despite several attempts we 
were unable to recover lentiviruses encoding RdRp270-900. The explanation for this 
was unclear, but was not investigated further. Instead, we attempted to generate 
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lentiviruses from a larger constructs (RdRp223-900), which was chosen because it 
encompasses the entire polymerase domain (Figure 6.3 C). We successfully 
recovered lentiviruses encoding RdRp223-900. Therefore, lentiviruses encoding 
MTase1-260 and RdRp223-900 were used to transduce K562 cells as previously 
described. We used GFP expression as a marker of successful transduction, but 
protein expression could be assessed directly only for the RdRp domain, since the 
anti-NS5 polyclonal antibody available to us only recognises the region between 
amino acids 397 and 778 (A. Davidson, personal communication). Detection of a 
band at the expected size (78 kDa) suggested that the RdRp223-900 is correctly 
expressed (Figure 6.4, A). 
6.3.1.3 The RdRp223-900 is sufficient to inhibit cellular response to IFN- 
Cells expressing either MTase1-260, or RdRp223-900 were treated with 100 IU/ml 
of IFN- for 24 hours and cell surface expression of the IFN-inducible molecules 
HLA-ABC was measured by flow cytometry, gating only on GFP positive cells 
(Figure 6.4, B). Cells expressing full-length NS5 and cells transduced with empty 
lentiviral vector were included as controls. As expected (Figure 6.4), in response 
to IFN-, cells expressing full length NS5 but not cells transduced with empty 
vector, failed to up-regulate HLA-ABC molecules. In cells expressing RdRp223-900 
up-regulation of HLA-ABC was also reduced, although this effect appeared to be 
slightly less than in cells expressing full length NS5. In contrast, we did not 
observe reduced HLA-ABC expression in cells transduced with MTase1-260. This 
implies that the RdRp domain of NS5 is sufficient to antagonise the type I IFN 
response, but maybe less efficiently than the full length NS5 protein.  
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Figure 6.3|  
Schematic representation of DENV NS5 sequence and of the 
truncated versions generated in this study. A. Full length NS5 
proteins and its sub-domains: the MTase (amino acids 1-250), the 
RdRp (amino acids 251-900), and the NLS (amino acids 316-
404). Dashed lines separate the N-terminal domain (amino acids 
1-54), the core domain (amino acids 55-222), and the C-terminal 
domain (amino acids 223-250) of the MTase, and the -NLS 
(amino acids 316-368) and the -NLS (amino acids 369-404) 
of the NLS. B and C. Cloning strategy to individually express the 
MTase and the RdRp domains. The MTase was expressed from 
amino acids 1 to 260, while the RdRp was initially expressed 
from amino acids 270 to 900 (B). Technical problems in 
lentivirus production led to the extension of the polymerase 
domain from amino acids 223 to 900 (C). D. Deletion of the 
region 223-404, including the NLS, from the RdRp domain. E 
and F. Expression of the NLS region alone (amino acids 223-
404, E) and at the C-terminal of the MTase domain (amino acids 
1-404, F). 
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Figure 6.4| 
IFN- antagonism is mediated by the polymerase domain of NS5.  
K562 cells were transduced with individual functional domains of NS5: the MTase 
(Methyltransferase 1-260) or the RdRp223-900 (RNA dependent RNA polymerase 
223-900). A. Expression of NS5 and of the RdRp domain was tested by 
immunoblotting. Cells were lysed and proteins separated by SDS-PAGE; 
immunoblotting was performed using an anti-NS5 antibody recognising the region 
397-778. No antibodies specific for the MTase domain were available. Cells 
transduced with the empty vector were included as a control. B. Response to IFN- 
was tested treating the cells for 24 hours with (open histogram and dot plots) or 
without (grey histogram) 100 IU/ml of IFN-cell surface expression of the IFN- 
inducible molecules HLA-ABC was measured by flow cytometry, gating on GFP 
positive cells only. Dot plots show expression of HLA-ABC (y axis) after IFN- 
treatment in the GFP positive fraction (right gate, x axis) and in the GFP negative 
fraction (left gate, x axis) for each transduced sample. Cells transduced with the 
empty vector and with full length NS5 were included as controls.  
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6.3.2 Deletion of the region containing the NLS abolishes the 
IFN antagonism 
6.3.2.1 Cloning strategy and development of K562 cell lines expressing the 
RdRp405-900 domain 
In the previous experiment, we showed that expression of amino acids 223-900 
of DENV NS5 is sufficient to inhibit type I IFN-mediated up-regulation of HLA-
ABC. Residues 223-260 overlap the MTase construct previously tested, while 
residues 251-404 constitute the first finger of the polymerase domain and the 
NLS. The region from amino acid 223 to 404 therefore encompasses parts of both 
the MTase and of the RdRp domains, but in view of its location and composition 
the fragment 223-404 will subsequently be referred to as the “inter-domain”. In 
order to test whether the “inter-domain” is absolutely required for IFN- 
antagonism, we expressed the polymerase domain from amino acid 405 to 900 
(Figure 6.3, D). As previously described, the required sequence was amplified by 
PCR from the NS5 gene, and the restriction sites for BamHI and NotI were 
introduced in 5` and 3` ends respectively. The sequence was subcloned into the 
vector pGEM®-T Easy, and finally cloned into the lentiviral vector, as described 
in chapter 2. Correct sequence and insertion were checked by double digestion 
(BamHI-NotI) and by DNA sequencing. The construct was successfully used to 
generate lentiviruses and transduce K562 cells, as described previously. Protein 
expression was assessed by immunoblotting: the presence of a band of the 
expected size (57 kDa) suggests that the protein is expressed (Figure 6.5, A). 
6.3.2.2 The region 223-404 is critical to type I IFN inhibition 
Cells expressing RdRp405-900 were stimulated with 100 IU/ml of IFN-for 24 
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hours, and expression of the IFN-inducible molecules HLA-ABC on cell surface 
was measured by flow cytometry, gating only on GFP positive (transduced) cells 
(Figure 6.5, B). Cells expressing full length NS5 and cells transduced with the 
empty lentiviral vector were included as controls. Once again, differently from 
cells transduced with empty vector, cells expressing full-length NS5 did not up-
regulate HLA-ABC in response to IFN- (Figure 6.5). In contrast, we did not 
observed reduced up-regulation of HLA-ABC in cells expressing RdRp405-900. 
This suggests that at least part of the “inter-domain” 223-404 must be expressed 
to retain the ability of the RdRp of antagonising the IFN response.  
6.3.3 IFN inhibition occurs only when the “inter-domain” 223-
404 is expressed in the context of the RdRp 
6.3.3.1 Cloning strategy and development of K562 cell lines expressing the 
“inter-domain” 223-404 alone or at the C-terminal of the MTase 
domain 
We next investigated whether the “inter-domain” 223-404 alone could inhibit 
the IFN response, or whether it could function as an IFN antagonist other than in 
association with the RdRp. We therefore cloned the “inter-domain” either alone 
(amino acids 223-404), or at the C-terminal of the MTase (amino acids 1-404) in 
the lentiviral vector. A schematic representation of the two constructs is shown in 
Figure 6.3 E and F. Cloning and transduction of K562 cells were carried out as 
described above. Although lentivirus transduction of cells could be assessed by 
GFP expression, expression of the relevant fragments of NS5 could not be tested 
directly because no antibodies that recognise these portions were available. 
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6.3.3.2 The “inter-domain” 223-404 alone or at the C-terminal of the MTase 
does not inhibit IFN- response 
Cells transduced with lentiviruses encoding either the “inter-domain” (amino 
acids 223-404) or the extended MTase1-404 were stimulated with 100 IU/ml of 
IFN- for 24 hours. Expression of HLA-ABC molecules on cell surface was then 
assessed by flow cytometry, gating only on GFP positive cells (Figure 6.6, A). 
Cells expressing full length NS5 and cells transduced with empty lentiviral vector 
were included as controls. As shown in Figure 6.6 B, only cells expressing full-
length NS5 fail to up-regulate HLA-ABC in response to IFN-; in contrast, in 
both cells transduced with the “inter-domain” and cells transduced with the 
extended MTase1-404, up-regulation of HLA-ABC after IFN- treatment is 
comparable to cells transduced with empty vector. Taken together these 
observations might suggest that the “inter-domain” (223-404) and the RdRp have 
to be expressed together in order to antagonise the IFN response. However, we 
cannot exclude the possibility that the “inter-domain” is simply not expressed, or 
does not adopt the correct conformation when expressed in a context different 
from the RdRp. 
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Figure 6.5| 
Deletion of the region 223-404 of NS5 RdRp restores cellular 
response to IFN-. 
K562 cells were transduced with a truncated form of NS5 RdRp 
spanning from amino acid 405 to 900. A. Expression of NS5 and of the 
RdRP405-900 domain was confirmed by immunoblotting. Cells were 
lysed and proteins separated by SDS-PAGE; immunoblotting was 
performed using an anti-NS5 antibody recognising the region 397-778. 
Cells transduced with the empty vector were included as a control. B. 
Cells were treated for 24 hours with (open histogram and dot plots) or 
without (grey histogram) 100 IU/ml of IFN-and cell surface 
expression of the IFN- inducible antigen HLA-ABC was measured by 
flow cytometry, gating on GFP positive cells only. Dot plots show up-
regulation of HLA-ABC (y axis) after IFN- treatment in the GFP 
positive fraction (right gate, x axis) and in the GFP negative fraction 
(left gate, x axis) for each transduced sample. Cells transduced with the 
empty vector and with full length NS5 were included as controls. 
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Figure 6.6| 
Transduction of K562 cells with the region 223-404 alone or in association 
with NS5 MTase domain does not inhibit IFN- response.  
K562 cells were transduced with the “inter-domain” of NS5 alone (“inter-
domain”223-404) or at the C terminal of the MTase domain (MTase 1-404). Cells were 
treated for 24 hours with (open histogram and dot plots) or without (grey 
histogram) 100 IU/ml of IFN-and cell surface expression of the IFN- inducible 
molecules HLA-ABC was measured by flow cytometry, gating on GFP positive 
cells only. Dot plots show up-regulation of HLA-ABC (y axis) after IFN- 
treatment in the GFP positive fraction (right gate, x axis) and in the GFP negative 
fraction (left gate, x axis) for each transduced sample. Cells transduced with the 
empty vector and with full length NS5 were included as controls. 
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6.3.4 Nuclear translocation of NS5 is not required for the 
inhibition of type I IFN signalling 
6.3.4.1 Development of a K562 cell line expressing a mutant of NS5 that 
does not translocate into the nucleus 
Since the “inter-domain” incorporates the NLS, we next considered whether the 
loss of IFN- antagonism of NS5 RdRp after deletion of the “inter-domain” was 
due to the absence of nuclear translocation. In order to test this, we employed a 
mutant of NS5 (NS5_A1A2) in which five lysine residues (K371/K372 and 
K387/K388/K389) in the distal cluster of basic residues of the -NLS, were 
replaced by alanine, preventing nuclear translocation (Pryor et al. 2007). Such a 
minor alteration selectively prevents nuclear translocation but does not disrupt the 
conformation of the NLS and does not alter any residues in the -NLS, which has 
been shown to be critical for the interaction with the viral protease NS3 and for 
virus survival (Pryor et al. 2007). 
The gene encoding NS5_A1A2 was amplified by high-fidelity PCR from the 
vector pcDNA-3.1_A1A2 (kindly provided by Dr Andrew Davidson) and cloned 
into the lentiviral vector as described previously. Correct sequence and insertion 
were checked by double digestion (BamHI-NotI) and by DNA sequencing.  
The construct was then used to generate lentiviruses and transduce K562 cells as 
before. Published data show that NS5_A1A2 does not translocate into the nucleus 
(Pryor et al. 2007), but despite several attempts at optimisation, it was not 
possible to demonstrate this conclusively by immunofluorescence due to 
insufficient specificity of the available polyclonal anti-NS5 antibody in K562 and 
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to the particular cell morphology (K562 cells have a very large nucleus in relation 
to cytoplasm).  
6.3.4.2 NS5 inhibition of cellular response to IFN- is preserved in the 
absence of nuclear translocation 
In order to examine whether nuclear translocation of NS5 is important for 
inhibition of type I IFN signalling, we treated K562 cells expressing NS5_A1A2 
with and without 100 IU/ml of IFN- for 24 hours and then measured expression 
of the IFN-inducible molecules HLA-ABC on cell surface by flow cytometry, 
gating only on GFP positive cells (Figure 6.7, A). Cells expressing wild type NS5 
and cells transduced with empty lentiviral vector were included as controls. As in 
all previous experiments, we observed reduced up-regulation of HLA-ABC in 
cells expressing NS5, but not in cells transduced with empty vector (Figure 6.7, 
B). We also observed reduced up-regulation of HLA-ABC in cells expressing 
NS5_A1A2. This suggests that NS5 preserves its ability to inhibit the IFN 
response even in the absence of nuclear translocation, and that the importance of 
the region containing the NLS previously described (Figure 6.5) does not depend 
on its ability to direct NS5 into the nucleus. 
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Figure 6.7|  
IFN- antagonism does not require NS5 nuclear translocation.  
K562 cells were transduced with a mutant of NS5 unable to translocate into the 
nucleus (NS5_A1A2). Cells were treated for 24 hours with (open histogram and 
dot plots) or without (grey histogram) 100 IU/ml of IFN-and cell surface 
expression of the IFN- inducible molecules HLA-ABC was measured by flow 
cytometry, gating on GFP positive cells only. Dot plots show up-regulation of 
HLA-ABC (y axis) after IFN- treatment in the GFP positive fraction (right 
gate, x axis) and in the GFP negative fraction (left gate, x axis) for each 
transduced sample. Cells transduced with the empty vector and with full length 
NS5 were included as controls. 
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6.4 DISCUSSION 
Identifying the region of DENV NS5 that acts as an IFN antagonist is critical for 
complete understanding of the mechanism of inhibition. In this chapter we first 
aimed to identify which domain of NS5 -MTase or RdRp- is responsible for the 
inhibition of type I IFN signal transduction. For this purpose, we separately 
expressed the MTAse domain (amino acids 1-260) and the RdRp domain (amino 
acids 223-900) in K562 cells and tested cellular response to IFN-. The exact N-
terminal start of the RdRp domain is debated and still not clearly identified. Even 
though the sequence deposited in NCBI (accession number NP_739590.2) defines 
the RdRp of DENV-2 NS5 to start at amino acid 251, the crystal structure of 
DENV-3 NS5 could be obtained only by expressing residues 273-900 (Yap et al. 
2007), and Malet and colleagues (Malet et al. 2007) suggest that in WNV the 
region 260-270 represents a linker domain between the MTase and the RdRp. 
According to these works, we initially decided to express the RpRp from residue 
270, but for reasons that we did not further investigate, we could not rescue 
lentiviruses for this construct. We therefore decided to employ a different 
construct starting from residue 223. Although it overlaps the C-terminus of the 
MTase (amino acids 223-260), this construct was chosen because it includes the 
entire polymerase domain and because we were able to rescue sufficient titres of 
lentivirus.  
After stimulation with IFN-, we showed that only the RdRp when expressed 
alone retains the capability of inhibiting cellular response to type I IFN. We also 
observed that this inhibitory effect is slightly less pronounced than in cells 
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expressing full-length NS5: it is possible that different expression levels are 
responsible for this difference, or that the presence of the MTase domain is 
important to maintain the correct protein conformation required for optimal IFN-
antagonism. Alternatively, as suggested for TBE virus (Werme et al. 2008), the 
MTase domain might allow the correct localisation of the polymerase on cell 
membrane in proximity of the IFN receptors, helping the interaction of NS5 with 
early components of the signalling cascade.  
As discussed in chapter 4, a role for NS5 in IFN inhibition has been shown for 
other flaviviruses. Interestingly, the IFN inhibitory activity of NS5 of LGTV has 
also been mapped in the RdRp domain (Park et al. 2007). According to this work, 
the region involved in IFN antagonism in LGTV NS5 maps between residues 355 
and 735. Site directed mutagenesis to alanine in the region between amino acids 
342 and 735 suggests the involvement of two sequences in IFN inhibition: 
between amino acids 374-380 (375-381 in DENV-2) and 624-637 (622-636 in 
DENV-2) (Park et al. 2007). Even though alanine scanning mutagenesis does not 
distinguish whether a specific residue is critical because of its specific function or 
because of conformational issues, this work provides a first indication about the 
regions within the RdRp that are important in preserving the IFN inhibitory 
activity. 
 
As described in chapter 1 (section 1.2.4.5), the RdRp includes a NLS and a 
NES. This region appeared particularly intriguing to us because NLS/NESs have 
been identified in some other viral proteins involved in IFN inhibition. Ebola 
virus VP24 protein interacts with karyopherin-1, 5, and 6, which are the same 
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NLS receptors for phosphorylated STAT1: such interaction prevents STAT1 
translocation to the nucleus and therefore the activation of the IFN response (Reid 
et al. 2007). Even though a specific interaction between the NLS and STAT1 has 
not been shown, the P protein of Rabies virus, containing both a NLS and a NES, 
binds phosphorylated-STAT1, and retains it either in the nucleus or in the 
cytoplasm, preventing DNA binding (Vidy et al. 2007). Nsp2 of Semliki forest 
virus also inhibits IFN and a correlation with Nsp2 nuclear translocation has been 
shown (Breakwell et al. 2007). Finally, a direct correlation between the NES and 
STAT binding/retention has been identified for Nipah and Hendra viruses 
(paramyxoviruses): the V protein has been shown to bind both STAT1 and 
STAT2 through specific regions mapping inside the NES (Rodriguez et al. 2004). 
NLSs have also been identified in the suppressor of cytokine signalling SOCS1. 
SOCS 1 downregulates Jak-STAT signalling pathway in several ways: by 
proteasomal degradation of Jak, by competition with STAT for receptor domains, 
or by binding Jak2. SOCS 1 translocates to the nucleus through a bipartite NLS 
localising between the SH2 domain and the SOCS-box motif; full inhibition of 
IFN signalling is achieved in the presence of functional NLS and SOCS-box 
(Koelsche et al. 2009). All these examples suggest some correlation between 
NLS/NESs and proteins involved in the control of the IFN system, but whether 
NLS/NESs are only responsible for protein localisation or are directly involved in 
other inhibitory mechanisms is not clear. 
Unfortunately, since the NLS does not localise at the beginning of the RdRp but 
only after the first finger, and since we were not able to express the construct 270-
900, we could not test the specific role of the NLS alone (amino acids 316-404) in 
IFN inhibition, but we examined the entire region 223 to 404, which encompasses 
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also part of the MTase domain and the first finger of the RdRp domain (amino 
acids 273-315). According to Yap and colleagues (Yap et al. 2007), the first 
finger of the RdRp is composed of an -helix, a -sheet, and a segment of 35 
amino acids which connects the finger with the first helix of the NLS, deeply 
buried in the thumb domain (see Figure 6.2). Residues 309-321 and 342-347 in 
the NLS form two flexible loops that link the fingers and the thumb and probably 
transmit conformational changes between the two domains and/or restrict their 
mobility. Interestingly, a similar structure has been identified in WNV RdRp, but 
WNV NS5, which has been shown to inhibit type I IFN response (Laurent-Rolle 
et al. 2010), has never been found in the nucleus (Malet et al. 2007); this might 
suggest an important role for the NLS region, beyond it nuclear translocation 
function.  
In order to test whether this N-terminal region was involved in IFN inhibition, 
we expressed a truncated portion of the RdRp, starting from amino acid 405, and 
we showed that in the absence of the region 223-404 the RdRp domain loses its 
ability to inhibit IFN-. This observation is difficult to interpret, since loss of IFN 
antagonism does not necessarily imply that the “inter-domain” is responsible for 
STAT2 binding; in fact, the “inter-domain” might simply have a role in 
preserving the correct conformation of the region involved in IFN inhibition. Even 
though we could detect protein expression at the expected size by 
immunoblotting, we cannot exclude the possibility that truncation of such a large 
region (181 amino acids) might destabilise the structure or introduce misfolding. 
Moreover, since the NLS constitutes only part of the deleted portion, we cannot 
conclude that IFN antagonism specifically depends on the NLS. 
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We finally tested response to IFN- in K562 cells transduced with lentiviruses 
carrying either the region 223-404 alone, or associated with the MTase domain. 
After IFN treatment we could not detect any inhibition of the IFN signalling. 
Taken together, this and our previous observations suggest that neither the “inter-
domain” nor the RdRp are dispensable for IFN inhibition. This is in agreement 
with the work of Park and colleagues on LGTV mentioned above (Park et al. 
2007), which suggests that most of the polymerase is required to preserve the IFN 
antagonism (amino acids 355-735). However, our inability to prove the expression 
of both constructs calls for caution in the interpretation of these observations, 
since the proteins might be not correctly expressed. Tagging the constructs would 
only partially solve the problem, since correct folding would still remain dubious. 
Even though we could have tried to identify the minimal RdRp portion required to 
preserve IFN antagonism by progressive truncations at the N-terminal from amino 
acid 223, addressing functional issue by protein truncation always raises 
uncertainties, since any minimal structural alteration can potentially generate 
dramatic changes in protein folding and stability. For these reasons, we have 
decided to investigate the interaction between DENV RdRp and STAT2 directly 
by protein crystallography and ongoing work is currently focusing on this target.  
 
In the previous chapters we have demonstrated that NS5 inhibits the type I IFN 
signalling by interacting with cytoplasmic targets (STAT2). Therefore we 
hypothesised that loss of IFN inhibition after deletion of the “inter-domain” is 
related to the conformation of the site involved in IFN antagonism rather than to 
NS5 nuclear translocation. To investigate this hypothesis we tested the response to 
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IFN- in cells expressing a mutated form of NS5, in which five alanine 
substitutions in the NLS prevent its translocation into the nucleus (Pryor et al. 
2007). We showed that even in the absence of nuclear trafficking, NS5 inhibitory 
effect on the IFN signalling is preserved, supporting the observation that the 
inhibitory activity of NS5 occurs in the cytoplasm, and that, if the region 
encompassing the NLS has a role in IFN inhibition, such function does not depend 
on nuclear entry.  
6.5 CONCLUSIONS 
Taken together these observations suggest that the site responsible for the 
inhibition of type I IFN response/STAT2 binding maps within the RdRp domain 
and that inhibition of type I IFN mediated signal transduction occurs in the 
cytoplasm, in keeping with the cytoplasmic location of the putative target STAT2.  
The region spanning from the first finger of the polymerase domain to the end of 
the NLS seems to be critical to IFN antagonism, either preserving protein 
conformation, or being part of the inhibitory site itself. Possible alteration of 
protein stability and conformation cannot be excluded when using extended 
protein truncations. For this reason, in ongoing work, we are attempting to co-
crystallise the complex RdRp-STAT2. 
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Chapter 7.  
FINAL DISCUSSION 
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This project starts from the hypothesis that type I IFN inhibition and STAT2 
degradation in DENV infected cells are due to some DENV non-structural 
components. This hypothesis is supported by the fact that both phenomena can be 
observed also in human cells stably expressing the DENV replicon, i.e. a self-
replicating DENV RNA genome in which the genes coding for the structural 
proteins C, prM, and E have been removed. The initial aim of this thesis was to 
identify the NS protein (or combination of proteins) involved in the antagonism of 
the IFN system.  
In the first part of this work, by using a lentivirus vector system we developed 
five K562 cell lines, each one stably expressing a different DENV NS protein 
(NS4A, NS4B, and NS5) or combination of proteins (NS1/NS2A, and 
NS2B/NS3) (Chapter 3). Next, we tested the effect of each individual NS protein 
on both STAT2 degradation and IFN- inhibition. Surprisingly, none of the 
DENV NS proteins individually expressed is able to induce degradation of 
STAT2, but we showed that the expression of NS5 alone is sufficient to inhibit 
type I IFN mediated signal transduction. Furthermore, we showed that the 
inhibition is specific for the type I IFN and that the IFN- signalling is unaffected. 
Inhibition of the type I IFN response in the presence of NS5 is not a peculiarity of 
the particular viral strain in use (DENV-2_NGC), since we could observe the 
same antagonistic effect in the presence of NS5 from a different strain (DENV-
2_TSV01) (Chapter 4). We demonstrated that inhibition of the IFN signalling 
pathway by DENV NS5 occurs at the level of STAT2 phosphorylation. Taken 
together with earlier data using DENV replicons, this suggests that STAT2 is the 
target for DENV inhibition of the type I IFN response. We hypothesised that NS5 
could specifically bind STAT2, and demonstrated this by co-immunoprecipitation 
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(Chapter 5). To explain STAT2 degradation in the presence of the DENV 
replicon, i.e. of all the NS proteins together, we also hypothesised that while NS5 
binds STAT2, some other NS protein might be required to direct STAT2 to 
proteasome-mediated degradation. By analogy with an unrelated virus, RSV 
(Elliott et al. 2007), whose non-structural components bind STAT2 and recruit the 
ubiquitination complex required for STAT2 degradation, we identified a short 
consensus sequence in DENV NS4B: such a sequence, called BC-box, is known 
to be involved in the recruitment of the ubiquitination complex. However, co-
transduction of NS5 and NS4B, as well as different combinations of NS5 with 
other NS proteins, failed to induce degradation of STAT2, leaving the question 
unanswered (Chapter 5). The final part of this work was dedicated to a 
preliminary work aimed at better defining the interaction between NS5 and 
STAT2. By truncating different domains of NS5, we showed that the RdRp 
domain is sufficient to inhibit the IFN- signalling, and does not require the 
expression of the MTase domain. The inhibitory effect is less then when the full-
length protein is expressed, suggesting that the MTase is probably important in 
preserving the correct conformation of NS5. Finally, we showed that the nuclear 
translocation of NS5 is not involved in the inhibition of the IFN response, but the 
N-terminal region of the RdRp encompassing the NLS is critical to preserve IFN 
antagonism (Chapter 6). 
These findings have been discussed at the end of each chapter, together with the 
limitations of our approaches and the questions that will lead to future studies, 
extending beyond the aims of this thesis. Therefore, the objective of this final 
discussion is to place our findings in the broader context of the current knowledge 
of DENV pathogenesis, and to suggest possible practical applications and future 
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work. 
STAT2 binding and degradation 
As outlined in chapter 1, when this project started little information was 
available about DENV inhibition of the IFN system, and neither the mechanism 
nor the NS proteins involved were entirely clear. Our finding that DENV NS5 is a 
potent type I IFN antagonist had never been reported before. Even though a role 
in IFN inhibition for the NS5 of other flaviviruses such as YFV (Lin et al. 2006) 
and TBEV (Best et al. 2005; Park et al. 2007; Werme et al. 2008) has been 
suggested, the mechanism of inhibition was unknown. Our observation that NS5 
binds STAT2 and prevents its activation was entirely new. While this work was in 
progress, a parallel study by Ashour and colleagues (Ashour et al. 2009) reached a 
very similar conclusion. This is the first time that the same mechanism of IFN 
antagonism by DENV has been described by different investigators, using 
different experimental techniques, cell lines and DENV strains. This suggests that 
taken together our studies have identified a biologically relevant mechanism. 
 
The lack of an adequate animal model has been a great hindrance to the study of 
DENV pathogenesis. Mice are not susceptible to DENV infection and this has 
been correlated to their effective IFN response (reviewed in Williams et al. 2009). 
Due to the high divergency between human and murine STAT2 (Park et al. 1999), 
we suggest that STAT2 might act as a critical restriction factor against DENV 
infection in mouse. Should this be the case, we hypothesise that a STAT2 KO 
mouse could provide an invaluable tool for the study of DENV pathogenesis, or 
for testing vaccines and antivirals. Further studies investigating the IFN inhibitory 
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properties of NS5 in different species would be required and are likely to provide 
interesting insights on cross-species transmission. 
Type I IFN inhibition and DENV pathogenesis 
This thesis constitutes an important step forward in defining the molecular 
pathogenesis of dengue. As outlined in chapter 1, high viral titres are associated 
with DHF, and depend on viral factors, host factors, and host pre-existing 
immunity. However, high viral replication would not be possible in the presence 
of a functional IFN response. We suggest that, by allowing rapid viral replication 
in the first stages of infection, inhibition of the IFN response is a crucial element 
determining DENV pathogenesis. As mentioned in chapter 1, a correlation 
between IFN antagonism and pathogenicity has been shown for WNV, where 
strong IFN antagonism is associated to more severe outcomes (Keller et al. 2006; 
Tobler et al. 2008). Moreover, recent work has shown that NS5 from the virulent 
NY99 strain of WNV is an efficient IFN antagonist, while NS5 of Kunjin virus, a 
naturally attenuated subtype of WNV, is a poor suppressor of IFN (Laurent-Rolle 
et al. 2010). Further studies would be required to test whether a correlation 
between IFN inhibition and DHF exists, and whether differences in pathogenicity 
and disease outcome observed for different DENV strains can be correlated to 
differences in IFN antagonism.  
Having access to blood samples from DF and DHF patients, it would be possible 
to measure both NS5 expression and STAT2 levels in infected cells, and compare 
the activation of the type I IFN signalling pathway in cells expressing different 
levels of NS5. These experiments could be done by flow cytometry, and NS5 
intracellular staining would also allow to distinguish between infected and 
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bystander cells. Viral titration on the same samples would also allow to correlate 
viral replication with NS5 expression and with IFN inhibition/STAT2 
degradation, and finally to link these variables with disease severity. 
 
Future work 
The results of this study suggest new interesting lines of research. Of particular 
relevance would be the characterisation of the binding between NS5 and STAT2, 
and in ongoing work we are investigating such interaction by protein 
crystallography. In this thesis we narrowed down the region of NS5 involved in 
the IFN inhibition and suggest that future studies of the NS5/STAT2 interaction 
should focus on the RdRp of NS5. This information is particularly important since 
previous attempts to crystallise full-length NS5 have been unsuccessful, whereas 
the crystal structure of the RdRp domain alone has been solved (Yap et al. 2007). 
Furthermore, we have shown that the presence of the NLS is important to preserve 
IFN antagonism. No X-ray structure is available for full-length STAT2 and only 
the C-terminal portion has been crystallised (Wojciak et al. 2009). This suggests 
that expressing portions rather than full-length STAT2 might be of help in protein 
expression and crystallisation. Considering the specificity of the binding between 
NS5 and STAT2 we speculate that the C-terminal region is more likely to be 
involved in the interaction with NS5, since it does not have similarity with other 
domains on STAT1. However at present no further assumption can be made and 
we cannot exclude that the interaction between NS5 and STAT2 might be 
mediated by other cellular proteins. 
Current work is also trying to identify the molecular mechanism behind STAT2 
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degradation, by testing the hypothesis that correct processing of the N-terminal of 
NS5 might be critical to direct STAT2 to the proteasome, as suggested by Ashour 
and colleagues (Ashour et al. 2009, see chapter 5). As discussed in chapter 4 and 
5, since IFN inhibition occurs also in the absence of STAT2 degradation, we 
suggest that STAT2 degradation might have an important biological significance 
in viral replication, either allowing recycling of NS5, or maybe directly playing a 
role in viral replication. 
Further work investigating the interplay between DENV and other components 
of the innate immune response would also be of great interest. Our findings show 
that DENV-2 NS5 selectively inhibits cellular response to type I IFN but not to 
type II IFN. In recent years a new class of IFN-related cytokines has been 
discovered and called type III IFN (Kotenko et al, 2003; Sheppard et al, 2003). 
These cytokines do not bind to the type I IFN receptor, but they still activate 
STAT1 and STAT2 signalling pathway, resulting in the formation of the ISGF3 
complex and the activation of an antiviral response (Kotenko et al. 2003; 
Donnelly et al. 2004). Since NS5 binds STAT2, a downstream signalling 
components shared by both type I and type III IFN, it is tempting to hypothesise 
that NS5 probably also blocks the activation of type III IFN antiviral pathway. 
However, as discussed in Chapter 1, the association of STAT2 to the IFNAR 
receptor is critical for the activation of type I IFN response, and STAT2 
localisation might be important in determining whether NS5 will be able to bind 
the transcription factor. To investigate whether NS5 is able to inhibit cellular 
response to type III IFN would therefore would add important information about 
DENV evasion of the innate immunity, but also provide interesting details about 
NS5 localisation and the mechanism of STAT2 binding. Further experiment could 
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be designed in order to test the antiviral response to type III IFN of both cells 
expressing NS5 alone and of cells containing the DENV replicon, and to verify 
whether a potential inhibitory effect is due to the same mechanism responsible for 
type I IFN inhibition. Conversely, should the virus be susceptible to type III IFN 
response, this would open new interesting lines of research aiming at further 
characterising not only the binding between NS5 and STAT2, but also the 
specificity of the two signalling pathways. 
Potential applications 
Defining the precise interaction between NS5 and STAT2 and identifying the 
residues of NS5 involved would provide a potential new target for antiviral 
therapeutics, designed to block the interaction between NS5 and STAT2. 
Furthermore, characterising the residues involved in STAT2 binding may enable 
reverse genetic engineering of DENVs that are disabled in their ability to inhibit 
IFN signalling; this would provide a potential new strategy towards the design of 
rationally attenuated vaccine candidates. Neither strategy would be sufficient to 
overcome the main problems associated with the use of antivirals or live-
attenuated vaccines: in order to control viral replication an antiviral drug would 
still have to be administered at early stages of infection, and safety issues related 
to the use of a life vaccine, together with the risks associated to pre-existing 
immunity after secondary infections would still raise concern. However, this 
strategy of rational attenuation would have a particular advantage, since an 
engineered DENV unable to inhibit IFN could be easily grown at high titres in 
cells that do not produce IFN: this would overcome the typical low yield of 
attenuated vaccine strains, and, at the same time, it would still be much attenuated 
in humans, where the IFN response is functional. 
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In conclusion, this study opens several lines of research and represents an 
important step in defining the molecular pathogenesis of dengue. Since the 
absence of anti-DENV vaccines is mainly due to the complex pathogenesis of 
dengue disease and to the complex interplay between DENV and the host immune 
system, we believe that this work provides important clues to suggest potential 
new approaches to combat dengue disease.  
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